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Chapter 1
Introduction
This chapter attempts to explain the paradoxical dichotomy of transforming growth fac-
tor (TGF)-β in a physiological setting and in pathologies of cancer and fibrosis. TGF-β
control tissue homeostasis in normal cells and in primary tumors and later in pathogene-
sis of cancer and fibrosis acts, in part, as a promoter of malignancy in advanced diseases.
These latter responses depend on autocrine and paracrine effects of TGF-β on the cells
and the surrounding microenviroment. This two-sided pleiotropic nature of TGF-β in
disease pathogenesis, present both a challenge and an opportunity in the development
of new therapeutic intervention.
1.1 Transforming growth factor-β superfamily
TGF-β superfamily members include a large group of cytokines which control a myr-
iad of functions both in development and in adults. Thus far, 34 family members have
been identified including TGF-βs, bone morphogenetic proteins (BMPs)/growth differ-
entiation factors (GDFs), activins, inhibins, nodal, and anti-müllerian hormone (AMH).
TGF-β has a conserved motif of 9 cysteine residues. Eight of these form a tight cys-
teine knot and the ninth is crucial for dimerization (reviewed in [1]). The ligands are
encoded as large secreted precursor proteins which require proteolytic cleavage for acti-
vation. This gives rise to a mature 25 kDa homodimeric signaling peptide [2]. TGF-β
was discovered nearly three decades ago as a factor capable of inducing a transformed
cellular morphology and growth in soft agar [2, 3, 4, 5] and conversely as an inducer
of growth arrest [5, 6]. We now know that three highly homologous isoforms of TGF-β
exists in humans, TGF-β1, TGF-β2 and TGF-β3. They signal in very similar ways but
their expression levels varies depending on the tissue [7, 1].
BMPs were identified as factors capable of stimulating ectopic cartilage and bone for-
mation [8]. More than twenty BMP family members have been identified to-date [9, 1].
These are less homologous compared to the TGF-β isoforms and each serve different
physiological functions. Clustering analysis have revealed that BMP-2 and BMP-4 are
closely related as are BMP-5, BMP-6, and BMP-7 (reviewed in [9]). Activin was dis-
covered as a gonadal protein highly expressed in reproductive organs [10]. However, it
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is produced in a wide rage of cell types at nearly all stages of development [11]. Recent
findings suggest that activin may play important roles in diseases (reviewed in [11]).
This chapter will primarily focus on TGF-βs and BMPs and their mechanisms of action
in normal tissue homeostasis and tumorigenesis.
1.1.1 TGF-β signaling
TGF-β superfamily members bind to type II and type I serine/threonine kinase recep-
tors. In humans, seven different type I receptors, also termed activin receptor-like kinases
(ALKs)1 to ALK7, and five type II receptors have been identified. The type II recep-
tors are TGF-β receptor type II (TβRII), BMP receptor type II receptor (BMPRII),
activin receptor type II (ActRII), ActRIIB, and AMH receptor type II. A third group
of receptors, the type III receptors include endoglin (CD105) and β-glycan. These are
not directly involved in signal transduction but are believed to act as accessory receptors
which present ligands to the type II receptors (reviewed in [7, 12, 13, 14]). The possible
cytokine-receptor combinations are exemplified in table 1.1.
Table 1.1: Nomenclature of TGF-β superfamily receptors and possible type I and type II
receptor-ligand combinations. (adapted from [15]). Abbreviations: ActRII, Activin type II recep-
tor; ALK, activin receptor-like kinase; BMPRII, BMP type II receptor; TβRII, TGF-β type II receptor
[15, 16].
Ligand Type II Receptor Type I Receptor
TGF-β TβRII ALK5,1,2
Activin, Nodal ActRII, ActRIIB ALK4,7
BMP BMPRII, ActRII, ActRIIB ALK1,2,3,6
The TGF-β superfamily members bind to specific sets of heteromeric receptor com-
plexes. Solely, TGF-β signals via TβRII and it does so in a complex with ALK5 [17]
(see figure 1.1). Except in endothelial cells where TGF-β in addition signals via ALK1
[18, 19]. Activin and nodal signal via ActRII or ActRIIB and either ALK4 or ALK7
[17, 1]. The combinatorial nature of type I and type II receptors for BMP signaling
is more complex (see table 1.1). BMPs can use BMPRII, ActRII and ActRIIB as
type II receptor in association with either ALK1, ALK2, ALK3, or ALK6 in a cell-
type specific and contextual manner. BMP-2 and BMP-4 preferentially bind to ALK3
or ALK6 in complex with BMPRII whereas BMP-6 and BMP-7 most readily bind to
ALK2 or ALK6 in combination with either ActRII, ActRIIB or BMPRII (reviewed in
[20, 21, 22, 17, 23, 24, 25, 26, 27, 28]). Furthermore, BMP-9 and BMP-10 were shown to
signal via ALK1 and BMPRII in endothelial cells [29, 30]. The ligand-driven assembly of
the TGF-β and BMP receptors is schematically illustrated in figure 1.1. When BMP is
present at the cell surface the heteromeric receptor complex is simultaneous assembled.
Type I and type II receptors bind independently to different sites on the BMP ligand
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[15, 16]. TGF-β, on the other hand, bind to the type II receptors and this results in
an induced-fit conformational change in the receptor that enhances its affinity for ALK5
resulting in a six-piece puzzle of ligand and receptors [15, 16].
Figure 1.1:
Schematic illustration of ligand-receptor binding of TGF-β and BMP. (A) Active dimeric
TGF-β bind to TβRIIs which leads to an induced-fit conformational change in TβRII. This result in
recruitment of ALK5 and the type I receptor directly dock into the ligand-type II receptor complex.
(B) On the contrary, BMP cell surface avidity leads to simultaneous recruitment of type I and type II
receptors. The BMP ligand bridge the heteromeric receptor complex but there is no interaction between
the receptors. As an example is shown the binding of BMP to BMPRII, however ActRII and ActRIIB
are thought to bind BMPs in a similar manner [15, 16]. Abbreviations: ActRII, Activin type II receptor;
ALK, activin receptor-like kinase; BMP, bone morphogenetic protein; BMPRII, BMP type II receptor;
TGF-β, transforming growth factor β; TβRII, TGF-β type II receptor (reviewed in 285,273).
The activation and bridging of two constitutively active type II receptors with two
ALKs results in trans-phosphorylation of the type I receptor kinases. The signal is
then transduced through phosphorylation of, the intracellular mediators, the Smads (see
figure 1.2). Humans express eight Smad proteins, which can be categorized into three
groups; receptor regulated Smads (R-Smads), a common Smad, Smad4, and inhibitory
Smads (I-Smads) (reviewed in [12, 13, 14]. The activated ALKs phosphorylate the
signal transducing R-Smads, which associate in heteromeric complexes with Smad4 and
translocate to the nucleus [31]. Here they regulate transcriptional activation or repression
of a diverse array of target genes involved in angiogenesis, immune suppression, growth
inhibition, and epithelial-mesenchymal transition (EMT), just to name a few (reviewed
in [7, 13, 32]).
Specific R-Smads are used for a given growth factor, whereas Smad4 is a common
mediator for all superfamily signaling pathways (see figure 1.2). TGF-β signals via the R-
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Smads Smad2 and Smad3, as does activin and nodal. BMPs on the other hand signal via
the R-Smads Smad1, Smad5, and Smad8 (reviewed in [7, 32]). However, in endothelial
cells TGF-β can also signal via the Smad1/5/8 pathway [19, 18]. Structurally, R-Smads
and Smad4 share two homologous proteins domains, the N-terminal MH1 domain and
the C-terminal MH2 domain bridged by a less conserved linker region [7, 33]. DNA
binding is facilitated through an 11-residue β-hairpin in the MH1 domain. In Smad2 an
insert of 30 amino acids upstream of the β-hairpin motif prevents Smad2 from binding
directly to DNA [33, 34]. A nuclear localization-like sequence is also present in the MH1
domain. The proline-rich linker region is less conserved and phosphorylated at multiple
residues, a mechanism thought to integrate signaling from other kinase pathways. The
MH2 domain contains a SXS kinase motif at the extreme C-terminus and mediates Smad-
receptor, Smad-Smad and Smad-transcription factor interactions. In order for Smads to
bind DNA they must interact with DNA binding co-activators or co-repressors since the
affinity of MH1 domain for DNA is low (reviewed in [7, 34]).
Recently, the canonical signal transduction pathway of TGF-β was challenged by the
findings that TGF-β activate Smad1 and Smad5 in various tumorigenic cell lines, albeit
at much lower levels than Smad2 and Smad3. Phosphorylation of Smad1 and Smad5
occurs through an ALK5-dependent mechanism where the L45 loop in this receptor plays
a critical role. Also, ALK2 and ALK3 are needed for this kinase activation [35, 36, 37].
This mechanism of activation was not observed in immortal breast cancer cells and is
suggested to be involved in the switch of TGF-β signaling from being pro-apoptotic to
pro-invasive and metastatic [36].
The physiological functions of TβRIIIs, β-glycan and endoglin, are not entirely clear.
These receptors lack the cytoplasmic domains and are believed to present ligands to the
type II receptor [38]. β-glycan is crucial for the binding of TGF-β2 to TβRII, since by
itself TGF-β2 has low affinity for the receptors [39, 40]. Endoglin interact with TGF-
β1, TGF-β3, activin-A, BMP-7 and BMP-2 solely in the presence of type I or type II
receptors [41].
It seems intriguing that such a large range of ligands signal via such a small subset
of intracellular mediators. However, the growth factors, receptors, Smads and Smad co-
factors are expressed in a cell-type specific and contextual manner and hereby determine
the specificity and duration of the signal.
1.1.2 Non-canonical Smad signaling
TGF-β and BMPs can also signal via Smad-independent pathways. These pathways
include the rapid activation of mitogen activated protein kinases ERK1/2, JNK and
p38, the phosphatidylinositol 3-kinase (PI3K), and Rho-like small GTPases (reviewed
in [42, 43, 44]). The kinase kinetics induced by TGF-β or BMPs are cell-type and
context dependent. Signals are propagated through auto-phosphorylation of TβRII at
tyrosine residues, which leads to trans-tyrosine phosphorylation of the ALKs (reviewed in
[45, 43, 44]). Non-canonical Smad signaling pathways have been extensively reviewed in
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Figure 1.2:
Schematic illustration of TGF-β and BMP signaling. (Left), TGF-β binds to the TβRII which
leads to recruitment and activation of ALK5. Smad2 and Smad3 are phosphorylated by type I receptor
kinases and form heteromeric complexes with Smad4. R-Smad/Smad4 translocate to the nucleus and
regulate TGF-β target genes in conjunction with various co-factors. (Right). BMP simultaneously binds
type I and type II receptors on the cell surface. This triggers phosphorylation of the R-Smads, Smad1,
Smad5, and Smad8. These form complexes with Smad4 and translocate to the nucleus and regulate
specific BMP target genes. Abbreviations: ActRII, activin receptor type II; ALK, activin receptor-like
kinase; BMPRII, BMP type II receptor, R-Smad, Receptor-regulated Smad; TβRII, TGF-β type II
receptor.
[42, 43, 44] and will only be briefly discussed here. However, Smad-independent signaling
regulates, among others, ubiquitination and proteasomal degradation of Smads, as will
be introduced next.
1.1.3 Controlling TGF-β signaling
Due to the wide expression of TGF-β family members and their receptors tight regula-
tion is essential. Several regulatory mechanisms have been identified for the signaling
pathways. These include extra-cellular ligand encapsulation by natural binding proteins,
inhibition of activation factors of latent TGF-β, receptor-interacting partners (BAMBI,
SARA and FKBP12), I-Smads, post-translational modification by intracellular E3 ubiq-
uitin ligases, co-repressors, and phosphatases (reviewed in [46]).
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Figure 1.3:
Illustration of negative regulators of TGF-β and BMP signaling. TGF-β and BMP signaling
is controlled at various levels in the signaling cascade. The pseudoreceptor, BAMBI, antagonize signaling
by all receptors, except ALK2. Smad7 inhibit both TGF-β and BMP signaling at type I receptor and R-
Smad level. Smad6 dephosphorylates and target Smad1 and Smad5 and inhibits ALK3/6 in preference to
ALK1/2. Smurf1, Smurf2 and Roc1 target phosphorylated R-Smads for ubiquitination in the nucleus.
SnoN, Ski and Arkadia target signaling at a transcriptional level. SnoN and Ski are transcriptional
repressors which bind R-Smads and Smad4. Arkadia, on the other hand, is an E3 ubiquitin ligase
that enhance signaling by terminating Smad transcription through uncoupling the Smad heteromeric
complexes from DNA at post-transcriptional level hereby allowing new Smad complexes to bind the
promoter and start transcription (reviewed in [43, 46]). Abbreviations: BAMBI, BMP and activin
membrane-bound inhibitor; Ski, Sloan-Kettering virus; SnoN, Ski-related novel protein N; Smurf, Smad
ubiquitin regulatory factor
Natural occurring antagonists limit the access of TGF-β superfamily members to their
cognate receptors. Moreover, TGF-β family members are secreted as inactive complexes
with latency-associated peptide (LAP) which sequesters TGF-β in the ECM [47]. BMPs
signaling can be antagonized by proteins such as Noggin, Chordin, Gremlin, folistatin and
others (reviewed in [9, 48]). The BMP and activin membrane-bound inhibitor (BAMBI)
is an ALK-like receptor lacking the intracellular kinase domain. BAMBI antagonizes
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heteromeric receptor complex formation by binding to either type I or type II receptors.
BAMBI can form receptor complexes with all receptors of the TGF-β and BMP signaling
cascade with the exception of ALK2 [49, 50].
I-Smads, Smad6 and Smad7, negatively regulate TGF-β and BMP signaling. This
occurs through; directed ubiquitination or dephosphorylation of type I receptors, via
degradation of R-Smads, and through disruption of R-Smad-type I receptor interactions
and R-Smad-Smad4 complex formation [51, 52, 53]. Smad7 inhibits signaling from all
branches of the TGF-β superfamily whereas Smad6 strictly inhibits BMP signaling from
ALK3 and ALK6 in preference to ALK1 and ALK2 [54, 53, 51].
Another level of regulation occurs through Smad ubiquitin regulatory factor (Smurf)
1 and Smurf2. Smurfs are E3 ligases which bind Smads at specific PPYX motifs in the
linker region. This interaction results in cytoplasmic retention of Smads followed by poly-
ubiquitination. Smurf1 interacts with phosphorylated Smad1 and Smad5 and Smurf2
with activated Smad1 and Smad2. Smad3 is not directly targeted by Smurfs instead,
the ring finger protein, ROC1 controls the degradation of activated Smad3 (reviewed
in [46, 55, 56]). Several ubiquitin ligases and de-ubiquitinating enzymes regulate the
degradation of Smad4, including; Smurf1, Smurf2, ectodermin/TIF1γ and FAM/USP9x
(reviewed in [7, 46, 57, 58, 59]). In contrast, the E3 ubiquitin ligase Arkadia was recently
described to manipulate TGF-β signaling by controlling proteasomal degradation of
phosphorylated R-Smads on target genes [56, 46, 60]. This ubiquitination occurs after
Smad transcriptional activation and provide a mechanism for rapid signal termination
after gene transcription. This is speculated to potentiate the binding of more Smad
complexes the promoter and further induce transcription [60].
The co-repressors Ski and SnoN also negatively regulate TGF-β and BMP signaling
at transcriptional level by simultaneous binding to R-Smads and Smad4 or interacting
with co-factors such as p300/CBP. This inactivates the DNA bound Smad complex and
inhibit transcription of target genes and possibly prevent further binding of active Smad
complexes to a given promoter (reviewed in [57, 61, 56]).
Moreover, additional feed-back mechanisms have been described of these negative
regulators. Smad7 was shown to catalytically activate Smurfs which then evade from
the nucleus to the cytoplasm and start ubiquitination. In addition, Smurfs and Arkadia
target Smad7 for proteasomal degradation along with associated receptors (reviewed
in [46, 60]). Also, TGF-β directly up-regulate expression of SnoN, Smurf1, Smurf2,
and Arkadia which can results in targeted degradation of SnoN and Ski (reviewed in
[57, 46]). The exact sequence of events of these numerous regulatory mechanisms are
only beginning to be revealed. Later, we will discuss the roles of negative and positive
regulators in pathophysiological settings.
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1.2 TGF-β superfamily in development and devel-
opmental EMT
Having described the basic concepts of TGF-β superfamily signaling we will now discuss
the role of TGF-β and BMPs in a physiological context. Gene ablation studies targeting
TGF-β and BMP ligands, receptors, and Smads have identified crucial and differential
roles for these growth factors in embryonic development. Such findings have provided
new insights to the signalling pathways and led scientist on the track of potential mal-
functioning of TGF-β and BMP signaling in human diseases. In this section we will
provide a short insight into some important developmental discoveries. Table 1.2 below
summarizes the findings from gene ablation studies of players in TGF-β superfamily
signaling.
1.2.1 Ligands, receptors, and Smads in development
Homozygous deletion of tgfβ1 results in embryonic lethality (E9.5-11.5) in 50% of con-
ceptuses due to defects in vasculogenesis [62, 63, 64]. Tgfβ2 embryos are perinatally
lethal [65], and tgfβ3 knockout mice die shortly after birth [66, 67]. Bmp3, Bmp5,
Bmp6, and Bmp7 null mice are viable, though Bmp7 −/− mice die within the first 24
hours due to renal failure (reviewed in [68, 32]). Also, Bmp7 knockout mice have a
smaller skeleton and decreased bone mineralization whereas Bmp3 −/− mice displayed
increased bone density and trabecular volume [68]. BMP-3 is, therefore, speculated to
antagonize the bone morphogenetic properties of BMP-7. In contrast, homozygous dele-
tion of Bmp2, Bmp4, and the BMP type I receptors, Alk2, Alk3, and Alk6 all gave rise
to embryonic lethality (E7.5-10.5) (reviewed in [68]). Strikingly similar phenotypes were
observed when TGFβ receptors of either type I or II were targeted with mice showing
severe vascular disorders and exhibiting lethality at E10.5. A similar phenotype was
observed in Alk1−/− and endoglin (Eng−/−) homozygous embryos (reviewed in [68]).
Selective disruption of individual Smads have determined the specific and overlapping
function of these in development. Homozygous deletion of Smad1, 2, 4, or 5 result in
embryonic lethal phenotypes (E7.5-E10.5) (reviewed in [68]) while mice homozygously
deleted for Smad3, 6, 7, or 8 are viable though displaying distinct phenotypic abnormal-
ities (reviewed in [68, 69]) (see table 1.2). Embryos deficient in Smad4 present with the
most severe phenotype compared to any other Smad knock out mouse and die shortly
after implantation in the uterus [70, 71]. Also, Smad2 knock out mice fail to undergo
gastrulation and mesoderm formation [72]. Double mutants of Smad2−/− and Smad3−/−
exhibit an even more severe phenotype compared to Smad4−/− embryos [71], suggesting
that Smad4-independent mechanisms through either Smad2 or Smad3 play important
roles in development. Smad5−/− mice lack blood vessels in the yolk sac and have ab-
normal vessel formation suggesting severe defects in angiogenesis. Also, apoptosis in the
embryonic mesenchyme was observed resulting in lack of stromal cells in much of the
embryo, possibly suggesting a role for Smad5 in cell survival and in developmental EMT
[73, 71]. Smad3−/− mice are viable though they eventually die of impaired immunity [74]
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and are resistant to TGF-β-induced fibrosis (reviewed in [68]). Both Smad6 and Smad7
Table 1.2:
Knockout studies of TGF-β superfamily signaling components in mouse models
Gene Phenotype Lethality Ref.
Tgfβ1 Hematopoiesis and vasculogenesis defects E10.5 [62, 63, 64]
Tgfβ2 Cardiac, lung, craniofacial, limb, urogenital defects Perinatal lethal [65]
Tgfβ3 Cleft palate Post-natal lethal [66, 67]
Bmp2 Vascular disorders, heart malformation E7.5-E10.5 [68, 1]
Bmp3 Increased bone density Viable [1]
Bmp4 Gastrulation & mesoderm retarded, vascular disorders E7.5-E10.5 [68, 1]
Bmp5 Viable Viable [68]
Bmp6 Viable Viable [1]
Bmp7 Small skeleton and renal failure Perinatal lethal [75, 76]
TβrII Severe vascular disorders defects in hematopoiesis E10.5 [77]
BmprII Gastrulation defects lack mesoderm (as ALK3) E9.5 [78]
Alk1 Abnormal yolk sac and vascular defects E10.5-E11.5 [79]
Alk2 Primitive streak elongation failure, mesoderm malformation E7.5-E9.5 [80]
Alk3 Mesoderm formation & epiblast proliferation failure E7.5-E9.5 [81]
Alk5 Severe vascular disorders E10.5 [82]
Alk6 Normal HSC function E7.5-E10.5 [68]
Smad1 Embryonic lethal E9.5 [83]
Smad2 Gastrulation and mesoderm formation failure E7.5-E8.5 [72]
Smad3 Impaired immunity, protected from fibrosis Viable [74]
Smad4 No mesoderm, growth retardation E7.5-E8.5 [70, 71]
Smad5 Yolk sac & vascular disorders, mesenchymal apoptosis E9.5-E11.5 [73]
Smad6 Defects in self-renewal, aortic ossification Viable [84]
Smad7 Cardiac defects, increased self-renewal Viable [69]
mutant mice, were postnatally lethal due to cardiovascular abnormalities [84] and 90%
Smad7−/− embryos died in utero [69]. Thus, highlight the necessity of inhibitory Smads
in tissue specific modulation of TGF-β and BMP signaling.
Most of the phenotypes observed in genetically modified animals give rise to severe
defects in vasculogenesis. Similar pathophysiological characteristics are observed in pa-
tients which carry mutation in ALK1 or endoglin. Such patients present in the clinic
with hereditary hemorrhagic telangiectasia (HHT) and display vascular dysplasia and
hemorrhages (reviewed in [85, 86]). Other vascular disorders include Marfan and Loeys-
Dietz syndrome which are caused by mutations in the TGFBR1 and TGFBR2 genes
[87]. Also, mutations in BMPR2 and ALK1 were identified in patients with pulmonary
arterial hypertension [87].
Other genetic alterations have been identified in the BMP and TGF-β pathway.
An activation mutation was recently described in ALK2 giving rise to fibrodysplasia
ossificans progressiva (FOP) which causes endochondral bone formation at extra-skeletal
sites in response to tissue injury. Finally, patients with mutations in ALK5, TGFBR2,
Smad4 or Smad2 are predisposed to some cancers (reviewed in [88, 86]).
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1.2.2 TGF-β and BMPs in developmental EMT
Epithelial to mesenchymal transition (EMT) is a fundamental and reversible mechanism
governing morphogenesis during embryonic development. It takes place during meso-
derm and neural crest formation, palatogenesis, cardiogenesis and organ morphogenesis
(reviewed in [89, 90]). EMT is a process whereby epithelial cells acquire a mesenchymal
invasive phenotype and become migratory. The normal epithelium is polarized having
basal, lateral, and apical membrane domains and cells are laterally attached to one an-
other by tight cell-cell adherence junctions [90]. EMT results in dissolution of cell-cell
and cell-matrix adherence through transcriptional repression of cadherins, occludin, and
claudin. The cell loose apical-basal polarity followed by shifts in the cytoskeletal dynam-
ics and acquire a spindle-like morphology which facilitates cell migration (reviewed in
[89, 91, 90, 92]). Key players in this process include E-Cadherin, vimentin and other ad-
herence junction proteins. These are regulated by various transcription factors including
LEF-1/TCFs, SNAIL1, SNAIL2 (also referred to as Slug) [93, 94, 92, 95], the zinc-finger
E-box binding homeobox (ZEB1, also known as δ-EF1), ZEB2 (also referred to as SIP1),
E12, E47 and TWIST [96, 97, 98, 99].
TGF-β is a major inducer of EMT and is expressed in many embryonic tissues under-
going EMT such as palate, lung, heart, perichondrium [90, 38, 100]. Direct mapping of
the three TGF-β isoforms during cardiogenesis in the mouse embryo, led to the discovery
of a unique and overlapping pattern of expression which might explain the functional
redundancy between the TGF-β isoforms in some settings [101]. Though, in palatogen-
esis the three TGF-β isoforms play distinct roles when compared head to head [102, 38].
Here, TGF-β1 and TGF-β2 regulates growth and TGF-β3 regulate the transformation
of epithelium to mesenchyme [102]. Genetic ablation studies of TGF-β3 in this model
system led to complete halt of developmental EMT thus, highlighting the crucial role
of this isoform in embryogenesis [103]. The downstream mediators of TGF-β signal-
ing Smad2, Smad3, and Smad4 were also found to differentially regulate EMT i.e. in
palatogenesis, only Smad2 was expressed and necessary for TGF-β-induced EMT [94].
The reverse process of EMT, termed mesenchymal-epithelial transition (MET), direct
the development of polarized epithelial organs by mesodermal cells during embryogenesis
(reviewed in [89, 90]). The MET program is speculated to be controlled by BMP-7 which
counteract TGF-β-induced EMT processes [104, 105, 106]. Studying the role of TGF-βs
and BMPs in EMT and MET in development have provided great mechanistic insights
to the field and into potential levels of dysregulation of TGF-β superfamily signaling in
pathological conditions such as fibrosis, tumorigenesis and metastasis. The crucial role
of EMT in tumorigenesis will be reviewed in greater detail later in section 1.3.2. In the
next sections, we will closely examine the characteristic of TGF-β and BMP signaling
in pathobiology of breast cancer and fibrosis.
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1.3 Transforming growth factor-β in breast cancer:
Angel or devil
Cancer is pathologically defined as a set of diseases characterized by abnormal cell growth
leading to invasion of the surrounding tissue which ultimately can lead to metastasis.
Carcinogenesis is a result of genetic insults leading to accumulation of errors in vital
regulatory pathways or disruptive alterations in the extracellular matrix (ECM). The
result being progressive genomic alterations and loss of tissue architecture (reviewed
in [7, 107, 108]). Epithelial tissues are the most common site of cancers giving rise
to carcinomas [109]. Other types of cancer include, among others, sarcomas, blastomas,
lymphomas and leukemia [109]. The human breast is a mass of adipose and fibrous tissue
that consists of branching ductal networks which terminates in ductal lobular units (see
figure 1.4). Three epithelial cell types are found in these structures, an inner layer of
luminal epithelial cells, an outer layer of myoepithelial cells and tubular epithelial cells
lining the terminal lobular ducts. The epithelium consist of thin sheets of cells separated
from deep complex layers of stroma by the basement membrane [109, 107]. Breast cancer
can occur in the lobules but is most common in the ducts and invasive ductal carcinoma
(IDC) accounts for (80%) of breast cancer cases diagnoses. IDC is characterized by
abnormal growth of ductal epithelial cells which have penetrated the walls of the duct
and invaded through the basement membrane into the stroma and adipose tissue of the
breast as illustrated in figure 1.4 (reviewed in [7, 107, 108, 109]).
When the primary tumor mass expand beyond 1-2 mm3 there is a limited diffusion of
nutrients and oxygen to the cancer tissue. Solid tumors therefore stimulate the formation
of a new blood supply from pre-existing vessels through angiogenesis. Angiogenesis is
regulated by a plethora of factors, with hypoxia-inducible factor (HIF)-1 being a key
player (reviewed in [113, 114, 115, 116, 85]). The establishment of a new vascular network
allows the tumor to further expand and eventually escape the primary site of origin.
Cells acquire an invasive and motile mesenchymal phenotype through induction of EMT
[89, 117, 118]. Metastasis results as invasive cancerous cells escape from the primary
tumor mass. These cells evade the tissue and travel via blood or lymphatics to seek out
sites to establish micrometastatic colonies (reviewed in [110, 119, 112]).
In the 1880s, Fuchs and Paget postulated, the ”Seed and Soil theory” saying that
though studying cancer cells (the seed) is important for characterization of metastatic
diseases observing the properties of the tissue whereto cancer cell metastasize (the soil)
may also reveal valuable insights into metastatic peculiarities in cancer patients [120,
121]. Now 200 years later, this theory is still of high importance as it addresses the organ
specificity of metastatic progression and ascribes a key role of the primary and distant
microenvironments for directing cell fate in malignant progression [122, 107, 108, 110].
In this section we will discuss the dual roles of TGF-β in mammary carcinogenesis




From mammary cancer in situ to breast cancer bone metastasis. The human breast is com-
posed of ductal and lobular acini structures embedded in a fatty collagenous stroma. Polarized epithelial
cells line the lobules and ducts and are separated from the stroma by thin layers of myoepithelial cells
and the basal layer. In normal tissues, TGF-β controls cellular homeostasis. However, as a result of mul-
tiple oncogenic events cells start to hyper proliferate (cancer in situ) and the mass eventually becomes
invasive and breaks through the basement membrane. At this point in time the tumor-suppressive effect
of TGF-β is frequently lost and instead TGF-β promote invasion and metastatic dissemination through
induction of EMT. Cancer cells extravasate at secondary sites, such as the vascular bed of the bone,
partially de-differentiate through MET, and metastatic progression can proceed. In bone, (inset), the
tumor cells induce the establishment of a vicious cycle of osteoclastic bone resorption, growth factor
release, and cancer cell proliferation. Abbreviations: EMT, epithelial-mesenchymal transition; MET,
mesenchymal-epithelial transition. (adapted from [110, 111, 112])
1.3.1 The primary tumor
Sustained basal release of TGF-β controls homeostasis in normal tissues and prema-
lignant lesions. Growth factors of the TGF-β superfamily are essential regulators of
apoptosis, cytostasis or survival and angiogenesis depending on the cellular contextual
setting and the differentiation status of the target cells. Dysregulation of TGF-β signal-
ing is a critical event in multiple cancers. The pro- and anti-tumorigenic events which
takes place in early stages of mammary carcinogenesis will be discussed in this section.
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Cytokine expression in mammary carcinomas
Cancers can adopt several mechanisms to promote oncogenesis such as gene amplifi-
cation, epigenetic inactivation, frame-shift activation and silencing or gain-of-function
mutations. Such carcinogenic events can result in altered expression patterns of growth
factors such as TGF-βs and BMPs (reviewed in [7, 110, 123]). In breast cancer patients,
a functional polymorphism was recently identified in the promoter region of the TGFB2
gene [124]. This polymorphism enhances the transcriptional activity and expression lev-
els of TGFB2 and was correlated with lymph node metastasis independent of hormone
receptor status [124]. In contrast, a general polymorphism in the TGFB1 gene has
been identified which result in increased serum levels of TGF-β1 and is associated with
reduced risk of breast cancer in postmenopausal women [125].
In advanced mammary carcinomas, TGF-β expression can be observed in and around
malignant epithelial cells. Intensive staining is observed at the invasive front of tumors
and correlates with malignant progression and poor prognosis (reviewed in 11). Samples
from breast cancer patients with skeletal metastasis showed elevated TGF-β1 and TGF-
β3 protein in plasma, which may in part be derived from bone [126, 127, 128, 129, 130].
Also, intratumoral determination of TGF-β1 protein levels (median of 86.7 pg/mg) were
correlated with menopausal status. Premenopausal women displayed increased TGF-β1
levels and high intratumoral TGF-β1 was associated with shorter disease free survival
in node-negative patients [126]. Together, these findings suggest that increased systemic
levels of TGF-β could predict the severity and stage of invasive breast cancer.
The BMP isoforms are expressed at various levels in carcinoma cell lines [131, 132].
Specifically, BMP-2 was shown to induce tumor growth via ALK3 [133, 131]. On the
contrary, increasing aggressiveness of a panel of breast cancer cell lines was associated
with loss of BMP-7 expression [134, 135]. Moreover, in clinical samples of primary
mammary carcinomas, loss of BMP-7 expression was correlated with poor prognosis
[134]. In estrogen receptor (ER) negative breast tumor samples, hyper-methylation and
silencing of the BMP-6 promoter was observed [136, 137].
Thus, epigenetic regulation of TGF-β superfamily ligands results in altered expression
patterns and genetic dysregulations may confer either a tumor suppressor or tumor
promoting effect depending on the stage of malignancy and cytokine affected.
Alterations in TGF-β superfamily receptors or Smads
The type II receptor gene is sensitive to loss of mismatch repair function in tumors with
microsatellite instability (MSI). MSI frame-shift mutations in the third exon of TGFBR2
results in loss of receptor function and have been identified in gastric, colon, glioma, and
lung cancers but not observed in breast tumors with MSI (reviewed in [7, 123]). One
group have reported the occurrence of somatic point mutations in the TGFBR2 gene in
breast cancer [138]. This was correlated with advanced and recurrent carcinomas. Such
mutations were bi-allelic missense mutations in the kinase domain or transmembrane
domain of TβRII and thought to mediate receptor conformational changes or inhibit the
kinase activity (reviewed in [43]). In line with these findings, loss of TβRII, assessed
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immunohistochemically, was observed in 55% of women with DCIS and 68% with invasive
mammary carcinomas and directly correlated with a more aggressive phenotype [139].
Together, these two studies suggest that loss of TβRII could define a transition from
low- to high-grade neoplasia and that this loss of TGF-β responsiveness is an important
event in progression of mammary carcinomas [138, 139].
Alterations in type I receptors have also been identified in cancer. A somatic inacti-
vation mutation was identified in the kinase domain of ALK5, S387Y, in 16% of invasive
ductal carcinomas [140]. The occurrence of this mutation was 40% in lymph-node metas-
tasis [140]. Albeit, another study failed to identify this point mutations in breast cancers
[141]. Also, epigenetic hypermethylation of the TGFBRI promoter was reported in other
cancers resulting in suppression of ALK5 expression (reviewed in [123]). For BMP re-
ceptors, germline mutations in ALK3 have been implicated in disease pathogenesis of
juvenile polyposis syndrome (reviewed in [43, 123]). Moreover, in ER-positive breast
cancers, expression of ALK3 was demonstrated to be a major hallmark of progression,
anti-apoptotic activity and poor prognosis [142].
As mentioned above, higher stromal expression of TβRII is associated with poorer
prognosis in patients with breast cancer [138]. When the same set of primary breast
cancer samples were analyzed for Smad4 expression, 23% of the biopsies were negative for
Smad4 and 41% showed a weak staining compared to the surrounding normal epithelia.
Loss of Smad4 was correlated with loss of TβRII and ALK5 and a trend for longer 5-year
survival was observed in patient with Smad4 negative tumors [143].
In breast cancer patients, homozygous deletion of SMAD4 was identified in 12% of
cases analyzed and in another report 2% had lost SMAD4 expression (reviewed in [123]).
Also, a commonly used human breast cancer cell line, MDA-MB-468, which originates
from a pleural effusion of a patient with distant recurrent disease, lacks both SMAD4
and SMAD8 as a result of epigenetic silencing [143]. Moreover, the MCF10 series of
human mammary cell lines ranging from non-malignant to metastatic display an inverse
correlation between Smad4 expression and increased malignancy [143]. Furthermore,
germline mutations have been reported in SMAD4 and can result in familial juvenile
polyposis as reported for ALK3 and patients with this syndrome are predisposed to
develop intestinal cancers (reviewed in [43]).
SMAD2 mutations have been reported in the MH1 or MH2 domain though these
occurs at very low frequency (reviewed in [144, 123]). Strikingly, in patients with stage
II breast cancer, reduced P-Smad2 staining was correlated with a shorter overall survival
[145]. In line with these findings, in invasive breast carcinomas nuclear localization of
P-Smad2 was an indicator of better prognosis and a less invasive aggressive phenotype
[146]. In contrast, P-Smad2 staining in the stromal compartment was correlated with
an invasive phenotype [146]. Homozygous deletion of Smad2, in a skin cancer model,
result in direct induction of EMT and enhanced tumor aggressiveness [147]. In addi-
tion, Smad2 heterozygous mice displayed accelerated tumor formation and progression
compared to wild type control animals. Epigenetic silencing of SMAD8 was described
in a third of breast cancers (reviewed in [148, 123]). No other genetic alterations have
been reported for R-Smads or I-Smads in mammary cancers. Genetic alterations and
1.3 Transforming growth factor-β in breast cancer: Angel or devil 15
epigenetic silencing of TGF-β, its receptors, and intracellular mediators are considered
rare events in breast cancers thus highlighting the pivotal role of TGF-β in malignant
breast cancer progression.
Cytostatic and proapoptotic function of TGF-β
The tumor suppressor actions of TGF-β in primary tumors occur mainly through cell-
cycle arrest at the early G1 phase. This is mediated via several mechanisms; (i) by
induced expression of cyclin-dependent kinase (CDK) inhibitors, (ii) through direct sup-
pression of c-myc expression and (iii) through repressed expression of CDK-inactivating
phosphatase cdc25A. (i) TGF-β and BMP induce expression of the INK4 (inhibitor of
CDK4) kinase inhibitor p15INK4b which bind to CKD4 and CDK6 and prevent their
interaction with cyclinD (reviewed in [43, 112]). TGF-β further up-regulate the expres-
sion of the CDK inhibitors p21 CIP1 and p27 KIP1 in epithelial cells [149, 150] and p57
KIP2 in hematopoietic cells [151] which bind complexes of cyclinE/A-CDK2. The net
result being blockage of CDK activity and cell cycle arrest at G1 to S phase transition
[149, 150, 151]. (ii) The oncogene c-myc is a key transcriptional inducer of cell prolifer-
ation. TGF-β suppress c-myc transcription by direct binding of Smad3/4 to the c-myc
promoter (reviewed in [43, 112]). Furthermore, (iii) TGF-β both suppresses expres-
sion of the CDK-inactivating phosphatase cdc25A and negatively regulates it through
RhoA/p160ROCK mediated phosphorylation, which acts downstream of TGF-β [152].
Phosphorylation of Cdc25A inhibits its phosphatase activity ultimately leading to inhi-
bition of CDK2 kinase activity and G1 cell-cycle arrest [152].
TGF-β has a dual role in apoptosis and can either target a cell for death or survival.
In a physiological setting, whether a cell lives or dies is determined by cell-autonomous
and environmental factors [153, 89]. Much remains elusive in this field and the search for
transcriptional cofactors and target genes which can induce or disrupt the pro-apoptotic
signals continues. Critical target genes of TGF-β have been identified in various cell types
i.e. the TGF-β-inducible early response gene 1, a transcription factor, is involved in the
regulation of apoptotic genes, the signaling protein GADD45β, an upstream activator
of p38 kinase, which induces apoptosis via activation of the caspase pathway (reviewed
in [43]), Bcl2-homology domain-only factor is an activator of apoptotic factors which
mediate mitochondrial activation and apoptosis, PI3K, which promotes survival through
phosphorylation of Akt and others (reviewed in [153, 43, 154, 89]).
The inhibitor of TGF-β and BMP signaling, Smad7, additionally promotes TGF-β-
induced apoptosis of epithelial cells through transcriptional repression of an inhibitor
of the pro-survival factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated
B cells) (reviewed in [153]). Smad7 might also interact with β-catenin and LEF-1 in
a TGF-β-dependent manner and hereby promote nuclear β-catenin translocation and
apoptosis [155]. Furthermore, Smad7 was found to activate p38 via TGF-β-activated
kinase 1 (TAK1) and MAPK kinase (MKK)3 and hereby induce apoptosis [156]. In
line with these findings, overexpression of Smad7 induced apoptosis and downregulation
of Smad7 decreased the sensitivity of the cells to TGF-β-induced apoptosis in epithe-
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lial cells (reviewed in [153]). Though in the highly metastatic 1205-Lu melanoma cells
overexpression of Smad7 did not alter the proliferative capacity or their resistance to
TGF-β-induced growth arrest [157].
Recently, the human telomerase reverse transcriptase (hTERT) was found to be a
direct downstream target of TGF-β. Smad3 bind the hTERT promoter with the tran-
scription factor E2F-1 and rapidly repress gene transcription resulting in inhibition of
telomerase activity and eventually senescence or apoptosis [158]. BMP-7 can also repress
telomerase activity through a similar mechanism resulting in programmed cell-death of
cervical cancer cells [159, 160]. Also, BMP-2 and BMP-5 were shown to induce apop-
tosis in a cell contextual manner [161, 162, 163]. BMP signaling via the canonical
Smad pathway is thought to promote survival whereas BMP-induced MAPK signal-
ing promote apoptosis. Additional, pro-apoptotic mechanisms of TGF-β through both
Smad-dependent and Smad-independent signaling and the crucial cross-talk with other
signaling pathways have been extensively reviewed in [43].
TGF-β and BMP can confer their actions through direct regulation of ID (inhibitors
of differentiation/DNA binding) proteins. ID proteins, i.e. ID1, ID2, ID3, and ID4
are dominant negative transcriptional repressors belonging to the basic-helix loop helix
(bHLH) family of transcription factors. They lack the basic DNA binding basic region
but can dimerise with conventional bHLH transcription factors and antagonize their
actions [164]. ID1, ID2, and ID3 are abundantly expressed in most tissues and con-
fer critical regulation of angiogenesis both during embryogenesis and cancer [165, 166].
TGF-β inhibits the expression of ID1, ID2, and ID3 which results in inhibition of cell
proliferation and mitogenic signals [167] and reviewed in [112]. Paradoxically, ID1 is
an immediate-early TGF-β target gene and later ID1 expression is repressed by TGF-β
[167, 168]. ID1, ID2 and ID3 are also classical BMP target genes which mediate differ-
entiation of osteoblasts, fibroblasts, epithelial cells, and endothelial cells. (reviewed in
[167]). Though BMP enhance p21CIP1 and suppress c-myc expression, the BMP-induced
ID1 response limit the cytostatic response in epithelial cells [169]. The antagonistic reg-
ulation of ID genes by TGF-β and BMPs is thought to partly explain the dichotomous
roles of these cytokines in disease pathogenesis [167]. The regulation of ID genes by
TGF-β family members are cell-contextual and the exact mechanisms remains to be
elucidated.
Thus, in a primary tumor setting, TGF-β and BMPs efficiently activates pro-apoptotic
or cytostatic responses either through inhibition of CDK activity, suppression of critical
cell-cycle genes, through inhibition of telomerase activity or by induction or repression
of ID proteins.
Tumor angiogenesis
The primary driving force of angiogenesis is low oxygen tension. Tissues respond to
hypoxia by producing soluble pro-angiogenic factors which induce the remodeling of the
local microenvironment, stimulate endothelial cell proliferation and migration, and form
new capillary networks. HIF-1 is a key mediator of angiogenesis and its expression is
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directly stabilized in response to hypoxia (reviewed in [116, 170, 171]). HIF-1 activates
a myriad of hypoxic-responsive genes a crucial target being vascular endothelial growth
factor (VEGF) [172].
TGF-β superfamily members play pivotal roles in vasculogenesis and angiogenesis. This
was immediately evident from findings in genetically modified mouse models where an-
giogenesis is dramatically affected by defects in TGF-β signaling components (see table
1.2)(reviewed in [85]). TGF-β has a dual role in vascular remodeling with pro-angiogenic
and anti-angiogenic properties [19, 18, 85]. In endothelial cells TGF-β can signal via
ALK5/Smad2/3 or through ALK1/Smad1/5/8 [19, 18]. A delicate balance between
these two routes of signaling determines the distinct angiogenic response. Signaling via
ALK1 stimulates endothelial cell proliferation and invasion via ID1. Signaling via ALK5
mediate maturation resulting in decreased endothelial cell proliferation and migration
via primarily plasminogen activator inhibitor (PAI)-1 [18]. Endoglin, the TβRIII, might
selectively influence the balance and determine the functional outcome by indirectly
inhibiting ALK5 and activating ALK1 signaling [173, 174].
Besides the direct effect of TGF-β on endothelial cells, it can also stimulate secretions
of pro-angiogenic factors in tumor and stromal cells such as VEGF-A and connective tis-
sue growth factor (CTGF). Also, a synergistic interplay on target gene expression can be
observed between TGF-β and HIF-1 [172, 175, 176, 116, 177]. In addition, both TGF-β2
and TGF-β3 are direct target genes of HIF-1 (reviewed in [116].)
Moreover, endothelial cell migration is further facilitated through TGF-β-mediated ex-
pression of metalloproteinase such as, MT1-MMP, MMP-9 and MMP-2 and inhibition of
tissue inhibitor of MMP (TIMP) 1 in tumor and stromal cells [178, 114]. Blocking TGF-
β signaling by administration of a small molecule antagonist to ALK5 or anti-TGF-β
antibodies potently inhibit the pro-angiogenic functions of TGF-β in vivo [176, 179, 40].
BMP-2, BMP-4, and BMP-6 can also stimulate angiogenesis in various settings
through direct up-regulation of VEGF-A secretion in various cell types [180]. Moreover,
exogenous addition and ectopic expression of BMP-2 promote tumor vascularization in
vivo and endothelial cell migration in vitro possibly through ID1 and p38 and/or ERK-
1/2 MAPK [131, 181]. In addition, BMP-2 stimulates VEGF and placenta growth factor
(PlGF) secretion in mesenchymal stem cells (MSCs) and this mechanism is thought to
mediate recruitment of nearby hematopoietic stem cells (HSCs) and endothelial cells
[182]. Also BMP-6 was identified as a direct stimulator of endothelial cell migration and
tube formation through ID1 [165] and ID1 and ID3 are highly expressed in later stages of
tumorigenesis [166]. In contrast, BMP-9 and BMP-10 inhibits basal and VEGF-induced
angiogenesis in vitro [29, 30].
Interestingly, the BMP antagonist Gremlin was identified as a pro-angiogenic factor
and shown to be highly expressed in stromal and endothelial cells in tumor xenografts
in mice and in the tumor vasculature in tissue samples [183]. Surprisingly, Gremlin did
not block BMP-4 but potentiated BMP-4-induced angiogenic responses in vivo [183]. In
contrast, the antagonist of BMP-2 and BMP-4, Noggin, blocked basal levels and BMP-
2-induced angiogenesis of human tumor xenografts in mice [131]. Collectively, evidence
from in vitro and in vivo demonstrates critical roles of TGF-β and BMP in tumor
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angiogenesis through direct and indirect angiogenic stimuli on tumor cells and cells in
the host microenvironment.
Having introduced the pleiotropic nature of TGF-β in several aspects of primary
tumorigenesis, we will in the next section review the tumor promoter functions of TGF-
β in EMT, a later stage of malignancy critical for distant metastatic spread.
1.3.2 Epithelial plasticity
Epithelial-mesenchymal transition is an important mechanism during embryogenesis
whereby quiescent epithelial cells acquire a motile mesenchymal phenotype, as was briefly
introduced in section 1.1.2. In pathogenesis, EMT provides a crucial mechanism for can-
cer cells to acquire a motile, invasive phenotype with enhanced disseminative capacities
[90, 38, 184, 89]. Carcinoma cells displaying an EMT-induced mesenchymal phenotype
are often apparent at the invasive border of a tumor mass (see figure 1.4). However, EMT
has received skepticism from pathologists who claim that spindle-shaped cell carcinomas
is a rare phenomenon in human cancers (reviewed in [185]). EMT is generally thought
to explain the reversible plasticity and enhanced motility of immobile epithelial cancer
cells. This section will present the functions of EMT in cancer and the recent findings
of EMT inducers and inhibitors in breast cancer settings.
The epithelial plasticity program
In a normal quiescent epithelium, cells are tightly packed and attached by cell-cell and
cell-matrix interactions in a cobble-stone like pattern (reviewed in [89, 184]). Epithe-
lial cells are polarized with an apical, lateral, and basal surface and separated from
the stromal compartment by a monolayer of myoepithelial cells and a highly proteinous
basement membrane [107] (figure 1.4). As a result of carcinogenic events cells become
hyper-proliferative and loose their apical-basal polarity through shifts in cytoskeletal
dynamics [38, 111, 117]. A hallmark of EMT is the functional loss of the adherence junc-
tion protein, E-cadherin and the concomitant loss of the tight junctions and desmosome
proteins occludin, claudins, zona occludens (ZO)-1, and desmosome cadherins (reviewed
in [89, 91, 118, 117, 111]). Simultaneously, the expression of mesenchymal markers, such
as the cytoskeletal protein vimentin is up-regulated and there is an increased deposition
of ECM components including fibronectin and collagens [111]. Enhanced expression of
α-smooth muscle actin (α-SMA) further supports the rearrangement of the actin cy-
toskeleton, which align into stress fibers. Furthermore, up-regulation of N-cadherin and
matrix proteases lead to the degradation of ECM proteins and render tumor cells inva-
sive. Finally, the disassembly of lateral junctions results in complete loss of apical-basal
polarity, reorganization of the cytoskeleton and complete phenotypic transitions of cancer
cells into a fibroblast-like mesenchymal cells (reviewed in [184, 89, 117, 111]).
Besides TGF-β, several oncogenic signaling cascades can trigger EMT, such as recep-
tor tyrosine kinases, Wnt and Notch. However, TGF-β is potent inducer that regulate a
plethora of factors involved in transitional epithelial plasticity. Downstream mediators
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Figure 1.5: EMT induced by TGF-β and reversion by BMP-7-induced MET
The murine mammary epithelial cell line, NMuMG, undergo EMT in response to TGF-β. The cy-
toskeletal changes can be visualized by staining actin stress fibers with phalloidin. Complete transition
from a cuboidal to an elongated fibroblastoid phenotype is observed and extensive mesh of actin stress
fibers are formed in response to TGF-β. BMP-7 is suggested to counteract TGF-β-induced EMT and
reverse the mesenchymal phenotype through MET and restore the epithelial cobble-stone characteristics
though this have not been observed in NMuMG cells [89, 91, 134, 106].
and target genes of TGF-β include transcription factors, matrix protease, proteolytic
enzymes, and cytoskeletal molecules (reviewed in [89, 91, 118]).
In vitro EMT models
There are a few in vitro models which recapitulate the events of TGF-β-induced EMT
[186]. Most of these cellular systems originate from either kidney or mammary epithelium
and include, NMuMG (namru murine mammary gland) epithelial cells [186], murine
mammary carcinoma cell lines RT3 and 4T1 [187], MDCK (Madin-Darby canine kidney
cells), murine MCT proximal tubular epithelial cells, the murine mammary EpH4-EpRas-
EpXT cell system [188, 189], the MCF10 human breast cancer cell series consisting of
four cells lines ranging from nonmalignant to metastatic [190], human primary mammary
epithelial cells (HMECs) [99] and primary keratinocytes [147]. Figure 1.5 illustrates the
mesenchymal-like changes in the actin cytoskeleton occurring in NMuMG epithelial cells
which undergo EMT in response to TGF-β.
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TGF-β superfamily receptors and Smads in EMT
Studies in cellular model systems have provided important cues about the precise se-
quence of events and mechanisms governing EMT and the role of TGF-β herein. Ec-
topic expression of a constitutive active ALK5 receptor mediated trans-differentiation
in NMuMG cells [186, 191]. In addition to ALK5, the activin and nodal receptors,
ALK4 and ALK7 could also induce EMT when constitutive active receptors were over-
expressed in NMuMG cells [191]. Direct inhibition of these receptors, with small molecule
antagonists, potently blocked and reversed TGF-β-mediated EMT in NMuMG cells
[37, 192, 193]. Also, the TGF-β-induced migratory and invasive properties of RT3,
4T1, and MDA-MB-231 cells could be blocked by ALK5 kinase inhibitors [187, 194].
Smad4 was shown to be crucial in this process since depletion of Smad4 by RNAi
resulted in a complete halt of TGF-β-induced EMT in NMuMG cells [195]. Smad3
and more weakly Smad2, when over-expressed in combination with Smad4, could induce
EMT of NMuMG cells [186, 191]. Furthermore in this cell line, ectopic expression of
Smad7 completely inhibited TGF-β-induced EMT [191].
In a model system of embryogenic EMT, the palate system, only Smad2 was expressed
and necessary for TGF-β-mediated EMT [102, 38]. Also, in a squamous skin tumorige-
nesis models over-expression of activated Smad2/3 was shown to increase cell motility
[196]. In contrast, a homozygous deletion of Smad2 in keratinocytes triggered EMT in
skin tumors in mice [147]. This was observed by down-regulation of E-cadherin expres-
sion and induction of vimentin, α-SMA, and SNAIL1 [147]. Together these observations
strongly confirm a critical role for TGF-β as a potent inducer of EMT.
Transcription factors in EMT
EMT is driven in part by a set of transcription factors that mediates either gene repres-
sion or activation of key EMT players. Many transcriptional regulators are responsive
to TGF-β and functionally repress the cell-cell adhesion molecule E-cadherin (reviewed
in [89, 91, 98]). These include the zinc-finger transcription factors SNAIL1, SNAIL2,
ZEB1, ZEB2, and the bHLH transcription factors TWIST, and E12/E47 [197, 198]. The
transcriptional regulator HMGA2 (high mobility group A2) is an additional factor with
an important regulatory role in EMT [199, 200]. Recent studies show that TGF-β require
HMGA2 to orchestrate the EMT program [200, 201]. HMGA2, Smad3, and Smad4 form
a ternary complex on the promoter sequence of SNAIL1 and mediate gene transcription
[201]. Ectopic expression of HMGA2 induce the mesenchymal phenotype in mammary
epithelial cells, independent of TGF-β [201]. This occur through direct up-regulation of
SNAIL1, SNAIL2, ZEB1, ZEB2, and TWIST but not E47 and E2-2 [201]. SNAIL1 is a
major regulator of EMT but cannot complete the transition single handed. Knockdown
of SNAIL1 can reverse the HMGA2-induced mesenchymal phenotype but not restore
cell membrane expression of E-cadherin [201]. Loss of SNAIL1 results in a concomitant
decrease in SNAIL2, ZEB1, and ZEB2. TWIST expression levels are not affected by
SNAIL1 depletion. Thus, TWIST is required for full blown EMT and can explain the
continuous repression of E-cadherin in SNAIL1 knockdown cells [201]. Furthermore,
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the transcription factor LEF-1, which plays a crucial role during embryonic EMT was
recently identified to suppress E-cadherin gene transcription [38, 100, 95, 202]. LEF-1
expression is directly up-regulated by Smad2-Smad4 complexes [102] and recently, both
SNAIL1 and LEF-1 were shown to be necessary for complete loss of E-cadherin and
induction of vimentin by TGF-β1 in MDCK cells [95, 202].
The ID protein family can antagonize signaling by bHLH transcription factors, as
previously introduced [91, 200, 167]. At early time points, TGF-β induces ID gene
expression and can later suppress their transcription, whereas BMPs continuously induce
ID1, ID2, and ID3 gene expression [167]. These opposite functions of TGF-β and
BMP on ID gene regulation is suggested to control the delicate balance of mesenchymal
transformation or maintenance of an epithelial phenotype [203, 167]. In the EpH4-EpH-
XT cell system, expression of Id1, Id2 and Id4, was strongly down-regulated as a result
of TGF-β-induced EMT [189]. ID1, ID2, and ID3 specifically inhibit the E-cadherin
repressors E12 and E47 [203]. Ectopic expression of ID2 blocks TGF-β-induced EMT
and migration in mammary epithelial cells [203] and ID2 was identified as the most
potent inhibitor of TGF-β1-induced EMT [167]. Paradoxically, when SNAIL1, SNAIL2,
or E47 was stably overexpressed in MDCK cells, ID1, ID2, ID3 and ID4 were highly
induced and most strongly in SNAIL2 and E47 expressing cells [204]. Together, these
observations suggest the existence of delicate balance of negative self-regulatory feed-
back-loops.
BMP-7 and MET
BMP-7 can reverse TGF-β-induced EMT (see figure 1.5) [105, 167, 205]. BMP-7 hereby
stimulates the maintenance of an intact epithelial phenotype in non-transformed cells
or even induce mesenchymal-epithelial transition [105, 134]. This mechanism is crucial
in early development and in various pathogenic settings such as kidney fibrosis and
malignancy. In a mouse model of renal fibrosis, BMP-7 was described to reverse the
TGF-β-induced tubular injury through induction of MET of renal fibroblasts and hereby
repair organ function [205, 105]. In line with these observations, BMP-7 was found to
counteract TGF-β-induced up-regulation of the mesenchymal marker vimentin in highly
metastatic breast cancer cells [134]. Also, reversion of EMT to MET was also observed
when a dominant-negative TβRII was over-expressed in mesenchymal cancer cells [185].
The MET program is hypothesized to be the mechanism whereby metastatic tumor cells,
subsequent to intravasation and extravasation, reconcile and initiate metastatic tumor
growth at the distant site (see figure 1.4) (reviewed in [89, 91, 117]). Although the exact
downstream mediators which control the dichotomous functions of BMP-7 and TGF-β
on EMT/MET remain to be elucidated the regulation is thought to be partly mediated
by the differential regulation of ID proteins [167].
microRNAs in EMT
MicroRNAs (miRs) are small single stranded RNAs that function as transcriptional and
post-transcriptional regulators of gene function acting either as oncogenes or as tumor
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suppressors depending on the context (reviewed in [206, 207, 208]). Recently, some
miRs have been demonstrated to play critical roles in EMT [209]. MiRs implicated
in tumorigenesis include let-7, miR-7, miR-10b, miR-21, miR-29a, miR-122a, miR-126,
miR-199a*, miR-205, miR-206, miR-221, miR-222, miR-335, miR-373, miR-489, miR-
520c and the miR-200 family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429)
[210, 211, 206, 209, 208, 212, 213, 214] and the list is rapidly expanding. For example,
the oncogenic miR-10b was found to be overexpressed in breast cancer and correlate with
clinical progression. Furthermore, miR-10b was shown to be directly induced by TWIST
[215]. In contrast, loss of the miR-200 family and miR-205 correlates with metastatic
breast cancer and these miRs are down-regulated in response to TGF-β-induced EMT
[209]. These miRs target the E-cadherin repressors ZEB1 and ZEB2 and hereby inhibit
EMT [206]. Furthermore, ZEB1 was found to directly repress transcription of miR-
141 and miR-200c. Thus, ZEB1 promotes an EMT-stabilizing feed-forward loop by
down-regulating miR-141 and miR-200c expression which relieve ZEB1 and TGF-β2
[206]. When ectopically expressed the miR-200a, miR-200b, and miR-205 synergistically
reversed the TGF-β-induced mesenchymal phenotype through MET [209]. MiR-21 is
described as an oncogenic EMT-specific miR which is highly over-expressed in breast
tumors [216]. TGF-β1, BMP-2, and BMP-4 could induce post-transcriptional expression
of mature miR-21 and miR-199a [216, 210]. Smad1,2,3, and 5 were found to interact
with the DROSHA microprocessor complex and be recruited to the pre-miR-21 complex
[210]. Interestingly, BMP-6 was shown to inhibit miR-21 expression by down-regulating
the expression of ZEB1 [212]. Finally, TGF-β was shown to induce the expression of
miR-155 which is needed for TGF-β-mediated EMT, cell migration, and invasion of
breast epithelial cells [217].
Cancer stem cells and EMT
A subject of intense investigation is tumor-initiating cells or cancer stem cells. Recent
evidence suggest a role for the EMT program in self-renewal in cancer stem cells [218]. A
small population of cells in breast cancers express high CD44 and low CD24 cell surface
markers. This minority population is postulated to constitute tumor-initiating breast
cancer cells with self-renewal or stem cell properties [219]. Mani et al. recently found
that human immortalized mammary epithelial cells that had undergone EMT acquired
similar tumor initiating properties as mammary cancer stem cells. When these cells were
transformed to a mesenchymal-like state by ectopic expression of SNAIL or TWIST or by
stimulation with TGF-β1 a significant increase in the CD44high/CD24low population was
observed [218]. Albeit, to render the human immortalized epithelial cells tumorigenic in
vivo oncogenic H-Ras transformation was additionally required [218].
Smad-independent signaling and EMT
Crosstalk of Smad-dependent and Smad-independent signaling is necessary to drive and
maintain TGF-β-induced EMT (reviewed in [38, 188, 44]). Oncogenic Ras cooperates
with TGF-β to induce EMT through a series of downstream mediators [196]. In brief,
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ERK/MAPK signaling promote disassembly of adherence junctions and induction of
cell motility through up-regulation of SNAIL1 [93]. JNK/p38/MAPKs are crucial for
reorganization of the actin cytoskeleton [220, 221] and Rho-like GTPases play a role in
dissolution of tight junctions [222]. Furthermore, TGF-β-induced activation of PI3K-
Akt disrupts β-catenin/E-Cadherin complexes, which results in loss of tight junctions
and partial loss of E-cadherin [196, 38, 95].
Thus, TGF-β is a central regulator of EMT acting through a complex network of
effectors in cooperation with various signaling pathways. Although we have gained a
deeper understanding of EMT in the last decades much still remains to be discovered
in this rapidly moving field of science. Through dynamic and transient EMT cancer
cells can metastasize to distal loci and commence metastatic tumor growth. Mammary
carcinoma cells often spread to bone, liver and lung [9, 223, 224].
Having described the role of TGF-β and BMP signaling at the primary neoplastic
site we will in the following sections review what makes the bone such an attractive soil
for the breast cancer cells and the recent findings on breast cancer bone metastasis.
1.4 Breast cancer bone metastasis
Dissemination of tumors to secondary organs cannot solely be explained by the blood
circulation from the primary carcinoma to the site of metastasis [119, 195, 109]. One third
of distant recurrent breast cancers display specific tissue- or organotropic characteristics.
Some microenvironments represent a fertile soil for metastatic tumor growth and allow
expansion of macrometastasis (reviewed in [108, 109, 110, 225]). The vast majority of
micrometastases remain in a non-dividing dormant state due to insufficient growth and
survival stimuli in the new microenvironment. One third of women diagnosed with breast
cancer will have thousands of disseminated tumor cells but only half of these women will
suffer from macrometastatic relapse [109]. The colonization in the bone parenchyma is
a complex and a rate-limiting step of the metastatic cascade. In this section, we will
review the bone microenvironment and the interplay between malignant breast cancer
cells and cells in the bone stroma. The recent findings on models for studying these
interactions in animal models and the identification of gene signatures of breast cancer
bone metastasis will be highlighted.
1.4.1 The bone microenvironment
Bone is a highly dynamic tissue undergoing continuous remodeling. Bone resorption is
mediated by osteoclasts whereas osteoblasts are bone-forming cells. Bone remodeling
occurs at distinct sites of basic multicellular units [226] (see figure 1.6). Anatomically,
bone consists of diaphysial cortical compact bone and epiphysial spongy trabecular bone.
The spongy bone houses the red bone marrow whereas yellow marrow, also referred to
as the stroma of the bone, is found in the medulla cavity of diaphysis. Red marrow is a
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myeloid tissue whereas yellow marrow mostly consists of adipose tissue and fibroblasts,
macrophages, osteoblasts, osteoclasts, and endothelial cells (reviewed in [9, 227, 228]).
The mineralized bone matrix is a major reservoir for growth factors among others, TGF-
βs and BMPs (see table 1.3) [130, 229, 230]. The BMP storage remains stable with
age [230] whereas levels of TGF-βs decline. Expression of TGF-β1 and TGF-β2 varies
according to the sites of the skeleton suggesting regulation by mechanical stimuli [229,
130]. BMP-2, BMP-4, and BMP-7 are believed to be the most osteo-inductive BMPs
[230]. They attract mesenchymal progenitor cells and act as morphogens to direct the
conversion to the osteoblastic bone forming lineage [230].
Table 1.3: Physiological levels of TGF-βs and BMPs in mineralized cortical bone.







1.4.2 Physiological niches of the bone marrow
Circulating cancer cells extravasate into the red bone marrow in highly permeable fenes-
trated sinusoidal vessels as depicted in figure 1.6. Endothelial cells in sinusoids have no
connective tissue covering and are in direct contact with the parenchyma of the marrow.
These thin-walled dilated structures allow efficient exchange with the peripheral blood
and vice versa (reviewed in [228, 231]). Hematopoietic stem cell niches are anatomical
micro-structures located in the endosteum of the bone, around blood vessels, and in the
sinusoid networks. The niche is composed of fibroblastic stromal cells, adipocytes, and
osteoclastic and osteoblastic cells [9, 227] (see figure 1.6). These structures both sup-
port quiescence and direct progenitor cell differentiation and migration. In the endosteal
niche, hematopoietic progenitors (HPCs) are maintained in a hibernating undifferenti-
ated state and are shuttled to an active vascular stem cell niche to undergo differentiation
and exchange with the peripheral circulation [227, 231, 228].
It was recently proposed that pre-metastatic niches are primed in response to en-
docrine factors secreted by the primary neoplasm [232, 228, 233]. Also, bone marrow-
derived HPCs are recruited in vast numbers to primary tumor sites and support mi-
gration and intravasation of tumor cells. HPCs were shown to significantly increase
the metastatic potential of MDA-MB-231 cells when implanted co-orthotopically [233].
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Figure 1.6: The hematopoietic stem cell niche
Hematopoietic stem cell (HSCs) niches are located at the endosteal surface of trabecular bone. These mi-
cro structures support quiescence and hematopoiesis. Hematopoietic cells attach to shaped N-cadherin+
CD45- osteoblastic (SNO) cells which line the HSC niche and support long term quiescent HSCs. TGF-β
is a potent inhibitor of HSC growth and may maintain HSCs in a hibernating state. BMPs negatively
regulate the number of SNO cells and hereby indirectly control HSC numbers. Smad4 inhibits self-
renewal whereas Smad7 overexpression was shown to induce this capacity in hematopoietic progenitor
cells (reviewed in [228, 231, 227]).
This mechanism is critically dependent on CCL5 expression by HPCs [233]. In addition,
platelets transport growth factors and chemokines released from the primary tumor to
distant pre-metastatic niches and potentiate activation and mobilization of HPCs [228].
These bone marrow-derived progenitor cells prime the pre-metastatic niche by activating
bone fibroblasts and recruiting HSCs and myeloid progenitor cells [232]. (Such myeloid
progenitors express markers such as VEGFR-1, c-Kit, Sca-1, and CD11b [232]).
Tightly regulated mechanisms are crucial for the establishment of a pro-metastatic
microenvironment [232, 234]. Hypoxic conditions in the primary tumor stimulate secre-
tion of factors such as lysyl oxidase (LOX), via HIF-1-induced transcription, which are
crucial for pre-metastatic niche formation and myeloid progenitor recruitment [235, 236].
CD11b+ myeloid cells are speculated to be mobilized from the bone marrow to the tumor
via VEGF-A gradients and TGF-β/tumor necrosis factor-α (TNF-α) signaling pathways
[235]. Furthermore, the activated bone marrow-derived HPCs induce degradation of the
matrix at the pre-metastatic site through induced expression of MMP-9 [234].
Recently, osteopontin and angiopoietin-1 (Ang-1) were found to support tumor cell
recruitment to the bone. Physiologically these molecules stimulate osteoclast and HSC
adherence to bone [237, 238]. A similar adhesive function is hypothesized for Ang-
1 and osteopontin in tumor extravasation and micrometastatic growth. Homing and
retention of HSCs is regulated by CXCL12/CXCR4 chemokine gradients [239, 240].
Increased expression of CXCL12 by cancer-associated fibroblasts in the primary tumor
induces carcinoma cells to up-regulate CXCR4 and recruit endothelial progenitors [241].
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Bones are a major source of CXCL12 and cancer cells metastasize to bone in a CXCR4-
dependent manner ([239, 240] and reviewed in [228]).
In vitro, TGF-β is a potent negative regulator of hematopoietic progenitors and stem
cells [231] and ALK5 null HSC display increased proliferative capacity [242]. More com-
mitted progenitors are less affected by TGF-β growth inhibition and are even stimulated
to proliferate in some cases [243, 242]. Recently, TGF-β signaling was found to maintain
HSCs in the bone marrow niche in a quiescent/hibernative state and maintain intact
stemness properties in vitro [227]. On the contrary, in vivo ALK5−/− HSCs displayed
normal stem cell characteristics suggesting that TGF-β signaling is not a regulator of
hibernation [242] (see table 1.4).
BMP was shown to promote stem cell differentiation and exit from stem cell compart-
ments [244] though Smad5 null HPCs display normal stem cell functions in vivo [243].
The common mediator of TGF-β and BMP signaling, Smad4, on the other hand, was
found to be critical for self-renewal of HSCs [245] (see figure 1.6). Intriguingly, blocking
the Smad signaling pathway by forced overexpression of Smad7, potentiates self-renewal
capacities of HSCs in vivo and modulates cell-fate (reviewed in [231]). Taken together,
these findings suggest either an important role for non-canonical Smad signaling or a
redundancy between ligands such as TGF-β and activin or receptors such ALK5 and
ALK1 in maintenance of intact stemness and quiescence [231].
The interaction between HPCs, endosteal osteoblasts and osteoclasts is essential for the
Table 1.4: Conditional knockout models of hematopoietic stem cells
Conditional HSC KO Phenotypic changes (Ref)
ALK3 −/− Increased niche size and increased LT-HSC [246]
ALK5 −/− Normal HSC function [242]
SMAD4 −/− Defects in self-renewal [245]
SMAD5 −/− Normal HSC function [243]
SMAD7 ectopic expression Increased self-renewal, modulation of cell fate [231]
maintenance of the HSC niche and mobilization of stem cells [247, 246]. An elegant study,
by Gillette et al., describe the intimate interactions of HPCs and osteoblasts and sug-
gests that TGF-β signaling in osteoblasts is down-regulated in response to intercellular
transfer from HPCs [247]. Simultaneously, there is an elevated secretion of CXCL12 by
osteoblasts [247] thus suggesting that migration and adhesion of HPCs is induced. The
HPCs and osteoblasts interact through specific uropod protrusions in the HPC which
are phagocytozed by the osteoblasts and delivered to endosomes [247]. BMP signaling
through ALK3 was shown to control the size of the HSC niche through regulation of
shaped N-cadherin+/CD45− osteoblastic (SNO) lining cells. HSCs attach to SNO cells
in the niche and BMP signaling, through ALK3, thus regulate the number of HSCs by
negatively regulating osteoblast numbers [246] as illustrated in figure 1.6.
Co-cultures of bone marrow stromal cells and various cancer cell lines display de-
creased endoglin expression and attenuated Smad2/3 and Smad1 signaling in the bone
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stromal cells and decreased cell proliferation [248]. Thus, suggesting that cancer cells
modulate TGF-β responsiveness of bone marrow stromal cells to facilitate cancer cell
growth in the bone [248]. Taken together, these observations suggest inverse functions
of BMP and TGF-β on HSC migration and a key role of the osteoblastic lineage in
regulating HSC numbers.
That only a minority of micrometastatic clones evolve into overt bone metastatic
lesions is a paradigm. However, this can in part be explained by the concept of tumor
stem cells or the necessity of a primed pre-metastatic niche. On one hand, thousands
of tumor cells escape from the primary tumor and are circulating in the body. They
arrest in sinusoid but only those with stem characteristics can survive, self-renew and
form metastasis and perhaps cells of the osteoblastic lineage are critical for their survival.
Alternatively, only a limited number of pre-metastatic niches are primed for the tumor
cells.
1.4.3 The vicious cycle of bone metastasis
Common sites of skeletal breast cancer metastasis include the pelvis, vertebrae, ribs, cra-
nium, and less commonly the appendicular bones such as long bones [119, 225, 110]. Os-
teolytic mammary metastases are destructive and associated with pathological fractures
and severe patient morbidity [119, 113]. Once settled in a pro-metastatic environment,
in the bone marrow, the micrometastatic lesions may evolve into overt macrometas-
tasis through a tumor-induced vicious cycle of osteolysis and tumor progression [249]
and reviewed in [110]. This vicious cycle is a result of an advanced symbiotic interplay
between cancer cells, bone cells and the bone matrix [113] see figure 1.7. Tumor cells
secrete PTHrP, RANKL, IL-1, IL-8, IL-6, and IL-11 which further stimulate RANKL
expression by osteoblasts and stromal cells. Simultaneously, cancer cells inhibit secre-
tion of ostoprotegerin (OPG) by osteoblasts and stromal cells. OPG is a soluble decoy
receptor which can antagonize RANKL binding [250]. RANKL bind to RANK on osteo-
clast progenitors and trigger osteoclastogenesis and activation of osteoclasts (reviewed
in [119, 110]). Mature and activated osteoclasts resorb bone and release bone matrix en-
capsulated growth factors, such as TGF-β. This increase in locally active TGF-β alters
tumor-cell behavior and further promotes growth and bone destruction at the metastatic
site. The net result being a highly efficient self-amplifying feed-forward loop of osteolysis
and tumor cell progression [249, 113, 119, 110].
1.4.4 Animal models of osteotropic breast cancers and in vivo
imaging
Human breast cancer cell lines which give rise to bone lesions when inoculated in im-
munodeficient mice include selected clones of MDA-MB-231, MCF-7, SUM1315, T-47D
and ZR-75-1 [195, 226, 251, 252, 253]. Also, murine epithelial breast cancer lines such
as 4T1 and cell lines derived from a conditional knockout mouse of E-cadherin and p53
(the K14cre;Cdh1F/+;Trp53F/F model) develop skeletal metastasis when implanted or-
28 Introduction
Figure 1.7: The vicious cycle of bone metastasis
Metastatic cancer cells settle in bone marrow along the endosteal bone surface. The cancer cells secrete
various osteolytic factors such as PTHrP, RANKL, IL-1, IL-6, IL-8, IL-11, CTGF, and others. PTHrP
and RANKL are key stimulaters of osteoclastogenesis. Mature multinucleated osteoclasts resorb the
bone and release matrix encapsulated growth factors such as TGF-β, insulin-like growth factor and
others. These growth factors act back on the cancer cells and the bone precursors and stimulate further
growth of cancer cells and osteolysis and so the cycle goes. The net result being overt osteolytic
bone lesions causing severe patient morbidity and pathological fractures (adapted from [249, 119, 113,
110]). Abbreviations: CTGF, connective tissue growth factor; OB, osteoblast; OC, osteoclast; PTHrP,
parathyroid hormone related peptide; IL, interleukin; RANKL, receptor activator of nuclear factor-κB
ligand.
thotopically in mammary glands [254]. It is important to note that the MDA-MB-435,
is a highly metastatic melanoma cell line frequently mistaken for a breast cancer cell line
and a commonly used metastasis model [255].
The best described osteolytic breast cancer cell line is the MDA-MB-231 and the vast
majority of studies on breast cancer bone metastasis is performed with this model system.
Systemic metastasis can be induced with this cell line by intracardiac or tail vein inoc-
ulation of approximately 105 luciferase positive cancer cells resulting in micrometastatic
lesions [226, 134, 256]. These metastases models recapitulate the later stages of tumori-
genesis such as survival in the blood circulation, homing and extravasation in a distant
parenchyme, establishment and survival in the new stroma, and finally expansion from
a micrometastasis to a full blown macrometastatic lesion. Alternatively, cells can be
surgically implanted directly in the tibia [134, 256]. Both routes of inoculation give rise
to aggressive osteolytic or osteo-inductive lesions [195, 223, 252, 253, 256, 226].
A range of optical imaging techniques are now available for small laboratory animals
and include 2D and 3D bioluminescent imaging (BLI), µ-CT and fluorescent imaging. An
extensively used modality is BLI which allows quantitative and spatiotemporal analysis
of tumor growth of luciferase positive cancer cells [256, 257]. By combining 3D BLI and
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µ-CT both the tumor growth and the pathogenic loss of bone microarchitecture can be
monitored [257, 258] (see figure 1.8).
Figure 1.8: Non-invasive 2D and 3D imaging techniques
Two dimensional bioluminescent imaging of an anaesthetized mouse six weeks post intra-cardiac inoc-
ulation of osteotropic MDA-MB-231/luc breast cancer cells (left). We additionally imaged this mouse
by 3D BLI and scanning µ-CT. The two modalities were combined by computer analysis and a three
dimensional surface image produced (right). Abbreviations: BLI, bioluminescent imaging; µ-CT, micro-
computed tomography. [257, 258].
1.4.5 Gene signatures of breast cancer bone metastasis
Transcriptomic profiling of human primary carcinomas have identified gene expression
patterns that correlate with poor prognosis and tissue tropism of metastasis (reviewed in
[110, 7]). Characterizing such signatures in cancer cells used in metastatic animal models
can help to identify clinically relevant and functional mediators of metastatic relapse in
breast cancer patients [259, 7, 260, 261, 262]. Systemic administration of parental MDA-
MB-231 breast cancer cells result in metastasis of with various tissue tropism such as
soft tissues and bone. Re-establishment of cell lines from these metastasis led to the
identification of specific gene signatures with lung or bone metastatic activity [260, 261,
262, 259, 263]. Genes which are up-regulated include molecules which mediate survival
advantages of the cancer cells in the circulation, in the new microenvironment and which
assist in extravasation at specific secondary sites (see table 1.5)[263, 261, 262, 260].
MDA-MB-231 subclones with a specific lung metastatic phenotype were unable to
survive and progress when implanted in bone and vice versa for osteotropic clones used
in lung metastatic animal models [261]. Thus, highly organ-specific properties of the
respective subclones are observed [261]. The lung metastatic clones displayed enhanced
expression of ID1 and knockdown of this gene inhibited orthotopic growth and lung
metastatic activity of the breast cancer cells [260]. Except for ID1, no other gene could
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Table 1.5: Metastatic gene signatures of MDA-MB-231 cells with specific tissue tropism for
lung or bone. [261, 262, 260, 263, 259, 264, 265].
Gene Bone clone Lung clone
CXCR4 ; chemokine receptor up down
ID1 ; transcriptional inhibitor down up
MMP1 ; matrix metalloproteinase - up
MMP2 ; matrix metalloproteinase - up
IL-11 ; cytokine up -
CXCL-1 ; chemokine ligand - up
CTGF ; growth factor up -
ANGPTL4 ; angiopoietin-like 4 - up
VCAM-1 ; cell adhesion molecule down up
SPARC ; cell adhesion molecule - up
solely induce lung metastasis suggesting that a whole program of events has be initiated
for metastatic recurrence [260, 264].
Comparison of the MDA-MB-231 bone metastatic gene signature with primary hu-
man breast tumors of patients which presented with distant recurrent skeletal metastasis
revealed that CTGF, IL-11, and CXCR4 were indeed up-regulated in the primary mam-
mary tumor tissues [263]. In line with these observations, a similar study in GI101A
human breast cancer cells and the lung metastatic clone, GILM2, identified CXCL-1,
CTGF, ID1, and ID2 as being highly expressed in lung metastatic cells versus parental
cells along with IL-8 and E2F2 [266].
In these reports, tumor metastasis were initiated by systemically inoculating breast can-
cer cells either intracardially or via the tail vein. Such metastasis models obviate the
critical steps of invasion and intravasation and could fail to identify genes involved in
early stages of metastasis [99].
A recent report identified a 31 gene profile which could predict whether primary
mammary cancers would metastasis to bone with a 50 % probability [267, 268]. Tran-
scriptomic profiling of microdissected RNA from 107 primary tumors with known relapse
to the bone, identified the trefoil protein encoding genes TFF1 and TFF3 to have the
highest differential expression profile in osteotropic recurrent tumors [269]. Also, the
FGFR-MAPK signaling cascade was up-regulated in tumors with bone preferences [269].
The gene fingerprint identified correlated to findings in osteotropic MDA-MB-231 versus
lung signature MDA-231 cells [263].
Furthermore, bone sialoprotein and osteopontin, two secreted glycoproteins regulated by
TGF-β, play important roles in bone turnover and were found to be highly overexpressed
in malignant breast tissue and correlate with tumor grade [270]. In patients, serum and
mRNA levels of bone sialoprotein and osteopontin were identified to be prognostic indi-
cators for osteotropic metastasis [270].
Moreover, an elegant study by McAllister and Weinberg et al. [271], illustrated how
an actively growing tumor inoculated at one site in a host animal can induce tumori-
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genesis in a collaterally xenografted dormant tumor [271]. The pro-tumorigenic stimuli
was regulated by endocrine activation and migration of host bone marrow cells to the
dormant tumor site by the initiating tumor. This was in part induced by systemic secre-
tion of osteopontin by the pro-active tumor [271]. Distant activation of tumors is not a
novel observation. In 1985 Dolberg et al. [272] found that a tumor xenografted in wings
of chickens could migrate collaterally to the opposite wing where a wound was inflicted
and establish growth at this secondary site [272].
Together, these findings stratify the critical role of the host microenvironment and
the systemic activation of bone marrow derived cells in tumorigenesis. The fact that
metastatic gene signatures can be identified in primary breast cancers and distant metas-
tases suggests that the metastatic phenotype is acquired early during tumorigenesis in
the parental cancer population [261]. Many genes have been identified whose expression
correlate with metastasis and specific tropism of cancer cells and some have been shown
to play a causal role in this process [263, 260, 264, 273, 262]. Delineation of specific
signatures for each step of the metastatic cascade will lead to a better understanding
of the pathobiology of metastases and the molecular mechanisms predictive of distant
metastatic recurrence in women diagnosed with breast cancer.
1.5 Disrupting TGF-β signaling in breast cancer metas-
tasis
Metastatic breast cancer remains an incurable disease [113, 251]. Currently available
therapies reduce patient morbidity but cannot induce regression of established bone
metastasis [119, 110]. New drug candidates are therefore in desperate need in the clinic
along with biomarkers for early detection of breast cancer patients with predilection
for bone metastasis. The dichotomous role of TGF-β in malignancy represents a great
therapeutic challenge. Targeted strategies must be directed towards the pro-metastatic
functions of the signaling pathway and protect the normal homeostatic role of TGF-β,
its potent anti-inflammatory actions and the anti-mitogenic effects of TGF-β on primary
tumors [274, 275]. In this section, we will review the novel insights and current status of
anti-TGF-β therapeutics and present the clinical complications encountered in the fight
against cancer.
Several modalities have been attempted to target the TGF-β signaling pathway.
These include applications of neutralizing antibodies to TGF-β ligands, small-molecular
weight antagonists inhibiting receptor kinase activity, administration of soluble recep-
tors or antisense oligonucleotides to TGF-β (reviewed in [274]). Figure 1.9 and table
1.6 provides overviews of the inhibitory approaches attempted to manipulate TGF-β
signaling.
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Figure 1.9: Targeting the TGF-β superfamily in breast cancer bone metastasis
Several strategies for targeting the TGF-β pathway have been attempted in cancer models including ad-
ministration of anti-TGF-β antibodies, small-molecule inhibitors of ALK5 and TβRII, soluble Fc:TβRII,
overexpression of dominant negative (DN) receptors or kinase inactivated ALK5, ectopic expression of
mutated R-Smads and I-Smads, by inhibiting activation of latent-TGF-β or deletion or overexpression of
downstream target genes of TGF-β or BMP signaling and finally by overexpression of BMP-7. Symbol:
￿, synthetic inhibitor; ￿, antibody; ￿, shRNA.
1.5.1 Targeting ligands
Functional antagonism of TGF-β and BMP signaling can be conferred by anti-ligand
antibodies, administration of soluble receptors or natural antagonists, or by silencing
ligand expression by RNAi. A neutralizing TGF-β antibody (1D11, Genzyme), recog-
nizing all three isoforms, was used to treat orthotopic metastasis of 4T1 cells in nude
mice [276, 270]. A clear reduction in the amount of lung metastatic lesion was observed
in mice treated with 1D11 [270]. A downstream mediator of TGF-β signaling, bone
sialoprotein was shown to directly mediate the pro-metastatic functions of TGF-β in
both MDA-MB-231 and 4T1 cells. This factor was identified by comparing metastasis
from treated versus untreated animals by gene array analysis [270, 277]. Artega et al.
similarly administered the pan-TGF-β-neutralizing mouse antibody 2G7 to mice with
subcutaneous MDA-MB-231 tumors [278]. They similarly found that the antibody could
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suppress primary growth and lung metastasis. This was correlated with an increase in
the activity of natural killer cells in athymic nude mice [278]. Though antibody ad-
ministration regimens are approaching the clinic for treating renal diseases these agents
have not been tested in a cancer setting [279, 280, 281, 282]. The pharmacokinetics and
selectivity of an antibody regimen is generally preferred in the clinic compared to the use
of small-molecule kinase inhibitors even though, synthetic inhibitors have better tissue
delivery properties (reviewed in [283, 274]).
Targeted knockdown of TGF-β1 by RNAi was pursued in PyVmT and the MDA-
MB-435 melanoma cell lines [284, 255]. Loss of TGF-β1 had minor or some effects on
primary orthotopically implanted tumor growth, but significantly reduced the number of
mice with lung metastasis [284, 255]. The reverse experiment was performed by Muraoka-
Cook et al. who engineered a doxycycline-inducible TGF-β1 transgenic mouse model
[284]. They observed that enhanced expression of TGF-β1 in late stages of mammary
tumorigenesis markedly accelerated metastasis formation [284].
Additionally, the drug tranilast, which is a clinically used anti-inflammatory agent
that suppress protein synthesis of all TGF-β isoforms was found to inhibit TGF-β-
induced Smad2 phosphorylation [285, 286]. It was shown to inhibit growth of gliomas in
vivo supposedly through inhibition of invasion and migration of malignant cells [285]. In
addition, oral administration of tranilast reduced primary tumor growth of xenografted
4T1 mammary carcinoma cells and potently blocked metastasis to lungs from the ortho-
topic site [286].
Another agent which acts through a similar mechanism is the naturally occurring
proteoglycan, decorin. This protein neutralizes the biological function of TGF-β1 by
binding the ligand and sequestering it extracellularly [287]. This results in reduced
TGF-β gene transcription and protein synthesis [288]. When decorin was delivered to
tumor bearing rats by gene-therapy it significantly prolonged survival of treated animals
[288]. Furthermore, systemic administration of decorin to mice with orthotopic mam-
mary tumors reduced primary tumor progression and prevented pulmonary metastasis
[289]. Finally, agents which target the catalytic activation of latent TGF-β isoforms are
being explored and include small molecule and antibody therapy to αvβ6 integrin [290].
1.5.2 Targeting TGF-β receptors
Over the last decade several groups have studied the function of the TGF-β receptors,
ALK5 and TβRII, and examined the changed tumorigenic and metastatic characteristics
of breast cancers when expression of these is altered. A few mechanistic studies will be
described here and additional information on small molecule antagonists of ALK5 will
be described in a later section.
An elegant study by Safina et al. [178] compared ectopic expression of the inactive
K232R-ALK5 (KD-ALK5) mutant versus the continuous active T204D-ALK5 (caALK5)
mutant in MDA-MB-231 cells. When injected in the tail-vein of SCID mice, the caALK5
cells gave rise to four fold more lung metastasis compared to control mice. Tumors ex-
pressing caALK5 grew significantly faster orthotopically than tumors expressing control
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and KD-ALK5 cells and the lung metastatic potential of the caALK5 cells was enhanced
in athymic mice [178]. There was no difference in primary tumor growth rate of the KD-
ALK5 expressing cells versus controls however, KD-ALK5 tumor-bearing mice developed
significantly less metastases. Angiogenesis was enhanced in caALK5 expressing tumors
compared to control and KD-ALK5 tumors [178]. Depletion of MMP-9 by siRNA in the
caALK5 MDA-MB-231 cells inhibited their angiogenenic, tumorigenic and metastatic
potential to levels in control injected animals [178]. In a similar approach, caALK5
was found delay Neu-induced mammary tumorigenesis and promote metastasis to lungs
[291, 292]. These findings were correlated to enhanced extravasation potential in caALK5
tumor cells [292].
In the tumor same model, expression of TβRII lacking the intracellular kinase do-
main, resulted in accelerated tumor growth. However, the number of lung metastases
was reduced due to the impaired ability of these cells to extravasate the lung parenchyme
[292]. Yin et al. overexpressed a dominant negative TβRII in MDA-MB-231 and induced
metastasis by intracardiac inoculation [249]. Mice bearing DN-TβRII expressing cells
exhibited prolonged survival, decreased tumor burden and reduced bone osteolysis. This
was directly ascribed to diminished TGF-β-induced PTHrP secretion in DN-TβRII ex-
pressing tumors [249]. In correlation with previous findings, expression of DN-TβRII in
the tumor cells had no effect on xenografted tumor growth [249]. The inhibitory effects
on breast cancer bone metastasis could be circumvented by expression of the T204D
caALK5 receptor in the DN-TβRII in the tumor cells [249].
The development of TGF-β receptor antagonists was initially focused on large-molecule
inhibitors such as antibody and antisense therapies [274]. Now, several small-molecule
competitive antagonists of the ALK5 kinase have been developed (see table 1.6 for de-
tails). These inhibitors can block the ATP-binding site in the ALK5 kinase domain
and efficiently prevent downstream signaling [37, 293, 274, 294]. This results in abro-
gation of TGF-β-mediated responses such as target gene regulation, EMT, migration,
and invasion [37, 192, 194]. Several groups have systemically administered ALK5 kinase
inhibitors in vivo, in small animal models, and reported selective inhibition of TGF-β
without adverse side-effect (see 1.6). A few lead compounds have been used in the treat-
ment of metastatic breast cancer and these include Ki26894 [194], an inhibitor from Eli
Lily [295, 296], and SD-208 [187].
Ki26894 was given orally to immunodeficient mice (at 0.08 mg/kg) in a preventive
setting. It efficiently decreased metastasis formation of MDA-MB-231, reduced osteolytic
bone resorption, and increased survival [194]. Another ALK5 inhibitor from Eli Lily was
systemically administered (at 25 and 100 mg/kg/day intraperitoneal) to mice injected
intracardiac or in the mammary fat pad with MDA-MB-435 cells. This compound had
no effect on primary tumor growth but significantly inhibited the incidence and size of
pulmonary and skeletal metastasis [295]. The suggested mechanism for reduced metas-
tasis is blockage of TGF-β-induced αvβ3 integrin expression [295]. Furthermore, SD-208
was recently applied in a glioma mouse model and found to enhance survival [297]. Inter-
estingly, these effects were conferred through inhibition of the immunosuppressive effect
of TGF-β alone without affecting tumor angiogenesis, proliferation or apoptosis [297]. In
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addition, syngeneic 129S1 mice inoculated with 4T1 or R3T mammary tumors received
the SD-208 (at 20 or 60 mg/kg/day) in a curative treatment regimen [187]. SD-208
caused a growth delay of both tumor types and dose-dependently reduced the number
of metastasis. However, SD-208 had no effect on tumor growth or metastatic potential
of R3T mammary tumors in athymic mice [187].
Together these lead compounds hold great promises for the future use of TGF-β
inhibitors in clinical applications. Though, one thing to keep in mind is that these
inhibitors also target the structurally related type I receptors ALK4 and ALK7 which
are used by activin and nodal, respectively [37]. The impact of abrogation of these
signaling pathways in tumor biology is currently not known (reviewed in [274, 88]).
Finally, targeting TGF-β signalling intracellularly was attempted through inhibit-
ing endogenous Smad molecules either by gene transfer of the inhibitory Smad7 or by
treatment with SARA peptide aptamers [54, 157, 298], both of which can inhibit TGF-β
mediated EMT [298].
Table 1.6: Therapeutic strategies to target TGF-β. Abbreviations: NSCLC, Non-small cell
lung carcinoma; Vac., vaccine.
Drug Target Inhibitory effect Clinical Phase Company and Ref
GW788388 ALK4,5,7 TβRII EMT,fibrosis Pre-clinical GSK [37, 293]
Ki26894 ALK4,5,7 Metastasis Pre-clinical Kirin [194]
SM305 ALK4,5,7 Fibrosis Pre-clinical Biogen [299]
SD-208 ALK4,5,7 Metastasis Pre-clinical Tocris [187, 297]
Ki26894 ALK4,5,7 Metastasis Pre-clinical Kirin [194]
A-83-01 ALK4,5,7 EMT Pre-clinical Kyoto Uni. [192]
SX-007 ALK4,5,7 Glioma Pre-clinical Scios [274]
LY580276 ALK4,5,7 Oncology Pre-clinical Eli Lilly [274]
LY2109761 ALK4,5,7 Oncology Pre-clinical Eli Lilly [300]
Tranilast TGF-β Metastasis Clinic Nuon Ther. [285, 286]
Lerdelimumab anti-TGF-β2 Fibrosis Phase III Cam. A. Tech. [274]
Metelimumab anti-TGF-β1 Fibrosis Phase I/II Cam. A. Tech. [274]
AP-12009 TGF-β2 antisense Oncology Phase III Antis. Phar. [274, 301]
AP-11004 TGF-β2 antisense Oncology Pre-clinical Antis. Phar. [274, 301]
Lucanix Anti-TGF-β2 vac. NSCLC Phase III NovaRx [302]
Glionix Anti-TGF-β2 vac. Glioma Phase I/II NovaRx [274]
rhBMP-7 TGF-β EMT,Metastasis Pre-clinical [134, 303]
1.5.3 Alteration of BMP and accessory receptors
Targeted disruption of the BMP signaling pathway has been studied in breast cancer bone
metastasis. This was achieved through ectopic expression of a dominant negative BMP
receptor, DN-ALK3, in MDA-MB-231 cells. When used in a metastasis model in nude
mice DN-ALK3 was shown to reduce breast cancer-induced bone osteolysis compared to
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controls [133]. Surprisingly, overexpression of DN-ALK3 blocked IL-11 expression and
secretion in comparison DN-TβRII had no effect on the expression of this cytokine [133].
Loss of function of β-glycan impaired motility, invasiveness and induced apoptosis
of MDA-MB-231 cells [304]. When orthotopically implanted, β-glycan knockdown cells
grew slower and showed no sign of distant metastasis [304]. Thus, suggesting a tumori-
genic role of β-glycan in MDA-MB-231 breast cancer cells. In contrast, overexpression
of β-glycan could sequester active TGF-β and when MDA-MB-231 cells were subcu-
taneously inoculated in athymic mice a reduced tumor incidence and growth rate was
observed [305]. Overexpression of endoglin in MDA-MB-231 enhanced the invasive prop-
erties of the cells in vitro through enhanced proteolysis and migration in a 3D co-culture
model [306]. Moreover, elevated plasma levels of soluble endoglin in breast carcinoma
patients were correlated with shorter overall survival [307] and high metastatic risk [308].
1.5.4 Disrupting the common Smad4 and R-Smads
Overexpression of mutated R-Smads or ALK5 mutated at the R-Smad binding site was
shown to disrupt TGF-β signaling in MCF10A breast cancer cells [309, 144]. These cells
displayed enhanced primary tumor growth whereas invasion and metastasis to lungs
were reduced after tail vein injection [309, 144]. Overexpression of activated Smad2/3
was shown to increase cell motility in a squamous skin tumorigenesis models [196]. In
contrast, homozygous deletion of Smad2 triggered complete EMT in skin tumors [147].
Recently, Daly et al. found that TGF-β could activate Smad1 and Smad5 signaling in
MDA-MB-231 cells and that this activation mediate the complex formation of mixed
BMP and TGF-β R-Smads [35]. Smad1/5 activation by TGF-β did not induce BMP
target genes. However, when silencing Smad1 and Smad5 in metastatic EpHRasXT cells
the TGF-β-induced tumorigenicity was lost in vitro [35].
Depletion of Smad4 in MDA-MB-231 cells increased metastasis-free survival in nude mice
and reduced the growth rate of bone-metastatic lesions after intracardiac inoculation
[259, 195]. Smad4 depletion correlated with loss of TGF-β-induced IL-11 secretion [195].
Neither intra-osseous nor s.c. injection of the shRNA Smad4 MDA-MB-231 in nude mice
affected tumor progression suggesting that Smad4 is crucial for extravasation and initial
growth of the micrometastases formation [195]. Together, these results strongly imply
that Smad4 signaling is needed for breast cancer progression.
1.5.5 Targeting I-Smads, co-repressors and ubiquitin ligases
Ectopic expression of Smad7 in mouse mammary and human melanoma cells reduced
their capacity to form metastasis in lungs and bone, respectively [54, 157]. Osteolysis
was significantly reduced and survival prolonged in mice with Smad7 over-expressing
metastases compared to controls [157]. These effects are thought to be a result of reduced
MMP-2 and MMP-9 activity and reduced expression of PTHrP, IL-11, CXCR4, and
Osteopontin in response to TGF-β [157]. Strikingly, ectopic expression of Smad6 had no
effect on the metastatic potential of the murine mammary carcinoma cells [54].
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Targeting the co-repressors of Smads, Ski and SnoN, in MDA-MB-231 cells enhanced
TGF-β signaling and rescued TGF-β-induced growth arrest [61, 310]. The EMT in-
ducers HMGA2 and SNAIL2 were up-regulated in response to knockdown of Ski [310]
and Twist in cells depleted of SnoN [61]. Whereas loss of SnoN in MDA-MB-231 cells
suppressed subcutaneous tumor growth in nude mice [61] knockdown of Ski displayed no
inhibitory effect on primary tumor growth [310]. Targeted deletion of either SnoN or Ski
enhanced metastasis formation after intracardiac inoculation in nude mice [61, 310]. To
recapitulate, SnoN may thus play a dual role tumorigenesis which can be inversely cor-
related with the role of TGF-β signaling in breast cancer metastasis [259, 195, 249, 61].
Ski, on the other hand, has no or little effect on primary tumorigenesis but display
anti-metastatic effects in breast cancer [310].
Lastly, knockdown of either Smurf1 or Smurf2 expression by siRNA in MDA-MB-
231 reduced their invasive and migratory potential in vitro [311]. Ectopic expression
of these proteins increased the number of lung lesions of metastatic MCF10A breast
cancer cells after tail vein injection in nude mice [311]. An E3 ligase-defective mutant
of Smurf2, significantly abrogated the pro-metastatic effect Smurf2 [311]. Surprisingly,
neither knockdown nor overexpression of Smurfs induced a concomitant change in TGF-β
signaling at Smad2, Smad3, or ALK5 level [311].
1.5.6 Downstream mediators of TGF-β and BMP
Twist is a master regulator of EMT and its expression is enhanced upon TGF-β stim-
ulation in breast epithelial cells [201, 117, 99]. In the 4T1 in vivo model system Twist
was identified as a key player in invasion and intravasation. Loss of Twist had no ef-
fect on primary tumor growth but drastically reduced the lung metastatic potential of
orthotopically implanted tumor cells [99]. Blood colony formation was inhibited and
the EMT phenotype and in vitro migratory potential of the cells abrogated in Twist
knockdown cells [99]. High expression of Twist in human breast cancers clustered with
invasive lobular carcinoma which directly correlated with loss of E-cadherin expression
[99].
Another key player in EMT is Snail1. Silenced expression of this protein significantly
reduced the metastatic potential of MDA-MB-231 cells [312].
Onder et al. recently studied the function of E-cadherin, either through protein deple-
tion by shRNA or expression of a truncated form of E-cadherin lacking the ecto-domain
(DN-Ecad) [313]. Both methods disrupted cell-cell adhesion of primary HMECs though
cells expressing shRNA additionally displayed a fibroblast like morphology [313]. The
metastatic potential of the shRNA E-cadherin, tumors, when inoculated orthotopically,
was enhanced compared to controls and DN-E-cad [313]. When additionally silencing
β-catenin in these cells their ability to form lung metastasis was significantly impaired.
In response to E-cadherin knockdown N-cadherin, vimentin, fibronectin, TWIST, and
ZEB-1 were highly up-regulated. Thus, loss of E-cadherin results in the induction of its
own repressors TWIST, and ZEB-1 [313].
Expression of the homeobox gene Goosecoid (GSC ) is highly elevated in DCIS and
38 Introduction
IDC compared to matched healthy breast tissue [314]. TGF-β can induce the expression
of GSC in HMECs. Ectopic expression of GSC in HMECs or MDA-MB-231 resulted in a
morphological transformation to a mesenchymal-like phenotype with increased migratory
potential. Tail vein inoculation of GSC-MDA-MB-231 cells highly increased the number
of lung metastasis in immunodeficient mice [314].
1.5.7 Interplay between TGF-β and BMPs
We have learned that TGF-β signaling is active in the bone microenvironment in es-
tablished skeletal metastasis and that TGF-β plays a key role in the self-amplifying
process of bone metastasis [119, 315, 113, 224]. BMP-7 can reverse TGF-β-induced re-
sponses such as EMT and restore an epithelial morphology possibly through induction
of MET, as introduced in section 1.3 (reviewed in [89, 104]). In primary breast cancer,
loss of BMP-7 mRNA expression is correlated with formation of clinically overt bone
metastases in patients [134]. Also, in line with these clinical observations, BMP-7 ex-
pression is inversely related to tumorigenicity and invasive behavior of human breast
cancer cell lines [134]. Systemic administration of human recombinant BMP-7 to mice
bearing MDA-MB-231 bone metastasis significantly inhibited tumor growth and reduced
the cancer-induced osteolytic response in vivo [134]. To support of these findings, BMP-
7 was overexpressed in MDA-BO2 and skeletal metastases were induced by either tail
vein or direct intra-osseous injection. BMP-7 overexpression significantly reduced the
number and size of metastatic bone lesions of MDA-BO2 cells [134]. Similar results were
obtained in models of metastatic prostate cancer [303]. Taken together, these findings
strongly suggest that BMP-7 can inhibit micro-metastasis formation and progression of
osteolytic breast cancer. Thus, BMP-7 could be considered a clinically relevant TGF-β
antagonist and be used in the treatment of osteolytic bone metastasis.
1.5.8 BMP antagonists
Extracellular BMP antagonists include Noggin, Chordin, twisted gastrulation (TSG),
and DAN family members such as DAN and Gremlin1 (reviewed in [48]). Negative
regulators of BMPs have been found to be involved in the establishment and progression
of osteolytic bone metastasis. Gremlin1 is undetectable in normal and benign breast
tissues but highly expressed in tumor-associated stromal cells. Furthermore, 55% of
breast cancer tissues, in a large selection of patient samples, were positive for GREMLIN1
[244]. In line with these observations, the BMP2 and BMP4 antagonists TSG1 and
CHORDIN were similarly expressed at higher levels in tumor tissues compared to normal
tissue sections [244]. Noggin inhibits BMP-2, BMP-4 and BMP-7, albeit with much lower
affinity for BMP-7 [252, 48]. This BMP antagonist was shown to be highly expressed
in osteolytic MDA-MB-231 versus the osteo-inductive T-47D or ZR-75-1 breast cancer
cells lines [252]. In addition, when Noggin was overexpressed in osteotropic cancer cells
progression of cancer-induced bone metastatic lesions was inhibited [252]. Thus, negative
regulators of BMPs might confer important restrictions on BMP signaling in the primary
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tumor but probably more importantly to the bone stroma and cells herein.
1.5.9 Targeting the breast cancer stroma
Loss of myoepithelial cells and basement membrane leads to progression of breast can-
cer from DCIS to invasive carcinoma (reviewed in [107]). These observations suggest
that breast tumorigenesis is determined not only by somatic or heritable properties of
tumor epithelial cells but also by complex interaction with cell types that compose the
breast cancer microenvironment. TGF-β is one of the signaling pathways that regulate
myoepithelial cell differentiation and play a crucial role in protecting the basement and
myoepithelial architecture [316]. This was directly evident when TβRII or Smad4 was
depleted which resulted in loss of myoepithelial cells and accelerated tumor progression
[316]. Also, resident fibroblasts within the interstitial compartment of a mammary carci-
noma transform from a quiescent to an activated state. Such mesenchymal cells support
malignant progression through enhanced invasive behavior, increased proliferation, and
induction of angiogenesis (reviewed in [317, 107]). Snail1, is a crucial regulator of the
aggressive gene expression program. Its expression is not only induced in cancer cells but
also in tumor infiltrated mesenchymal cells [317]. Strikingly, Snai1 -deficient fibroblast
showed impaired tissue-invasive and angiogenic functions in vivo due to defects in MT1-
MMP activity [317]. Thus, Snail1 activity is induced both in neoplastic epithelial cells
and in the interstitial fibroblasts and exerts key regulatory mechanisms in malignant
progression [317].
Collectively, these observations reinforce the findings that various types of human
cancers and cancer-associated stromal cells induce expression of normally latent, tran-
scription factors to acquire characteristics needed to execute invasion and metastasis.
Interference with the microenvironment could therefore also be targeted for treatment
of DCIS or metastatic disease.
Established minimal residual disease is incurable and although current palliative ther-
apies reduce morbidity, tragically they do not eliminate established bone metastasis
[113, 219, 119]. Clinically, at the time of diagnosis, tumor cells might already be present
at secondary sites. Therefore, inhibiting later stages of metastasis is a more appropriate
for therapy. Furthermore, targeting an inefficient biological process, such as progression
of micro- to macrometastatic lesion, should in theory be easier since fewer cells would
have to be inhibited [318]. Modulating the paracrine signaling between tumor cells with
the local host microenvironment present novel regimens for such therapies. Moreover,
careful stratification of patient groups according to the secondary site of metastasis is
crucial. Also, identification of markers of metastatic likely-hood and understanding of
the mechanisms and factors that influence organ-specific metastatic growth of breast
cancer are key steps towards developing such treatment regimes. Thus, tailored drugs
which target both the seed and the congenial soil hold great promises for future drug
discoveries in breast cancer.
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1.6 Pathobiology of TGF-β in fibrosis
In many pathological conditions the production of TGF-β is enhanced such as in dis-
eases of chronic fibrosis. This section will focus on the pro-fibrotic functions of TGF-β
in chronic organ fibrosis and the rational for directing therapies towards this pathway.
Figure 1.10: Schematic illustration of TGF-β signaling and its role in fibrogenesis. The TGF-β
signaling pathway contributes to the pathogenesis of fibrosis. Latent TGF-β is proteolytically activated
by matrix enzymes and the dimeric chemokine signal via heteromeric TβRII and ALK5 receptor com-
plexes and the intracellular mediators the Smads. TGF-β induce the transcription or repression of a vast
number of target genes. In fibrosis, enhanced TGF-β signaling results in excess accumulation of ECM,
inhibition of MMP activity, induction of EMT, and epithelial cell apoptosis (reviewed in [86, 294, 274]).
Thus, TGF-β promotes renal fibrogenesis by increasing the synthesis of ECM components and inhibit-
ing matrix degradation. Abbreviations: α-SMA, alpha smooth muscle actin; CTGF, connective tissue
growth factor; ECM, extracellular matrix; MMP, matrix metalloproteinase; PAI-1, plasminogen activa-
tor inhibitor-1; TIMP-1, tissue inhibitor of metalloproteinase-1; TSP-1, thrombospondin-1.
Fibrosis, is a disease that results from abnormal development of excess fibrous connective
tissue which typically induced by chronic inflammation [154, 86, 319]. In patients with
diabetic kidney disease, up-regulation of TGF-β1 mRNA and protein is found in the
glomerulus and tubulointerstitium [320, 321]. Patients suffering from diabetic nephropa-
thy present with increased urine and serum levels of TGF-β1 and this isoform is thought
to be predominantly responsible for fibrosis [322]. It is primarily produced by circulat-
ing monocytes and tissue macrophages and secreted in an inactive complex with latency
associated peptide (LAP). Several agents can activate the latent TGF-β by proteolytic
cleavage of the LAP and include thrombospondin-1 (TSP-1), MMP’s, αvβ6 integrin,
plasmin, and cathepsins (see figure 1.10). TGF-β is a pro-fibrotic factor operating at
several stages of fibrotic disease pathogenesis. One mechanism is through sustained
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deposition of extracellular matrix components which is triggered by TGF-β-induced ex-
pression of laminin, fibronectin, proteoglycans, type I collagen, type III collagen and
type IV collagen in tubular epithelial cells and glomerular mesangial cells (reviewed
in [154, 86, 323, 294]). CTGF expression is also enhanced upon TGF-β stimulation
[324] and this leads to further ECM accumulation through up-regulated expression of
fibronectin and type III and IV collagen. Furthermore, TGF-β-induced expression of tis-
sue inhibitors of metalloproteinases (TIMPs) and PAI-1 result in suppression of MMP’s.
The net effect being less matrix degradation [294, 154, 86]. Thus, TGF-β act on several
levels of fibrogenesis by enhancing synthesis of ECM components and inhibiting matrix
degradation thereby promoting pathological fibrosis (see figure 1.10). Moreover, an ad-
ditional pathomechanism of TGF-β is the induction of EMT in tubular epithelial cells
which transform into activated myofibroblasts [325, 326]. These myofibroblasts may be
responsible for additional deposition of interstitial matrix as they produce vast quantities
of ECM which accumulates in the kidneys.
Distinct functional roles for Smad2 and Smad3 have been identified in the TGF-
β1 induced fibrosis [326, 327]. Smad2 induce an anti-mitogenic response distinct from
Smad3 [327] and is specifically required for maintenance of an epithelial phenotype [327].
This is hypothesized to occur independently of TGF-β. In contrast, Smad3 is required
for TGF-β1-induced EMT [327] and necessary for CTGF, SNAIL1, PAI-1, and collagen
I expression and E-cadherin repression [326, 327]. Smad2 is required for the induction
of secreted MMP-2 [326] and both R-Smads are needed for the up-regulation of α-SMA
in response to TGF-β1 [326].
An additional cellular pathomechanism, whereby the TGF-β signaling pathway con-
tributes to fibrosis is by inducing apoptosis in tubular epithelial cells. This results in
tubular atrophy and is an indicator of poor prognosis in patients presenting with chronic
renal failure (reviewed in [154]).
The pro-fibrotic functions of TGF-β can be antagonized by exogenous addition of
BMP-7 [205, 106, 328]. This results in amelioration of glomerular and interstitial fi-
brosis in experimental models. Moreover, in interstitial and mesangial renal cells, the
physiological renal functions were restored by the antagonizing actions of BMP-7 on
TGF-β-induced responses. In detail, TGF-β-mediated up-regulation of PAI-1 was re-
duced which lead to restoration of MMP2 activity resulting in regular ECM degradation
[328]. Additionally, systemic administration of BMP-7 reversed the EMT response in-
duced by TGF-β through MET resulting in restoration of the normal renal epithelial
morphology in animal models of chronic renal fibrosis [106, 325, 105].
1.6.1 Targeted therapy to TGF-β in fibrosis
Fibrosis is one of the largest groups of disorders for which no effective therapy is available.
As for anti-TGF-β cancer drug discovery, recognizing the pleiotropic function of TGF-
β is critical when designing anti-fibrotic drugs targeting TGF-β [283, 294, 274, 329].
Identification of key down-stream mediators of the pro-fibrotic actions of TGF-β could
represent potential targets for anti-fibrotic therapy. Current drugs under investigation
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as anti-fibrotic agents and their status in the pipeline towards the clinic are reviewed
here and some are shown in table 1.6.
Several modalities have been pursued in the search for anti-TGF-β therapies targeting
various levels of the signaling pathway. Inhibiting the function and expression of TGF-
β ligands have been attempted with anti-TGF-β antibodies, antisense oligonucleotides,
and with TGF-β binding proteins. In a model of diabetic nephropathy, long-term ad-
ministration of neutralizing anti-TGF-β antibodies, recognizing all isoforms, prevented
glomerulosclerosis and attenuated expression of matrix proteins [279]. Furthermore,
adenoviral-delivery of antisense TGF-β prevented liver fibrosis in a similar model (re-
viewed in [274]). Also, the natural inhibitor of TGF-β, decorin, was found to attenuate
the overproduction of ECM components in a experimental mouse model of glomeru-
lonephritis [330].
On the level of TGF-β-receptors, administration of the a soluble extracellular do-
main of TβRII [331] or local administration of adenovirus-expressing dominant-negative
TβRII both displayed anti-fibrotic effects in a model of liver fibrosis [332]. Similar re-
sults were found with administration of synthetic peptides of the TβRIII β-glycan [333].
In addition, small molecule antagonists to ALK5 can block the actions of TGF-β in
vitro such as TGF-β-induced EMT, up-regulation of critical pro-fibrotic target genes,
and TGF-β-induced apoptosis [37, 294, 274]. When such ALK5 antagonists were ad-
ministered to animals with renal disease, several compounds significantly ameliorated
the TGF-β-induced fibrotic responses [37, 293, 334, 335, 299]. No notable systemic
side-effects were observed with any of these therapeutic strategies [37, 279, 332].
Another class of anti-fibrotic drugs are aimed at inhibiting bioactivators of latent
TGF-β. Such candidate targets include thrombospondin (TSP)-1, αvβ6 integrin, plas-
min, cathepsins and MMPs [336, 47]. Antisense oligonucleotides to TSP-1 were shown
to inhibit activation of TGF-β and downstream Smad signaling resulting in diminished
accumulation of ECM and reduced glomerulonephritis in rats with progressive renal dis-
ease [336].
Moreover, CTGF, the downstream mediator and target gene of TGF-β was recently
identified to activate TGF-β signaling. Hence, functioning in a feed-forward proteolytic
autocrine loop [177]. Targeting CTGF by antisense oligonucleotides in experimental
mouse models of diabetic kidney disease resulted in inhibition of TGF-β activation, de-
creased ECM accumulation and reduced albuminuria [337]. A clinical trial is underway
where patients with diabetic nephropathy will be treated with anti-CTGF antibodies
(reviewed in [329, 283]).
Clinical disadvantages of TGF-β inhibition is the abrogation of immunosuppressive
and anti-tumor functions of this growth factor which could lead to hyper-inflammatory
and pro-tumorigenic states (reviewed in [283, 274]). Local and targeted drug adminis-
tration are therefore recognized as the most promising methods for inhibiting fibrosis.
Though it has yet to be shown that fibrosis progression can be halted by inhibiting
TGF-β signaling in patients, more and more evidence in animal models suggest that
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1.7 Outline of the thesis
Since the discovery and cloning of TGF-β tremendous scientific effort has led to a so-
phisticated understanding of the multifunctional actions of this pleiotropic growth factor.
TGF-β regulates a myriad of processes in normal tissues and in disease pathogenesis.
In cancer, TGF-β often suppress early tumorigenesis and later enhance tumor progres-
sion. The pathogenic role of TGF-β signaling is an attractive target for therapeutical
intervention. However, in order to specifically direct therapy to this branch of TGF-β
signaling a deeper understanding of its cellular actions in specific contextual settings is
crucial. Several studies are presented in this thesis, which aim at unraveling the molec-
ular mechanisms of TGF-β in the pathogenesis of breast cancer, bone metastasis and in
renal fibrosis.
• In chapter 2 we characterize the role of two downstream mediators of TGF-β
signaling, namely Smad2 and Smad3, in breast cancer metastasis. We identify
crucial differences in their target gene regulation patterns and their individual role
in breast cancer metastatic bone disease.
• Chapter 3 describes the function of HMGA2 a TGF-β-inducible, Smad-dependent,
gene. We identify how TGF-β employs HMGA2 to elicit epithelial to mesenchymal
transition of breast cancer cells.
• BMP-7 has been shown to inhibit progression of metastasis possibly through an-
tagonizing TGF-β-induced EMT. In chapter 4, we characterize the functional type
I receptor for BMP-7 in breast cancer cells and perform a head-to head compar-
ison of breast cancer cells over-expressing either BMP-7 ligand or a continuously
activated BMP-7 receptor. By this mean we analyze whether BMP-7 acts directly
on the breast cancer cells and/or on the cells in the bone stromal environment.
• In chapter 5 we characterize the in vitro and in vivo functions of a novel TGF-β
receptor kinase inhibitor, GW788388. We focus on the inhibitory effects of this
compound in TGF-β-induced EMT and growth arrest. Furthermore we administer
the compound to mice presenting with severe renal fibrosis caused by diabetes.
• Chapter 6 recapitulates the findings described in this thesis and we discuss how
our research contributes to the wider context of the TGF-β field.
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Abstract
Transforming growth factor (TGF)-β can suppress and promote breast cancer progres-
sion. How TGF-β elicits these dichotomous functions and which roles the principle
intracellular effector proteins Smad2 and Smad3 have therein, is unclear. Here we in-
vestigated the specific functions of Smad2 and Smad3 in TGF-β-induced responses in
breast cancer cells in vitro and in a mouse model for breast cancer metastasis. We stably
knocked down Smad2 or Smad3 expression in MDA-MB-231 breast cancer cells. The
TGF-β-induced Smad3-mediated transcriptional response was mitigated and enhanced
by Smad3 and Smad2 knockdown, respectively. This response was also seen for TGF-β-
induced vascular endothelial growth factor (VEGF) expression. TGF-β induction of key
target genes involved in bone metastasis, were found to be dependent on Smad3 but not
Smad2. Strikingly, whereas knockdown of Smad3 in MDA-MB-231 resulted in prolonged
latency and delayed growth of bone metastasis, Smad2 knockdown resulted in a more ag-
gressive phenotype compared to control MDA-MB-231 cells. Consistent with differential
effects of Smad knockdown on TGF-β-induced VEGF expression, these opposing effects
of Smad2 versus Smad3 could be directly correlated with divergence in regulation of tu-
mor angiogenesis in vivo. Thus, Smad2 and Smad3 differentially affect breast cancer
bone metastasis formation in vivo.
Abbreviations
ALK, activin receptor-like kinase; BLI, bioluminescent imaging; BMP, bone morphogenetic protein;
CTGF, connective tissue growth factor; EMT, epithelial to mesenchymal transition; GAPDH, glycer-
aldehyde 3’phosphate dehydrogenase; GFP, green fluorescent protein; IL-11, interleukin 11; miR RNAi,
micro RNA interference; MMP, matrix metalloproteinase; N-T control, non-targeting control; PAI-1,
plasminogen activator inhibitor 1; PTHrP, parathyroid hormone-related protein; SDS-PAGE, sodium
dodecyl sulphate-polyacrylaminde gel electrophoresis; P-Smad, phosphorylated Smad; R-Smad, receptor
regulated Smad; Smad, small phenotype and mothers against decapentaplegic related protein; TGF-




Metastatic breast cancer is one of the leading causes of death from cancer in women.
Transforming growth factor (TGF)-β is frequently overexpressed in human breast tu-
mors and the tumor-associated stroma and its expression correlates with poor prognosis
and metastasis [1, 2, 3, 4]. TGF-β is the prototypic member of a large family of evolu-
tionarily conserved pleiotropic cytokines, including three TGF-β isoforms, activins, and
bone morphogenetic proteins (BMPs) [5, 6, 7]. TGF-β family members have critical and
specific roles during embryogenesis and later in maintaining tissue homeostasis. Pertur-
bations in their signaling pathways have been linked to a diverse set of developmental
disorders and diseases, including cancer, fibrosis and auto-immune diseases [8]. These
factors signal through specific sets of type I and type II serine/threonine kinase recep-
tors. TGF-β bind to the TGF-β type II receptor (TβRII) which in turn trans-activates
the TGF-β type I receptor, also termed activin receptor-like kinase (ALK)5. Activated
ALK5 recruits and phosphorylates the receptor-regulated Smads (R-Smads) Smad2 and
Smad3. These can then form heteromeric complexes with Smad4, translocate to the
nucleus, and control the activation or repression of target genes [9]. Smad2 and Smad3
are also used by activin as downstream signaling mediators [10], whereas BMPs use the
R-Smads Smad1, 5, and 8 [11]. Smad2 and Smad3 are highly conserved proteins with
83.9% amino acid sequence identity (Fig. 1A) The major structural difference between
Smad2 and Smad3 is in the mad homology 1 domain where Smad2 has two short peptide
inserts, amino acids 21-30 and 79-108 [12]. The latter insert imposes steric constraints
that prevent Smad2 from binding to DNA [12]. Smad3 on the other hand readily binds
DNA in complex with Smad4.
TGF-β has a dual role in tumorigenesis [5]. It inhibits growth of early carcinomas
whereas in advanced stages of carcinogenesis TGF-β promotes tumor growth. TGF-β can
further stimulate tumor progression and metastasis by inducing epithelial to mesenchy-
mal transition (EMT) and invasion of epithelial cancer cells, [6, 13] and by suppressing
anti tumor immune responses [6, 8]. Furthermore, several studies have shown that TGF-
β can promote tumor angiogenesis and thereby create a favorable microenvironment for
rapid tumor growth and dissemination [13, 14]. In breast cancer bone metastasis target
genes of TGF-β are essential for cell homing, establishment of micrometastatic lesions,
and in the self-amplifying process of tumor-induced bone resorption [15, 16, 17].
The TGF-β signaling pathway has been extensively studied in cancer patients and
in animal models of xenografted tumors and metastasis. In human cancers diffuse phos-
phorylated Smad2 (P-Smad2) staining has been observed indicative of active TGF-β
signaling [18, 19, 20]. Disrupting TGF-β signaling in human breast cancer cells induced
tumorigenesis but inhibited invasion and metastasis to lungs after tail vein injection.
This was studied by ectopic overexpression of mutated R-Smads or receptors mutated
at the R-Smad binding site [21, 22, 23, 24]. Also, when using ALK5 inhibitors in vivo
primary tumor growth was inhibited and the number of metastases was reduced [25, 26].
In a model of mouse breast cancer metastasis of 4T1 cells, administration of anti-TGF-β
antibody to mice reduced the number of metastasis by 50-60% [27]. In the 4T1 and
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the MDA-MB-231 tumor models, systemic administration of a soluble TβRII protein or
dominant negative TβRII overexpression, respectively, displayed anti-metastatic effects
[16, 28].
Several studies have provided evidence that Smad2 and Smad3 have different tran-
scriptional functions and profiling studies have revealed distinct target genes for Smad2
and Smad3 [29, 30]. Also, whereas mice deficient in Smad2 are embryonic lethal, Smad3
deficient mice are viable [31, 32, 33]. These observations clearly suggest that Smad2
and Smad3 have distinct functions in vivo. In a skin cancer model in mice, homozy-
gous deletion of Smad2 in keratinocytes triggered an EMT phenotype in tumors. This
was observed by down-regulation of E-cadherin expression and induction of Vimentin,
α-smooth muscle actin, and the E-Cadherin repressor Snail [34]. In contrast, overex-
pression of activated Smad2/3 was shown to increase cell motility in a squamous skin
tumorigenesis models [21]. Nevertheless, the specific functions for Smad2 and Smad3 in
breast cancer are not known.
We and others previously reported that silencing Smad4 in breast cancer cells delayed
the formation of bone metastasis in vivo [19, 35]. To particularly study the contribution
of TGF-β signaling in metastasis and explore the exact role of either Smad2 or Smad3, we
stably silenced these molecules in an osteotropic clone of the human breast cancer cell line
MDA-MB-231. A mouse model of bone metastasis was used to study the differential role
of the R-Smads in metastatic progression [35, 36]. Tumor growth and metastasis were
quantified in vivo by bioluminescent imaging (BLI). Our results show that, depending
on the type of R-Smad silenced the metastatic potential of the human breast cancer cells
is differentially and significantly affected.
Results
Specific silencing of Smad2 or Smad3 using miR RNAi
The TGF-β signaling cascade plays crucial roles in breast cancer metastasis. We previ-
ously found that silencing Smad4 in MDA-MB-231 cells inhibits bone metastasis forma-
tion in vivo [35]. In order to examine direct effects of TGF-β signalling and in particular
of the TGF-β R-Smads, we designed and cloned miR RNAi constructs specifically target-
ing either Smad2 or Smad3. These R-Smads are highly homologous with the exception of
the MH1 domain (Fig. 1A) where Smad2 has two additional short peptide inserts com-
pared to Smad3 [12]. The targeting miR RNAi sequences were therefore designed to the
additional peptide stretches in the MH1 domain of Smad2 and to the flanking sequences
of this region in Smad3. We first examined the efficiency of knockdown of the miR RNAi
constructs in a pcDNA 3.1 vector by co-transfection with FLAG-tagged Smad2 or Smad3
in COS cells. A non-targeting (N-T) miR RNAi was used as control. As seen by im-
munoblot analysis (Fig. 1B lane 4 and 8) both Smad2 and Smad3 were specifically and
efficiently silenced by the corresponding miR RNAi. The miR RNAi pcDNA constructs
were tested on a specific TGF-β-inducible luciferase reporter in COS and MDA-MB-231
cells, the TGF-β Smad3/Smad4 responsive CAGA-luciferase reporter. The miR RNAi
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Figure 2.1: Specific silencing of Smad2 or Smad3 using miR RNAi vectors. (A) Schematic illus-
tration of the Smad2 and Smad3 proteins. (B) Immunoblot analysis of Smad2 and Smad3 in COS cells.
FLAG-tagged Smad2 or Smad3 were co-transfected with miR RNAi DNA constructs. Protein lysates
were separated by SDS-PAGE and analyzed by western blot analysis. Antibodies recognizing Smad3
and Smad2/3 were used. Actin served as a loading control. (C) CAGA-renilla luc reporter transiently
co-transfected in COS cells with miR RNAi and Smad3-FLAG constructs in the absence (white bars)
or presence (black bars) of TGF-β. Non-targeting (N-T) vs Smad3 miR RNAi ￿￿P (P=0.0088), TGF-
β-induced control vs TGF-β-induced Smad2 miR RNAi ∗∗∗P (P=0.0006), TGF-β-induced control vs
TGF-β-induced Smad3 miR RNAi with Smad3-FLAG ￿￿￿P (P=0.0005). (D) Quantitative immunoblot
analysis of lentiviral infected MDA-MB-231 clones stably expressing miR RNAi’s for Smad2, Smad3
or a N-T control. The relative band intensities of Smad2 or Smad3 are presented below. Values were
corrected for equal loading with a non- specific background band. Error bars indicate mean±S.D.
targeting Smad3 significantly reduced the TGF-β-induced CAGA-luc activity (Fig. 1C).
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The basal level of activity was similarly reduced suggesting that knockdown of Smad3
inhibits autocrine TGF-β signaling. This effect could be rescued by overexpression of
Smad3-FLAG. Smad2 miR RNAi significantly potentiated the TGF-β-induced activity
(Fig. 1C), suggesting that more Smad3 is accessible at the promoter when Smad2 is
eliminated. Neither of the miR RNAi constructs had an effect on the BMP-responsive
reporter indicating that the miR RNAi’s selectively target Smad2 or Smad3 and not
BMP R-Smads or Smad4 (data not shown). The miR RNAi constructs were sub-cloned
into lentiviral vectors and MDA-MB-231-luc cells were infected. Several single cell clones
stably expressing miR RNAi’s were selected and characterized. As shown in Fig. 1D,
the stable clones showed efficient knockdown for Smad2 or Smad3. The protein levels
of Smad2 in the Smad2 miR RNAi clones were 90-95% reduced. The best knockdown
clones with miR RNAi for Smad3 showed a 70-80% reduction of Smad3 protein levels.
No cross-targeting was observed for either construct.
Thus, Smad2 and Smad3 are potently and specifically silenced by lentiviral delivered miR
RNAi. Binding of TGF-β to its receptor leads to trans-phosphorylation of R-Smads. In
order to determine if the levels of phosphorylated Smad2 were elevated in clones silenced
for Smad3 and vice versa, we stimulated the stable cell lines with TGF-β (Fig. S1).
We further confirmed that a very sufficient knockdown is obtained with the miR RNAi’s
since no P-Smad2 or P-Smad3 were observed in Smad2 and Smad3 silenced clones, re-
spectively. Furthermore, we found that the level of phosphorylation of one R-Smad
was unchanged when the other was silenced. This suggests that the TGF-β-induced
activation of R-Smads in MDA-MB-231 cells is non-competitive.
Proliferation of miR RNAi stable clones
Next, we examined if silencing Smad2 or Smad3 would affect in vitro cellular proliferation
of MDA-MB-231 cells. Relative cell growth profiles for Smad2 miR RNAi, Smad3 miR
RNAi, and N-T control miR RNAi stable cell lines were monitored for four consecutive
days (Fig. 2A). The Smad3 and the N-T control miR RNAi clones displayed very similar
growth curves. The in vitro proliferation of the Smad2 miR RNAi clone was significantly
lower compared to the other two cell lines (Fig. 2A).
Smad2 and Smad3 are crucial for TGF-β-induced migration
Altered migratory and tumorigenic potential of cancer cells can be simulated by in
vitro model systems such as transwell migration. TGF-β induced transwell migration of
MDA-MB-231 cells and this was blocked by the ALK5 inhibitor, SB431542 (Fig. 2B).
We tested if silencing either Smad2 or Smad3 would affect the TGF-β-induced migratory
phenotype of these cells. When Smad2 or Smad3 were knocked down TGF-β failed to
stimulate migration. Thus, both Smad2 and Smad3 are critical for TGF-β induced
migration of MDA-MB-231 cells in vitro. To characterize the tumorigenic potential of
the cells we performed a colony formation assay in soft agar. We observed no difference
in the number of colonies formed or in the size of the aggregates (data not shown).
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Figure 2.2: Effect of miR-mediated knockdown of Smad2 or Smad3 on MDA-MB-231 cell
viability and TGF-β induced migration. (A) Cell proliferation assay of MDA-MB-231 stable clones.
The relative growth of Smad2 miR RNAi c1 (circle), Smad3 miR RNAi c3 (square), and N-T miR
RNAi c3 (triangle) cells was followed for four consecutive days by measuring mitochondrial activity
(MTS assay). Bars represent the mean of four measurements ±S.D. N-T control and Smad3 miR RNAi
versus Smad2 miR RNAi at day 3 and 4 ∗∗∗P (B) Quantification of transwell migration of MDA-MB-231
cells with or without TGF-β for 20 h. N-T miR RNAi cell lines c1 and c3 (black bars). MiR RNAi
silenced Smad2 c1 and Smad3 c3 (white bars). TGF-β induced migration was inhibited in cells treated
with the ALK5 inhibitor, SB431542 (grey bars). Values are given as mean ±S.D. ∗∗∗P of TGF-β-induced
Smad2 miR RNAi (P=0.0006), Smad3 miR RNAi (P=0.0002), and SB431542 (P≤0.0001) versus TGF-
β-induced N-T control c3. (C) Representative images of MDA-MB-231 stable clones on transwell filters,
fixed and stained with crystal violet after migration.
Silencing Smad3 affects TGF-β target genes
Important TGF-β responsive genes involved in the vicious cycle include interleukin (IL)-
11, parathyroid hormone-related protein (PTHrP), and connective-tissue growth factor
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(CTGF) [15, 16, 35, 37]. We hypothesized that silencing either Smad2 or Smad3 would
have an effect on the regulation of TGF-β target genes and perhaps give an indication of
the metastatic potential of the cells. In order to look at early target genes of TGF-β we
extracted RNA at 6 and 24 hours post stimulation and performed quantitative real time
PCR analysis. An increment of IL-11 mRNA levels was seen after 6 hours stimulation
with TGF-β in N-T control and Smad2 miR RNAi cells (Fig. 3A). When Smad3 was
silenced this induction was significantly inhibited in multiple clones. Also, TGF-β-
induced PAI-1 expression levels were significantly reduced in Smad3 knockdown cells
compared to the control and Smad2 knockdown cells (Fig. 3B). We also examined the
TGF-β-induced up-regulation of CTGF (Fig. 3C). CTGF mRNA levels were significantly
increased after TGF-β stimulation in the N-T control cells. In Smad2 and Smad3 miR
RNAi cells both basal and TGF-β-induced CTGF mRNA levels were reduced. However,
the fold induction with TGF-β stimulation was comparable to the N-T control. PTHrP
mRNA levels were 5 fold induced by TGF-β in all three cell lines (Fig. 3D). To control
for off-target effects of the miR RNAi’s we used Smad2 and Smad3 shRNAi lentiviral
constructs. This resulted in 70-80% knockdown of endogenous protein levels (Fig. S2A).
The gene expression analysis was repeated and the effect on TGF-β-induced target genes
were confirmed in MDA-BO2 cells stably expressing shRNAi for Smad2 and Smad3 (Fig.
S2B-F). Thus, independent approaches for Smad2 or Smad3 knockdown gave nearly
identical results indicating that effects of the miR RNAi’s are on-target.
Smad2 and Smad3 differentially affect bone metastasis
Our observations in vitro suggest that both R-Smads are necessary for TGF-β-induced
migration, whereas Smad3 appears to be more important in the regulation of TGF-β
target genes. We evaluated the specific effect of either Smad2 or Smad3 in an experi-
mental mouse model of bone metastasis where osteotropic MDA-MB-231-luc cells were
inoculated into the left heart ventricle [35, 36]. This model recapitulates late stages of
metastatic progression, namely, survival in the circulation, extravasation, and establish-
ment of metastases at secondary sites. Mice were injected with breast cancer cells stably
silenced for either Smad2, Smad3, or a N-T control. Establishment and growth of bone
metastatic cells was followed in time with BLI (Fig. 4A). The metastatic growth was
plotted as the average total body flux of each experimental group in time (Fig. 4B).
Smad2 miR cells showed a significantly more aggressive phenotype compared to both the
N-T control and Smad3 miR cell lines (P≤0.001 versus Smad3 miR RNAi). In contrast,
Smad3 silenced cells displayed a prolonged lag time of tumor growth in the bones (Fig.
4B). This can be more readily observed from the insert of Fig. 4B which demonstrates
the tumor growth from day 21 to 35. At this stage the Smad2 silenced metastases are
growing at an exponential rate, whereas the Smad3 miR RNAi cells are still in a ”lag
phase” (P=0.046 Smad2 versus Smad3 miR RNAi). N-T control miR RNAi cells are
also starting to grow exponentially at this phase. However, at the end of the experiment
there was no significant difference in the total BLI emission from Smad3 miR versus
N-T control miR injected mice (Fig. 4B). No significant differences were detected in the
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Figure 2.3: Knockdown of Smad2 or Smad3 differentially affects TGF-β-induced target gene
expression in MDA-MB-231 cells. Quantitative RT-PCR analysis of TGF-β-induced target genes.
Relative expression level of IL-11 (A), PAI-1 (B), CTGF (C), and PTHrP (D) correlated to GAPDH in
stable MDA-MB-231 miR RNAi knockdown clones. Cells were stimulated with (black bars) or without
(white bars) TGF-β for 6 hours. ∗∗∗P of stimulated N-T control miR RNAi versus Smad3 miR RNAi
cells of IL-11 and PAI-1 mRNA expression levels. Error bars indicate mean±S.D.
total number of metastases per animal in each of the three groups (Fig. 4C). However,
it appears that there is a tendency for more metastases at an earlier stage in the Smad2
miR RNAi group compared to the N-T and Smad3 miR RNAi groups. Fluorescence
imaging was used to visualize the spatial volume of the tumors in vivo and examine if
the miR RNAi were still actively being expressed. This can be done, since the lentivirally
inserted miR RNAi co-cistronically express GFP. As seen in Fig. 4D, showing a Smad2
miR RNAi injected mouse, the bone metastases were highly GFP positive. Radiogra-
phies of the same animal reveal the existence of osteolytic bone lesions at the same sites.
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Figure 2.4: Knockdown of Smad2 and Smad3 differentially affect the metastatic profile of
MDA-MB-231 cells. (A) In vivo BLI at day 21, 28, and 35 of three representative mice injected
with MDA-MB-231 luc cells stably expressing N-T control, Smad2, or Smad3 miR RNAi. Ventral
images are shown. (B) Average total flux of BLI from each experimental group followed in time. N-T
miR RNAi (Triangle, dotted line), Smad2 miR RNAi (circle) Smad3 miR RNAi (square). Asterisks
indicate statistically significant difference in total flux at day 45 between Smad2 and Smad3 miR RNAi
metastases ∗∗∗P. Insert show an enlargement of the lower graph from day 21-35. At day 35 Smad2
miR tumor-bearing animals have significantly higher tumor burden compared to Smad3 miR mice ∗P
(P=0.0462). A trend for reduced total flux in Smad3 miR animals compared to N-T control animals
was observed (P=0.162). (C) Average amount of metastases per animal in each experimental group.
(D) Fluorescent in vivo imaging of Smad2 miR RNAi mice and below the corresponding radiographies.
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By re-establishment of cell lines from bone marrow aspirates of metastases we found that
the stable cell lines were continuously silenced for the respective R-Smad even after in
vivo passaging (Fig. S3).
Bone metastases are detected as areas of low mineral density where the bone has been
extensively resorbed by tumor-induced osteoclasts (Fig. 5). All experimental groups dis-
played strong osteolytic metastases. In general, the bone metastases were located in the
distal femur, proximal tibia, vertebra, mandibula, and os coxae (Fig. 5A arrow heads).
When comparing radiographies of mice from different experimental groups, with similar
BLI emission, we found no apparent differences in bone destruction (Fig. 5A). This
observation was further substantiated by histomorphologic analysis (Fig. 5A and B).
Masson-Goldner staining revealed extensive bone loss and nearly complete replacement
of the bone marrow with breast cancer cells.
Figure 2.5: Figure 5 Radiographic and histological analysis of bone metastases in mice intrac-
ardially injected with MDA-MB-231 cells with or without Smad2 or Smad3 specific knockdown
(A) Radiographies of three representative mice with N-T control, Smad2, and Smad3 miR RNAi MDA-
MB-231 bone metastases. Arrowheads indicate sites of osteolytic lesions. The BLI values of the tibial
regions is given in the lower part of the X-ray. Dorsal side of mice are shown. (B) Histological analysis of
tibial proximal metaphyses corresponding to the radiography above. Massons-Goldner trichrome stain-
ing of sections to visualize mineralized bone. 4 x magnification. Abbreviations: B, bone; GP, growth
plate; T, tumor.
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Smad2 and Smad3 differentially regulate angiogenesis
We observed significant differences in metastatic growth of the Smad2 and Smad3 miR
RNAi cell lines in vivo. This was seen already at early stages of the metastatic process
where the initial growth of Smad3 miR RNAi tumors at the metastatic site was inhib-
ited. At this phase angiogenesis is critically important for metastatic growth [15, 38].
We therefore hypothesized that Smad2 and Smad3 could have differential effects on an-
giogenesis. VEGF is a key regulator of angiogenesis and directly associated with worse
prognosis in patients with invasive breast cancer metastasis [39]. Inhibition of VEGF
signaling results in inhibition of breast cancer metastasis [40]. VEGF is a direct TGF-β
target gene and Smad3, but not Smad2, was previously shown to mediate TGF-β-induced
VEGF production [41, 42].
We therefore analyzed the expression of VEGF-A in the stable miR RNAi clones
after 6 and 24 hour TGF-β stimulation (Fig. 6A). TGF-β significantly induced VEGF
expression at both time points. Interestingly, when Smad2 was silenced the basal VEGF
levels were dramatically increased. In cells lacking Smad3 the TGF-β-induced VEGF
expression was lost. We next examined the amount of VEGF secreted in conditioned
medium from the miR RNAi clones after TGF-β stimulation (Fig. 6B). In the N-T
control miR RNAi cells, TGF-β induced VEGF secretion by 3 fold. In Smad2 miR
RNAi cells, 3 fold more VEGF was secreted compared to the N-T control and Smad3
miR RNAi under un-stimulated conditions. This secretion could be further enhanced
by TGF-β stimulation. In Smad3 miR RNAi cells TGF-β was unable to induce VEGF
production. Thus, the VEGF secretion studies confirmed our transcription profiling
results.
To further verify if our observations in vitro would explain the differences in tumor
burden in vivo, we visualized the micro-vascular network in the bone metastastatic sec-
tions by CD31 (PECAM-1) immunolocalization [36, 38]. Images of the preparations were
evaluated by blinded quantification of the micro-vascular density (MVD) and computer
analysis of the % capillary area (Figure 6C, 6D, and 6E). Significantly more vascular
structures were observed in bone metastases originating from Smad2 miR RNAi cells
compared to N-T and Smad3 miR RNAi cells. Furthermore, the expression of the pro-
angiogenic factors hypoxia-inducible factor-1α and placenta growth factor (PlGF) was
enhanced in RNA isolated from Smad2 miR RNAi metastases compared to N-T and
Smad3 miR RNAi (Fig. S4). Together these results demonstrate that Smad2 and Smad
3 differentially regulate tumor angiogenesis thus, providing an explanation for the ob-
served differences in tumor growth at bone metastatic sites.
Discussion
The concept that the TGF-β signaling pathway plays an important role in tumorigenesis
and metastases of breast cancer is well established [5] in clinical and in vivo studies [43].
Recently, we and others demonstrated a pro-metastatic role of Smad4 in breast cancer
bone metastasis of MDA-MB-231 cells [19, 35]. Due to the nature of Smad4 as a central
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Figure 2.6: Smad2 and Smad3 differentially affect tumor induced angiogenesis (A) Real-time Q
PCR analysis of the relative VEGF-A mRNA expression in N-T control, Smad2, and Smad3 miR RNAi
MDA-MB-231 clones. GAPDH was used as a housekeeping gene. Cells were stimulated with TGF-β
(black bars) or without (white bars) for 6 hours. (B) VEGF protein secretion in the three stable miR
RNAi cell lines measured by ELISA. Data is presented at amount of VEGF secreted per ml conditioned
medium. ∗∗∗P of Smad2 miR RNAi versus Smad3 and N-T control miR RNAi cells. Black bars indicate
samples stimulated with TGF-β for 15 hours. Error bars indicate mean±S.D. (C) Quantification of
CD31 staining of bone tumor sections as the % stained area. Asterisks indicate statistically significant
more CD31 staining in Smad2 miR RNAi metastases ∗P versus Smad3 (P=0.033) and N-T control miR
RNAi (P=0.046) metastases. (D) Micro vascular density (MVD) in CD31 stained sections from N-T
control, Smad2, and Smad3 miR RNAi metastases. A significant higher MVD is observed in Smad2 miR
RNAi metastases ∗∗∗P versus N-T control and ￿￿￿P (P=0.0086) versus Smad3 miR RNAi metastases.
Error bars indicate mean±S.E.M. (D, right) Representative images of CD31 staining in bone sections
from mice injected with Smad2 and Smad3 miR RNAi MDA-MB-231 cells.
regulator of both TGF-β and BMP signaling [35, 36] we decided to further study the
role of the TGF-β Smad-dependent pathway in breast cancer metastasis by specific
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knockdown of either Smad2 or Smad3.
Smad2 or Smad3 expression was eliminated by miR RNAi in the highly aggressive breast
cancer cell line MDA-MB-231 and the effect of knockdown was evaluated in several in
vitro assays. Furthermore, the metastatic potential of the cells was characterized in a
mouse model of bone metastasis [38]. Our in vivo model recapitulates late events in the
metastatic cascade including survival in the circulation, homing to bone, extravasation
in the bone, and establishment of micrometastatic disease [44]. We show, for the first
time, that Smad2 and Smad3 have distinct roles in osteotropic breast cancer. Strikingly,
Smad2-silenced MDA-MB-231 cells were considerably more aggressive in vivo than cells
silenced for Smad3 or a non-targeting control, despite the fact that they displayed slightly
slower proliferation in vitro. In contrast, Smad3 knockdown cells showed a prolonged
lag phase of tumor growth in the bone microenvironment. These observations are in
line with recent findings by Hoot et al [34] who reported that homozygous deletion of
Smad2 potentiated EMT and tumor aggressiveness in a skin cancer model. In these
cells a direct up-regulation of critical EMT target genes such as SNAIL and Vimentin
was observed along with a reduced E-Cadherin expression in the Smad2−/− skin tumors
compared to wild type tumors. We were unable to study the role of EMT in our model
which recapitulates later stages of tumorigenesis [35]. Also, Smad2 heterozygous mice
displayed accelerated tumor formation and progression compared to wild type control
mice [45] and reduced P-Smad2 staining was correlated with a shorter overall survival
in patients with stage II breast cancer [20]. Taken together, these observations support
our findings regarding the pro-metastatic effects of Smad2 knockdown in breast cancer
and suggest that Smad2 has a tumor suppressor role. Bone metastases originating from
Smad3 knockdown cells took considerably longer to develop into overt bone lesions.
Nevertheless, at the end of the experiment growth of the Smad3 miR RNAi tumors
was similar to the N-T control miR RNAi tumors perhaps due to the fact that the
knockdown efficiency of Smad3 is not absolute (70-80%). Alternatively, the tumor might
induce alternative responses to compensate for the loss of Smad3 as suggested from our
findings on HIF-1α and PlGF expression in Smad3 miR RNAi metastases ([46, 47]).
The increased lag phase of bone metastatic growth of Smad3-silenced cancer cells may
be explained by altered expression of TGF-β target genes that were no longer responsive
to TGF-β when Smad3 was silenced, whereas Smad2 knock down had limited effect on
these target genes.
In particular, critical genes involved in the vicious cycle of osteolytic bone metastases,
including IL-11, CTFG, and PAI-1, were affected. IL-11 is an important osteolytic factor
secreted by the cancer cells to stimulate osteoclastic bone resorption. CTGF and PAI-
1 have been reported to stimulate survival in the bone microenvironment through the
induction of angiogenesis [15, 48]. Comparable observations were reported for MDA-
MB-231 cells knocked down for Smad4 [19, 35].
Blocking the function of endogenous Smad3 in the MCF10A-derived breast cancer cells
strongly suppressed formation of metastatic foci in lungs of mice [22, 23], thus supporting
our Smad3 findings. In the same study overexpression of a defective binding mutant of
Smad3 enhanced malignancy of primary tumors [23]. This is in line with previous findings
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where modulation of TGF-β receptors had no effect or even promoted primary tumor
growth and at later stages of tumorigenesis significantly reduced invasion and metastatic
progression [24, 25, 26, 27]. In our hands, TGF-β-induced migration of MDA-MB-
231 cells was dependent on both Smad2 and Smad3. Overexpression of a C-terminal
truncated mutant of Smad3 was previously shown to have the same effect on TGF-
β-induced migration of MCF10A cells [22]. Taken together these results suggest that
Smad3 is critical for stimulation of tumor growth and metastasis.
Angiogenesis is critically important for metastatic growth when the tumor reaches
a size that outgrow the normal blood supply [38, 44]. We reckoned that Smad3 miR
RNAi metastases grow slower in this phase, which can be explained by a diminished
ability to stimulate angiogenesis in the bone metastases. Indeed, significant differences
in VEGF-A mRNA expression and VEGF protein secretion were observed. In the Smad3
miR RNAi cell line the TGF-β-induced up-regulation of VEGF was lost, whereas in the
Smad2 miR RNAi cell line both VEGF expression and secretion was significantly en-
hanced. Enhanced angiogenesis was also observed in tumor metastatic sections in Smad2
miR RNAi inoculated animals in agreement with the notion that VEGF directly corre-
lates with the degree of malignancy [39]. In line with our findings, Smad2 was found
to mediate secretion of factors with anti-angiogenic properties, whereas Smad3 induced
the secretion of pro-angiogenic factors by other epithelial cells [49]. Furthermore, con-
ditioned medium from Smad2 knockout fibroblasts induced proliferation of endothelial
cells, whereas medium from Smad3 knockout cells had no effect [49]. These findings
support our observations namely that loss of Smad2 potentiate angiogenesis and loss of
Smad3 inhibit tumor angiogenesis in breast cancer cells.
We show, for the first time, that Smad2 and Smad3 play distinct roles in breast
cancer bone metastasis of MDA-MB-231 cells. Loss of Smad2 significantly increase the
metastatic potential whereas loss of Smad3 shows a delayed growth of micro-metastases.
These differences can be explained by the distinct roles of Smad2 and Smad3 in tumor-
induced angiogenesis. In conclusion, our observations provide evidence that the Smad3
pathway mediates pro-metastatic activities in invasive cells and suggest that Smad2 has
tumor suppressor activities. Current therapeutic strategies are aiming at antagonizing
the TGF-β receptors thereby completely blocking signaling of both Smad2 and Smad3.
Despite the validity of this approach our findings indicate that selectively targeting
of Smad3 may lead to more effective therapeutic responses in the treatment of bone
metastasis.
Materials and Methods
Cell culture and reagents
MDA-MB-231-luc, MDA-BO2-luc, COS, HEK293T cells were maintained as previously de-
scribed [35, 36]. Cells were stimulated with TGF-β3 and BMP6 at 5 and 100 ng/ml, respec-
tively. SB431542 (Tocris bioscience, Bristol, UK) was used at 10 µM as previously reported
[50].
82
Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor
angiogenesis
Constructs and cloning
We used BLOCK-iT Pol II micro RNA interference (miR RNAi) technology (Invitrogen, Breda,
The Netherlands) for transient and stable knockdown of Smad2 and Smad3 (see supplementary
methods for details).
Animals and surgical procedures
4-5 week old female BAlb-c nu/nu mice (Charles River, Maastricht, The Netherlands) were
anaesthetized with isofluorane 0.8 l/min and 1x105 freshly harvested MDA-MB-231-luc miR
RNAi cells in 100 µl PBS were inoculated into the left heart ventricle (n=10 per group) [35, 36].
Injections were done with 27G syringes. All animal experiments were approved and carried out
according to the guidelines provided by the local animal welfare committee.
Statistical analysis
All results are expressed as the mean±S.D. or mean±S.E.M. as indicated. Two-way ANOVA
followed by Bonferronis multiple comparison test and two-tailed Students t-test were used
where applicable. P≤0.05 was considered to be statistically significant.
Additional procedures
Descriptions of additional experimental procedures used are given in Supplementary Methods.
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[5] J. Massagué. TGFβ in cancer. Cell, 134(2):215–230, July 2008.
[6] A. Moustakas and C-H. Heldin. Signaling networks guiding epithelial-mesenchymal transitions
during embryogenesis and cancer progression. Cancer Sci., 98(10):1512–1520, October 2007.
[7] B. Schmierer and C.S. Hill. TGFβ-SMAD signal transduction: molecular specificity and functional
flexibility. Nat.Rev.Mol.Cell Biol., 8(12):970–982, December 2007.
[8] K.C. Kirkbride and G.C. Blobe. Inhibiting the TGF-β signalling pathway as a means of cancer
immunotherapy. Expert.Opin.Biol.Ther., 3(2):251–261, April 2003.
[9] P. ten Dijke and C.S. Hill. New insights into TGF-β-Smad signalling. Trends Biochem.Sci.,
29(5):265–273, May 2004.
[10] J.E. Burdette, J.S. Jeruss, S.J. Kurley, E.J. Lee, and T.K. Woodruff. Activin A mediates growth in-
hibition and cell cycle arrest through Smads in human breast cancer cells. Cancer Res., 65(17):7968–
7975, September 2005.
[11] J. Massague, J. Seoane, and D. Wotton. Smad transcription factors. Genes Dev., 19(23):2783–2810,
December 2005.
[12] S. Dennler, S. Huet, and J.M. Gauthier. A short amino-acid sequence in MH1 domain is responsible
for functional differences between Smad2 and Smad3. Oncogene, 18(8):1643–1648, February 1999.
[13] A. Nawshad, D. LaGamba, A. Polad, and E.D. Hay. Transforming growth factor-β signaling during
epithelial-mesenchymal transformation: implications for embryogenesis and tumor metastasis. Cells
Tissues.Organs, 179(1-2):11–23, 2005.
[14] D. Donovan, J.H. Harmey, D. Toomey, D.H. Osborne, H.P. Redmond, and D.J. Bouchier-Hayes.
TGF β-1 regulation of VEGF production by breast cancer cells. Ann.Surg.Oncol., 4(8):621–627,
December 1997.
[15] L.A. Kingsley, P.G. Fournier, J.M. Chirgwin, and T.A. Guise. Molecular biology of bone metastasis.
Mol.Cancer Ther., 6(10):2609–2617, October 2007.
[16] J.J. Yin, K. Selander, J.M. Chirgwin, M. Dallas, B.G. Grubbs, R. Wieser, J. Massagué, G.R.
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Relative densitometric analysis of western blot for P-Smad2 (A) and P-Smad3 (B). Cells were stimulated
for 1 hour with TGF-β (black bars) where indicated. Protein levels were normalized with a non-specific
background band.
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Figure 2.8:
Supplementary figure 2. (A) Immunoblot analysis of Smad2 and Smad3 protein levels in MDA-B02
cells stably knocked down for Smad2 or Smad3. Control cells were infected with a non-targeting (N-
T) control shRNAi vector. MDA-B02 cells were lentivirally infected with specific shRNAi expressing
vectors and selected for uptake of the shRNA vector by culturing the cells with puromycin. Real-time
analysis of PAI-1 (B) and CTGF (C) in Smad3 shRNAi MDA-B02 cells and PAI-1 (D), CTGF (E), and
IL-11 (F) in Smad2 shRNAi MDA-BO2 cells after 6 hours TGF-β stimulation (black bars).
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Figure 2.9:
Supplementary figure 3. Immunoblot analysis of MDA-MB-231 cells stably expressing miR RNAi
for N-T control and the cell line m4 originating from a N-T control miR RNAi metastasis. Smad3
miR RNAi cells and the re-established cell lines m0 and m2 both originating from Smad3 miR RNAi
metastases.
Figure 2.10:
Supplementary figure 4. Real-time PCR analysis of hypoxia inducible factor 1 α (HIF-1α) and
placenta growth factor (PlGF) in bone metastasis from mice inoculated with N-T control, Smad2 miR
RNAi or Smad3 miR RNAi breast cancer cells.
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We used the BLOCK-iT Pol II micro RNA interference (miR RNAi) technology (Invitrogen)
for transient and stable silencing of Smad2 and Smad3. The targeting sequence for Smad2
was 5’-ACC AAG CAC TTG CTC TGA AAT-3’ and for Smad3, 5’-AGA ACG TCA ACA
CCA AGT GCA-3’. The non-targeting (N-T) sequence was 5’-ACG TCT CCA CGC AGT
ACA TTT-3’. Oligonucleotides were cloned into pcDNA6.2 GW-EmGFPmiR expression vector
which co-cistronically express the miR RNAi and emerald green GFP (EmGFP) and transferred
to the pLenti6/V5-DEST vector (Invitrogen). Cells were lentivirally infected and single cell
clones selected with 5 ng/ml blasticidin (Invitrogen). We used shRNAi targeting Smad2 or
Smad3 from the MISSION lentiviral library (Sigma). After lentiviral infection transfectants
were selected with 1 µg/ml puromycin. ShRNAi for Smad2 was TRCN-0000010477 and for
Smad3 TRCN-0000020011 and TRCN-0000020012. As controls a non-targeting sequence and
a GFP targeting sequence were used. The N-terminally tagged Flag-Smad2 and Flag-Smad3
expression plasmids were previously described [51].
Cell transfection and cell viability assay
Cells were seeded in 24-well plates and the following day transiently co-transfected with miR
RNAi constructs and CAGA 12-Renilla or the BRE-Renilla luciferase reporter constructs in
which the firefly was replaced with Renilla luciferase ([52, 53] and unpublished data). The
ratio of reporter construct versus miR RNAi was 1:6. We used Lipofectamine (Invitrogen)
or FugeneHD (Roche) according to the manufacturers protocol. Two days after transfection,
cells were stimulated for 15 hours with the respective ligands and the relative Renilla/firefly
luciferase activity was measured. CMV-firefly luciferase was used to control transfection ef-
ficiency. Each transfection was done in triplicate and representative experiments are shown.
Cell viability was performed as previously described [50].
Western blot analysis
Proteins were separated on SDS-PAGE and subjected to Western blotting using standard
techniques [50]. Antibodies recognizing phosphorylated Smad2 (P-Smad2) and phosphory-
lated Smad 1/5 (P-Smad1/5) are described in [54]. P-Smad1/3 was a kind gift from Dr. E.
Leof (Rochester, Minnesota, USA). Smad2/3 (BD transduction laboratories, Belgium), Smad3
(Zymed, CA, USA or AbCam, MA, USA), and -Actin (AC-15, Sigma, Netherlands). Sec-
ondary antibodies were either HRP or near infrared (NIR) labeled and detection performed
with chemiluminescence or fluorescence scanning on the LI-COR Odyssey.
Quantitative real-time PCR
Total RNA and cDNA synthesis were performed as previously described [50]. Samples were
run in triplicates for each primer set. Gene expression levels were assessed as the threshold
cycle (Ct) values of the target gene and reference gene normalized to GAPDH (∆∆Ct method).
Relative expression levels are presented as mean±S.D. The following human primers were used;
CTGF, forward 5’-TTG CGA AGC TGA CCT GGA AGA GAA-3’ and reverse 5’-AGC TCG
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GTA TGT CTT CAT GCT GGT-3’; PAI-1 forward 5’-TCT TTG GTG AAG GGT CTG
CT-3’ and reverse 5’-CTG GGT TTC TCC TCC TGT TG-3’; HIF-1α forward 5’-GCA AGC
CCT GAA AGC-3’ G and reverse 5-GGC TGT CCG ACT TTG A-3’; PlGF 5’-ACG TGG
AGC TGA CGT TCT CT-’3 and reverse 5’-CAG CAG GAG TCA CTG AAG AG-’3; IL-11
5’-ACT GCT GCT GCT GAA GAC TC-3’ and reverse 5’-CCA CCC CTG CTC CTG AAA
TA-3’; PTHrP forward 5’-ACC TCG GAG GTG TCC CCT AAC-3’ and reverse 5’-TCA GAC
CCA AAT CGG ACG-3’; VEGF-A forward 5’-AGC CTT GCC TTG CTG CTC TA-3’ and
reverse 5’-GTG CTG GCC TTG GTG AGG-3’.
Transwell migration
Transwell migration was performed in 24 well plates with filter inserts of a pore size of 0.8
µm (Corning Costar, CA, USA). 30.000 pre-starved cells were seeded in the upper chamber
in 200 µl medium. 300 µl medium with or without stimuli was added to the lower chamber.
Experiments were done in triplicates. Cells were fixed after 20 hours with 4% paraformaldehyde
and stained with 0.1% crystal violet. Pictures were acquired with phase-contrast microscopy
at 10 x magnification. Three fixed positions were imaged of each membrane. The area covered
by cells was quantified by binary image analysis using the NIH/ImageJ software.
VEGF secretion
VEGF secretion in conditioned media from stable miR RNAi MDA-MB-231 cells was analyzed
by quantitative sandwich ELISA. Media were harvested 15 hours with or without stimulation
with TGF-β and the analysis was performed as previously described [55].
In vivo imaging and Radiography
Metastatic tumor growth was followed weekly by live BLI with the IVIS 100 (Caliper Life
Sciences) as previously described [35, 36]. The BLI signal intensity was quantified as the sum
of photons within a region of interest given as the total flux (photons per second). Fluorescence-
based imaging of EmGFP was measured with the CRi Maestro FLEX system [56] (Cambridge
Research Instrumentation). The skin was carefully removed from the tibial regions prior to
imaging. GFP emission was measured at 550 nm with an automatically estimated scan time of
360 ms. Radiographs were taken after in vivo fluorescent measurements as previously described
[35, 36].
Establishment of in vitro cell lines from metastases
Whole bone metastases were surgically excised for histochemical analysis and in vitro tumor
cell growth. Cell lines were established by removal of the tibial diaphysis and aspirating the
metaphysis with cell culture medium. Bone marrow aspirates were plated in tissue culture asks
and selection with neomycin was initiated the following day. This selects only for MDA-MB-231
cells expressing the CMV-luciferase construct enabling us to determine if cells have retained
Smad2 or Smad3 knockdown caused by the expression of the miR RNAi.
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RNA isolation from bone metastases
Whole bone metastases were surgically excised for RNA extraction. Samples were pulverized
with a hammer under sterile conditions and processed as previously described [35].
Histochemistry and immunohistochemistry
Tissue samples were embedded in paraffin and 5 µm sections were stained with the Masson-
Goldners method to visualize mineralized bone [35, 36]. The micro-vasculature in metastases
was visualized by CD31 staining using standard techniques [37] and images were acquired with
phase-contrast microscopy. The area covered by CD31 positive staining was quantified with
image analysis and quantification of the micro vascular density was done by counting vessels
in a given area.
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Abstract
Epithelial-mesenchymal transition (EMT) occurs during embryogenesis, carcinoma in-
vasiveness, and metastasis and can be elicited by transforming growth factor-β(TGF-β)
signaling via intracellular Smad transducers. The molecular mechanisms that control
the onset of EMT remain largely unexplored. Transcriptomic analysis revealed that the
high mobility group A2 (HMGA2) gene is induced by the Smad pathway during EMT. En-
dogenous HMGA2 mediates EMT by TGF-β, whereas ectopic HMGA2 causes irreversible
EMT characterized by severe E-cadherin suppression. HMGA2 provides transcriptional
input for the expression control of four known regulators of EMT, the zinc-finger proteins
Snail and Slug, the basic helix-loop-helix protein Twist, and inhibitor of differentiation 2.
We delineate a pathway that links TGF-β signaling to the control of epithelial differentia-
tion via HMGA2 and a cohort of major regulators of tumor invasiveness and metastasis.
This network of signaling/transcription factors that work sequentially to establish EMT
suggests that combinatorial detection of these proteins could serve as a new tool for EMT
analysis in cancer patients.
Abbreviations
ChIP, chromatin immunoprecipitation; EMT, epithelial mesenchymal transition; Gapdh, glycer-aldehyde-




Epithelial mesenchymal transition (EMT) converts polarized epithelial cells to motile
mesenchymal cells [1]. EMT operates during embryonic cell layer movements and tumor
cell invasiveness [2]. During EMT, the epithelial proteins E-cadherin and zonula occlu-
dens 1 (ZO-1) are downregulated, and the mesenchymal proteins vimentin, α-smooth
muscle actin, and fibronectin are up-regulated.
Receptor tyrosine kinase, Wnt, Notch, and TGF-β pathways trigger EMT [2]. TGF-β
binds to receptor serine/threonine kinases, which activate intracellular Smad and other
signaling pathways that regulate gene expression [3]. TGF-β inhibits epithelial cell
growth, acting as a tumor suppressor, but it also promotes carcinoma progression and
metastasis [4]. The tumor-promoting effects of TGF-β are based on its ability to induce
(a) EMT, matrix invasiveness, and blood vessel intravasation by carcinoma cells [2]; (b)
cytostatic effects on surveilling immune cells [5]; and (c) proangiogenic effects [6]. TGF-
β elicits EMT and in vivo metastasis via Smads and complementary non-Smad effectors,
such as Rho GTPases and p38 MAPK [7]. TGF-β represses inhibitor of differentiation
(Id) 2 and 3 expression and induces expression of the Notch ligand Jagged-1, which are
critical events during EMT [8, 9, 10].
Here, we describe the role of high mobility group (HMG) A2, also known as HMGI-
C, as an effector of TGF-β that causes EMT. HMGA2 and -1 constitute a family of
nuclear factors that bind AT-rich DNA sequences [11, 12]. HMGA factors contribute to
transcriptional regulation by organizing nucleoprotein complexes such as enhanceosomes
[13]. HMGA2 is expressed during embryogenesis and becomes silent in adult tissues [12].
However, HMGA2 is abundantly expressed by transformed cells or tumors of mesenchy-
mal and epithelial origin (for reviews see [14, 12]). In contrast, depletion of HMGA2
by antisense cDNA in thyroid cells eliminates their transformation by myeloprolifera-
tive and Kirsten murine sarcoma viruses [15]. Here, we show that HMGA2 regulates
the transcription factors Snail, Slug, Twist, and Id2, thus linking TGF-β signaling to
regulators of tumor invasiveness and metastasis.
Results and discussion
TGF-β/Smad signaling induces Hmga2 transcription
Transcriptomic analysis of TGF-βinduced EMT in mammary epithelial NMuMG cells
identified Hmga2 as a prominent TGF-β target [16]. Hmga2 mRNA increased after
2 and 8 h and returned to basal levels after 36 h of TGF-β stimulation (Fig. 1 A). In
contrast, Hmga1 mRNA was not regulated and dropped significantly upon cell confluence
at 36 h (Fig. 1 A). HMGA2 protein increased after 8 h and peaked at 12 h of TGF-β
stimulation (Fig. 1 B). A TGF-β type I receptor kinase inhibitor (LY580276; [17]) did not
affect basal HMGA2 levels, demonstrating the absence of autocrine TGF-β (Fig. 1 B).
Hmga2 mRNA induction by TGF-β was not impaired by the protein synthesis inhibitor
cycloheximide while it was blocked by the RNA polymerase inhibitor II actinomycin
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D (Fig. S1 A). A constitutively active form of the TGF-β type I receptor increased
Hmga2 expression more efficiently than TGF-β itself, whereas a kinase-dead mutant of
this receptor inhibited it (Fig. S1 B). When the constitutively active type I receptor
was expressed at higher levels, it often failed to induce Hmga2 at higher levels than
TGF-β [16]. This reflects mechanisms of pathway desensitization, as TGF-β signaling is
controlled in a timed fashion by activation and inactivation of receptor and Smads. The
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Figure 3.1: TGF-β/Smad signaling induces Hmga2 transcription. (A) RT-PCR analysis of
Hmga2 and Hmga1 expression in NMuMG cells stimulated with 5 ng/ml TGF-β for the indicated
times. (B) Immunoblot analysis of endogenous Hmga2 in NMuMG cells treated with vehicle (0), TGF-
β type I receptor inhibitor LY580276 (2.5 µM; LY) for 4 h, or stimulated with TGF-β for the indicated
periods of time. Histone H1 serves as a loading control. Molecular size markers are in bp (A) and
kDa (B).(C) Hmga2 promoter assays of the indicated deletion constructs in HepG2 cells stimulated
(grey bars) or not (white bars) with 5 ng/ml TGF-β for 24 h. The black box in the Hmga2 promoter
corresponds to a TCC repeat-rich sequence. (D) Quantitative RT-PCR analysis of Hmga2 expression
in NMuMG clones expressing dominant-negative Smad2 (S2 SA) or empty vector (mock) induced or
not with 10 µM CdCl2 for 24 h, before stimulation with 5 ng/ml TGF-β for 4 h. (E) Promoter assays
of the Hmga2 BaP construct in HepG2 cells transfected with Smad2 SA and stimulated (grey bars)
or not (white bars) with 5 ng/ml TGF-β for 24 h. (F, G) Quantitative RT-PCR analysis of Hmga2
expression in NMuMG (F) and MDA-MB-231 (G) clones expressing short hairpin vectors (sh-Smad)
directed against Smad2, Smad3 and Smad4, or the empty vector and treated with 5 ng/ml TGF-β for 6
h. Stars indicate statistically significant gene expression or promoter activity differences between TGF-
β-stimulated and non-stimulated conditions (p≤0.05). (H) ChIP assays in NMuMG cells treated or not
with 5 ng/ml TGF-β for 2 h using a Smad4 antibody or a preimmune serum (Ctrl) and amplification
of Hmga2 promoter fragments.
results suggest that Hmga2 is a direct TGF-β target.
Mouse Hmga2 promoter analysis showed that basal promoter activity varied accord-
ing to the deletion construct used, and TGF-β stimulation led to a 2.53-fold induction
(Fig. 1 C). Basal promoter activity and induction by TGF-β were lost when the proximal
region containing TCC repeats was deleted. Sequence inspection of 4 kbp upstream from
the transcription initiation site showed few noncanonical Smad binding elements between
-700 and -100 bp (unpublished data). We now examine the role of these elements on
Hmga2 transcriptional induction by TGF-β.
Hmga2 mRNA induction and promoter activation by TGF-β was blocked in cells
expressing dominant-negative Smad2 (Smad2 SA; Fig. 1, D and E), Smad2 SA cannot
be phosphorylated by the TGF-β type I receptor and blocks TGF-βinduced EMT [16].
Knockdown of Smad2 by 80% or Smad3 by 65% after RNAi had no effect on Hmga2
induction by TGF-β or on the EMT response (Fig. 1 F and Fig. S1, C and D). However,
knockdown of the common partner of Smad2 and 3, Smad4, by 95% effectively blocked
Hmga2 induction by TGF-β and the EMT response (Fig. 1 F and Fig. S1, C and D;
[18]). The lack of effect by knockdown of Smad2 or 3 may indicate that the protein
depletion achieved was insufficient. Alternatively, both Smad2 and 3 may be involved in
EMT, as we previously proposed [16], and for effective block of EMT, both Smad2 and
3 need to be depleted. Experiments are under way to test this possibility. In another
cell line, metastatic breast cancer MDA-MB-231 cells, TGF-β weakly induced HMGA2
expression, and knockdown of Smad3 or 4 blocked this response, whereas knockdown of
Smad2 did not (Fig. 1 G and Fig. S1, E and F). Based on these data, it appears that
single Smad3 or 4 knockdown is sufficient in blocking TGF-βinduced HMGA2 expression
(Fig. 1 G and Fig. S1 F). A more robust knockdown of Smad2 is needed to reach final
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conclusions about the role of this Smad isoform in HMGA2 regulation and EMT.
Finally, immunoprecipitation of chromatin bound Smad4 from NMuMG cells con-
firmed a TGF-βinducible association of Smad4 in the proximal (-195/+5) and upstream
(-495/+245) but not in the distal (-3420/-3320) promoter region of the Hmga2 gene
(Fig. 1 H). The -500 to +5 Hmga2 promoter region where Smad4 binds overlapped with
putative Smad binding elements. The results establish that Smad signaling is involved
in Hmga2 induction by TGF-β, with Smad4 clearly being implicated. However, we can-
not conclude whether Smad4 cooperates with Smad2, Smad3, or both during Hmga2
regulation.
Ectopic HMGA2 weakly inhibits epithelial cell proliferation
To address the functional role of HMGA2, we established stable NMuMG clones in-
ducibly expressing human HMGA2. Ectopic HMGA2 was expressed in the absence of
an inducer, and induction increased its expression further (Fig. 2 A). Ectopic HMGA2
localized in the nucleus as expected, and its localization was not affected by TGF-β (Fig.
2 B). In the absence of TGF-β, HMGA2 clones grew slower than mock cells (Fig. 2 C).
TGF-β inhibited growth of mock and HMGA2-expressing cells (Fig. 2 D). Thus, TGF-β
induces growth arrest despite ectopic HMGA2 expression.
HMGA2 mediates EMT in response to TGF-β
Mock NMuMG clones treated with an inducer displayed characteristic polarized epithe-
lial morphology (Fig. 3 A). TGF-β caused EMT, as mock cells acquired elongated,
fibroblast-like morphology. HMGA2 clones were constitutively elongated and lost cell-
cell contacts, suggesting induction of EMT, which was enhanced further by TGF-β (Fig.
3 A). EMT in HMGA2 clones was confirmed by visualizing actin cytoskeleton rear-
rangements and the loss of ZO-1 and E-cadherin from cell junctions (Fig. 3 B) and
by measuring the loss of expression of E-cadherin and Mucin-1 mRNA (Fig. 3 C).
Moreover, mRNAs of the mesenchymal markers PAI-1, Timp-3, and Fibronectin-1 were
constitutively expressed, and Vimentin was increased to a lesser extent. Immunoblot
analysis confirmed E-cadherin protein downregulation and enhanced expression of mes-
enchymal N-cadherin in HMGA2 clones (Fig. 3 D). These experiments demonstrate that
ectopic HMGA2 causes EMT.
The fact that ectopic HMGA2 mimicked the TGF-β response (Fig. 3, C and D) raises
the question of whether HMGA2 activates autocrine TGF-β, leading to EMT. In mock
NMuMG cells, the LY580276 inhibitor blocked TGF-βmediated EMT, as cells kept a
cortical actin distribution and did not downregulate E-cadherin (Fig. S2). However, in
HMGA2 clones, LY580276 had no effect on the elongated morphology, actin stress fiber
network, or lack of E-cadherin. Similar results were obtained with a TGF-βneutralizing
antibody added to the medium of HMGA2 clones for several days (unpublished data).
These experiments demonstrate that the profound effects HMGA2 shows on EMT cannot
be accounted for by the induction of autocrine TGF-β that signals in a constitutive
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Figure 3.2: HMGA2 inhibits cell proliferation. (A) Analysis of ectopic HMGA2 expression in
NMuMG clones (mock, 5, 13) transfected with empty or HMGA2 vector. Cells were stimulated with
5 ng/ml TGF-β for 36 h, 24 h after induction with 10 µM CdCl2. Immunoblots were incubated with
anti-HA antibody. β-tubulin is loading control. Molecular size markers are in kDa. (B) Immunostaining
with anti-HA antibody of mock NMuMG and HMGA2-clone 5 stimulated with 5 ng/ml TGF-β for 36
h (Bar = 10 µm). (C) Cell proliferation assays with mock (diamonds) and HMGA2-clones (5, squares;
13, triangles). (D) Cell proliferation assays with mock, HMGA2 clones 5 and 13 stimulated (grey bars)
or not (white bars) with TGF-β for 4 days.
manner.
Transfection of NMuMG cells with Hmga2 siRNA resulted in an 70% decrease in basal
and TGF-βinduced Hmga2 mRNA expression (Fig. 4 A). An even stronger reduction was
seen of the endogenous HMGA2 protein level (Fig. S3). Weak nuclear HMGA2 was seen
in control cells; TGF-β dramatically increased the nuclear HMGA2 levels, as the cells
became elongated and fibroblast like (Fig. S3). Upon HMGA2 depletion, its nuclear
staining was barely detectable. Immunoblot analysis of endogenous HMGA2 protein
upon chromatin extraction (Fig. 1 B) was not efficient enough in these transfected cells
to quantitatively monitor the degree of protein depletion upon RNAi (unpublished data).
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We reproducibly observed that the mammary epithelial cells enlarged their diameter by
Figure 3.3: HMGA2 induces EMT. (A) Phase-contrast microscopy of mock and HMGA2-clones.
HMGA2 induction with 10 µM CdCl2 was followed by vehicle (control) or 5 ng/ml TGF-β stimulation
for 36 h. (B) Visualization of actin cytoskeleton and the epithelial markers ZO-1 and E-cadherin by
immunostaining of mock and HMGA2-clones treated with vehicle (control) or 5 ng/ml TGF-β for 36
h (Bars = 10 µm). (C) RT-PCR analysis of EMT markers. HMGA2-clones were treated as in (A).
Parental NMuMG (par.) were treated with 5 ng/ml TGF-β for 36 h. (D) Immunoblot analysis of E-
and N-cadherin in cells treated as in (A). Molecular size markers are in bp (C) and kDa (D).
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roughly 1.82.2-fold when HMGA2 was depleted (Fig. S3). This effect was specific for
the Hmga2 siRNA, as we did not observe size changes by control (siLuc) or a panel of
siRNAs that target unrelated genes in this cell line (Fig. S3 and unpublished data).
TGF-β induced EMT in NMuMG cells transfected with control siRNA. In contrast,
cells transfected with Hmga2 siRNA do not undergo EMT. Indeed, these cells maintained
polarized morphology, ZO-1, and E-cadherin at their junctions and decreased the TGF-
βinducible levels of N-cadherin and Fibronectin-1 (Fig. 4, BE; and Fig. S3). Although
Hmga2 knockdown restored to a large extent epithelial tight and adherence junctions,
we observed only a weak block of total ZO-1 and E-cadherin protein down-regulation
by TGF-β (unpublished data). We conclude that endogenous HMGA2 is required for
TGF-βinduced EMT.
HMGA2 regulates expression of key regulators of EMT
The zinc-finger transcription factors Snail, Slug, δEF-1/ZEB-1, and SIP-1/ZEB-2 or
the basic helix-loop-helix factor Twist repress E-cadherin expression during embryonic
EMT [19] and promote tumor cell metastasis or cancer recurrence after therapy [20, 21].
The extreme down-regulation of E-cadherin expression in HMGA2 clones (Fig. 3, C
and D) prompted us to analyze some of these transcriptional repressors. In parental
NMuMG cells, Snail, Slug, and to a lesser extent Twist mRNA were induced by TGF-
β (Fig. 5, A and C). Repressor expression was dramatically up-regulated in HMGA2
clones even in the absence of TGF-β. Similar to regulation of endogenous Snail and
Twist mRNA, TGF-β induced Snail and Twist promoter activity (Fig. 5 B). Notably,
cotransfection of HMGA2 enhanced Snail and Twist promoter activity to significantly
higher levels than TGF-β stimulation alone. As specificity control, the Smad3/Smad4
dependent promoter reporter CAGA12-Luc was not regulated by HMGA2 (unpublished
data). Upon RNAi-mediated knockdown of Hmga2, endogenous Snail mRNA induction
by TGF-β was reduced by 50% (Fig. 5 D). This explains why total E-cadherin and ZO-
1 protein levels were still repressible by TGF-β after Hmga2 knockdown (unpublished
data). We conclude that partial depletion of endogenous Hmga2 by RNAi is sufficient to
restore epithelial differentiation in NMuMG cells and establishment of cellcell junctions;
however, it is not sufficient to block strongly enough Snail induction by TGF-β.
TGF-β down-regulates Id2 to induce EMT [8, 9]. Id2 mRNA and protein expression
were down-regulated in HMGA2 clones compared with mock cells, and TGF-β further
repressed Id2 levels (Fig. 5, E and F). The results demonstrate that HMGA2 regulates
Snail, Slug, Twist, and Id2, all key players of EMT. TGF-β induces Snail expression
either via Smad3 or via MAPK signaling [22, 23]. Our results add HMGA2 as a novel
regulator of Snail expression downstream of Smads. Whether HMGA2 cooperates with
Smad3 or MAPK signals to induce Snail is being explored. Twist is another gene target
of HMGA2 that is weakly induced by TGF-β. We conclude that TGF-β, via HMGA2,
primarily affects the Snail pathway and, to a lesser extent, the Twist pathway.
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Figure 3.4: HMGA2 mediates EMT by TGF-β. (A) Quantitative RT-PCR analysis of Hmga2
expression in NMuMG cells transfected with control (siLuc) or specific siRNA against Hmga2 (siHmga2)
and treated with vehicle (white bars) or 5 ng/ml TGF-β (grey bars) for 12 h. (B) Phase-contrast images,
(C) indirect immunofluorescence of ZO-1 and E-cadherin and (D) immunoblot analysis of N-cadherin
in NMuMG cells transfected as in (A) and treated with vehicle (control) or 5 ng/ml TGF-β for 36 h
(Bars = 10 µm). β-tubulin is loading control. Molecular size markers are in kDa. (E) Quantitative
RT-PCR analysis of Fibronectin-1 (FN1) expression in cells treated as in (A). Stars indicate statistically
significant gene expression differences compared to the ground condition (p≤0.05).
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Figure 3.5: HMGA2 regulates expression of key regulators of EMT. (A) Quantitative RT-PCR
analysis of Snail and Twist expression in parental or HMGA2-clones stimulated (grey bars) or not
(white bars) with 5 ng/ml TGF-β for 36 h. (B) Luciferase reporter assays of Snail and Twist promoter
constructs in HepG2 cells transfected with mock (-) or HA-hHMGA2 (+) vector and treated with 5
ng/ml TGF-β for 24 h. (C) Quantitative RT-PCR analysis of Slug expression under conditions as in
(A). (D) Quantitative RT-PCR analysis of Snail expression in NMuMG cells transfected with control
(siLuc) or Hmga2 (siHmga2) siRNA and treated with vehicle (white bars) or 5 ng/ml TGF-β (grey
bars) for 12 h. Stars indicate statistically significant gene expression or promoter activity differences
compared to the ground condition (p≤0.05). Expression pattern of Id2 using RT-PCR (E) or protein
(F) analysis in mock and HMGA2-clones induced with 10 µM CdCl2 24 h before stimulation with 5
ng/ml TGF-β for 36 h. Molecular size markers are in bp (E) and kDa (F). (G) Diagram of the role of
HMGA2 in TGF-β-induced EMT.
Concluding remarks
We describe a new target of TGF-β signaling, the nuclear factor HMGA2, and a new
transcriptional circuitry that mediates EMT by TGF-β (Fig. 5 G). HMGA2 links TGF-
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β signaling to major factors of tumor invasiveness and metastasis. This work suggests
that HMGA2 acts not only as an architectural chromatin factor as previously thought
but also as a gene-specific regulator that responds to signals from extracellular factors.
HMGA2 is overexpressed in a variety of tumors primarily of mesenchymal origin (for
review see [12]). However, the mechanism of HMGA2 action is not yet known. This
study demonstrates for the first time that HMGA2 is involved in EMT. Our results
are consistent with the specific presence of HMGA2 at the invasive front of squamous
carcinomas [24], a place where EMT occurs during cancer progression. On the other
hand, overexpression in MCF7 mammary carcinoma cells of HMGA1b, another member
of the HMGA family, but not that of the related HMGA1a, led to invasive tumor growth
in nude mice [11]. Histochemical and transcriptomic analysis of tumor samples from
such mice indicated that HMGA1b induced expression of genes with links to EMT.
Our study demonstrates that HMGA2 is necessary and sufficient for TGF-βinduced
EMT. Considering the variety of tumors where HMGA2 expression has been detected,
it will be interesting to determine in how many of them TGF-β is the upstream inducer
of tumor HMGA2 expression and to what extent the signaling network outlined here
explains the tumor promoting properties of TGF-β.
Materials and methods
Cells, adenovirus, and reagents
Mouse mammary epithelial NMuMG, human hepatocarcinoma HepG2, human MDA-MB-231-
Eco cells, and stable NMuMG clones expressing Smad2 SA (mutant with alanines in place of two
C-terminal serines that become phosphorylated by receptors) have been described [9, 16, 18].
Adenoviruses expressing control GFP (Ad-GFP) were a gift from B. Vogelstein (Johns Hop-
kins Medical Institutions, Baltimore, MD); adenoviruses expressing C-terminally HA-tagged
constitutively active TGF-β type I receptor (activin receptor-like kinase 5) ALK-5(TD) and
HA-tagged kinase-inactive ALK5(KR) receptor were a gift from K. Miyazono (University of
Tokyo, Tokyo, Japan) and have been described [16].
The mouse Hmga2 siRNA (available from GenBank/EMBL/DDBJ under accession no.
NM-010441), which was a single RNA oligonucleotide (D-043585-03), and control siRNA against
the luciferase reporter vector pGL2 (accession no. X65324) were obtained from Dharmacon
Research, Inc. Human HMGA2 cDNA, cloned by PCR from total normal human mRNA
in pcDNA3-HA C-terminally of the HA tag using EcoRIXhoI as restriction sites, resulted in
pcDNA3-HA-hHMGA2. The N-terminally HA-tagged hHMGA2 HindIIIXhoI fragment was
subcloned in the inducible vector pMEP4 to produce pMEP4-HA-hHMGA2.
The LY580276 inhibitor for the TGF-β type I receptor kinase was a gift from J.M. Yin-
gling (Eli Lilly and Company, Indianapolis, IN; [17]). Recombinant mature TGF-β1 was ob-
tained from PeproTech and TGF-β3 from K.K. Iwata (OSI Pharmaceuticals, Farmingdale,
NY). TGF-β1 was used in most experiments and TGF-β3 in experiments with stable NMuMG
and MDA-MB-231 clones for Smad shRNAs (Fig. 1 and Fig. S1). TGF-β1 and TGF-β3 have
indistinguishable effects on EMT or Hmga2 gene regulation.
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Cell counting
Cell monolayers were washed with PBS, trypsinized, and resuspended in PBS, and cell numbers
were calculated using a Z1 cell counter (Beckman Coulter).Numbers are plotted as means from
triplicate determinations with standard errors.
Cell transfections
pMEP4 and pMEP4-HA-hHMGA2 were transfected into NMuMG using Lipofectamine 2000
(Invitrogen). 2 d after transfection, cells were cultured in 400 µ/ml hygromycin-B (Cal-
biochem), and individual antibiotic-resistant clones were derived. For HMGA2 induction, cells
growing in hygromycin-B were treated with 10 µM CdCl2 (Sigma-Aldrich) for 24 h, and cells
were incubated with vehicle or TGF-β for another 24-48 h.
NMuMG cells were transiently transfected with Hmga2 siRNAs using Dharmafect 4 (Dhar-
macon Research, Inc.). After 2 h of stimulation with TGF-β, cells were retransfected with siR-
NAs to a final concentration of 50 nM for 10 h (RNA assay) or 36 h (protein/immunofluorescence
assay).
NMuMG and MDA-MB-231-Eco clones with Smad knockdown were established after infec-
tion with retroviral supernatants derived from cells transfected with pRetroSuper-expressing
shRNA against Smad2, 3, or 4 and were provided by M. van Dinther and P. ten Dijke (Leiden
University Medical Center, Leiden, Netherlands; [18]). The shRNA oligonucleotide sequences
were 5-GGA GTG CGC TTG TAT TAC A-3 (mouse/ human Smad2), 5-CGT CAA CAC
CAA GTG CAT C-3 (mouse/human Smad3), and 5-CCA GCT ACT TAC CAT CAT A-3
(mouse/human Smad4).
RT-PCR
Total DNA-free cellular RNA was extracted with the RNeasy kit (Qiagen). Reverse transcrip-
tion (RT)-PCRs were performed as described [9] and analyzed using specific primers (Table
I and II). Primers for mouse glyceraldehyde-3’-phosphate dehydrogenase (Gapdh) were used
for reference. Lack of DNA contamination was verified by omitting reverse transcriptase(-RT).
Quantitative real-time PCR reactions were as described [16]. Gene expression levels were de-
termined with the comparative Ct method using Gapdh as reference. The ground condition
was set to 1 and expression data are presented as bar-graphs of average values plus standard
deviations.
Perchlorate extraction of chromatin
NMuMG cells were lysed in 140 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl pH 8.6, 0.5%
NP-40, supplemented with protease inhibitors. After centrifugation (3 min, 6000 x g, 4 ◦),
nuclear pellets were resuspended, vortexed 30 s and rotated at room temperature for 1 h in
5% perchloric acid. Perchloric acid supernatants (5 min, 6000 x g, 25 ◦) were precipitated by 8
volumes cold ethanol, centrifuged (15 min, 10000 x g 4 ◦) and pellets were resuspended in lysis
buffer and analyzed by immunoblotting.
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Immunoblotting and immunofluorescence microscopy
Total protein extracts subjected to SDS-PAGE were analyzed by immunoblotting, as described
[9]. Mouse monoclonal anti-β-tubulin (T8535), anti-β-actin (AC-15) were from Sigma-Aldrich;
mouse monoclonal anti-HA (12CA5) from Roche Applied Science; mouse monoclonal anti-E-
cadherin (C20820) from BD Transduction Laboratories; rat monoclonal anti-ZO-1 (MAB1520)
from Chemicon Int.; mouse monoclonal anti-histone H1 (AE-4), anti-Smad2/Smad3 (H-2) and
anti-Smad4 (B-8) from Santa Cruz Biotechnology, Inc. Rabbit polyclonal anti-Hmga2 was
raised against a synthetic peptide (CSPSKAAQKKAETIGE where S maps at residue 59 of
mouse Hmga2), and recognizes mouse but not human HMGA2 (unpublished results). Sec-
ondary anti-mouse-IgG and anti-rabbit-IgG coupled to horseradish peroxidase were from Amer-
sham Biosciences. The enhanced chemilluminescence detection system was from Santa Cruz
Biotechnology, Inc. For immunofluorescence, cells were treated as indicated in the figure leg-
ends, fixed and stained with tetramethyl-rhodamine isothiocyanate (TRITC)-labeled phalloidin
(Sigma-Aldrich) or with rat anti-ZO-1, mouse anti-E-cadherin and rabbit anti-HMGA2 anti-
bodies as primary antibodies and TRITC-conjugated goat anti-rat-IgG and FITC-conjugated
anti-mouse- or anti-rabbit-IgG antibodies as secondary antibodies from Jackson ImmunoRe-
search Laboratories, Inc. as described [9]. Photomicrographs were obtained by a Zeiss Axioplan
2 microscope with a Hammamatsu C4742-95 digital camera, using the Zeiss Plan-neofluar 40
x/0.75 objective lens and photographing at ambient temperature in the absence of immersion
oil. Primary images were acquired with the camera’s QED software. Image memory content
was reduced and brightness-contrast was adjusted using Adobe Photoshop 6.0.
Promoter-reporter assays
HepG2 cells were transiently transfected with calcium phosphate and a panel of mouse Hmga2
promoter luciferase constructs, as described [25]. The Snail and Twist promoter luciferase
constructs were provided by A. Cano, Universidad Autónoma de Madrid, Madrid, Spain and
L. R. Howe, Weill Medical College of Cornell University, New York, NY, USA respectively. All
promoter constructs were co-transfected with the normalization reporter plasmid pCMV- -Gal
and the expression vector pcDNA3 (mock vector) or pcDNA3-HA-hHMGA2 for Snail and Twist
promoter analysis or pcDNA3-HA-Smad2 SA for Hmga2 promoter analysis. The enhanced
luciferase assay kit from BD PharMingen, Inc. was used. Normalized promoter activity data are
plotted in bar graphs representing average values from triplicate determinations with standard
deviations. Each independent experiment was repeated at least twice.
Chromatin immunoprecipitation (ChIP) assays
The equivalent of 107 cells was used per ChIP reaction. Crosslinking was performed using
1% formaldehyde followed by neutralization with 0.125 M glycine. Cells were lysed in 1%
SDS, 10 mM EDTA, 50 mM Tris pH 8.1 plus protease inhibitors on ice. DNA was sheared
by sonication to 200-1000 bp length. Sonicated cell pellets were diluted 10 times in a buffer
containing 0.01% SDS and were precleared with protein A-Sepharose in the presence of bovine
serum albumin (BSA) and salmon sperm DNA prior to incubation with 5 µg rabbit anti-Smad4
antibody (H-552; Santa Cruz Biotechnology Inc.) or preimmune rabbit antiserum as a negative
control. Protein-DNA complexes were precipitated with protein A-Sepharose in the presence
of BSA and salmon sperm DNA. Immunoprecipitated complexes were washed once with 150
107
mM NaCl, 0.2% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.1, once with an
identical buffer containing 500 mM NaCl, once with 0.25 M LiCl, 1% NP-40, 1% deoxycholate,
1 mM EDTA, 10 mM Tris-HCl pH 8.1, and twice with 10 mM Tris-EDTA. Immunoprecipitated
complexes were eluted with 1% SDS, 0.1 M NaHCO3. After reversal of crosslinks by heating in
0.2 M NaCl, proteinase K treatment, purification by classical phenol-chloroform extraction and
ethanol precipitation, DNA pellets were resuspended in 20 µl water. Input material prior to
immunoprecipitation corresponds to one third of the immunoprecipitated material. Input DNA
pellets were resuspended in 50 µl of water. PCR was performed using 2 µl of immunoprecipi-
tated or 0.5 µl of input material using Taq DNA polymerase (Invitrogen Corp.). Amplification
was carried out for 30 cycles for immunoprecipitated DNA and 25 cycles for input DNA. Primer
sets used to amplify different regions of the Hmga2 promoter are described in Table II.
Statistical analysis
Statistical analysis of real time PCR quantification and promoter assays was performed by
2-tailed paired Student’s t-test. Significance was considered at P value ≤ 0.05.
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Supplemental material
Figure 3.6: Figure S1. Hmga2 expression is induced by the TGF-β/Smad pathway. (A)
Quantitative RT-PCR analysis of Hmga2 expression in NMuMG cells stimulated (grey bars) or not
(white bars) with 5 ng/ml TGF-β in presence or not (NT) of 5 g/ml cycloheximide (CHX) or 1 g/ml
actinomycin D (ActD) for 1 h. (B) Quantitative RT-PCR analysis of Hmga2 expression in NMuMG
cells infected with control adenovirus GFP (Ad-GFP) or adenoviruses expressing constitutively active
(TD) or dominant-negative (KR) forms of ALK5 and stimulated or not with TGF-β (5 ng/ml) for
4 h. Stars indicate statistically significant differences between TGF-β/receptor-stimulated and non-
stimulated condition. (C) Phase contrast images of NMuMG cell lines expressing short hairpin RNAi
vectors (sh-Smad) directed against Smad2, Smad3 or Smad4, or the empty vector (pRS) treated or not
(control) with 5 ng/ml TGF-β for 48 h. A bar indicates 10 µm. (D) Immunoblot analysis of Smad2,
Smad3 and Smad4 levels in cell lysates from cells used in (C). In the Smad3 knockdown cells only Smad2
and Smad3 were assayed (middle shorter immunoblot). (E) Immunoblot analysis of Smad2, Smad3 and
Smad4 levels in cell lysates from MDA-MB-231 cells used in the HMGA2 expression analysis of panel
(F) and Fig. 1G. (F) Semi-quantitative RT-PCR assay of HMGA2 expression in MDA-MB-231 stable
clones with specific Smad knockdown, in the absence or presence of stimulation with 5 ng/ml TGF-β.
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Figure 3.7: Figure S2. HMGA2 does not initiate an autocrine TGF-β loop. (A) Phalloidin
staining of actin cytoskeleton in mock or HMGA2-expressing cells in the presence (LY580276) or absence
(DMSO) of the specific TGF-β type I receptor inhibitor LY580276 (2.5 µM) and treated (TGF-β) or
not (control) with 5 ng/ml TGF-β for 36 h (Bar = 10 µm). (B) Immunoblot analysis of E-cadherin
using protein extracts from cells treated as in panel (A).
Figure 3.8: Figure S3. HMGA2 mediates EMT by TGF-β Localization of endogenous HMGA2
and ZO-1 by indirect immunofluorescence in NMuMG cells transfected with control (siLuc) or specific
siRNA against Hmga2 (siHmga2) and treated with vehicle (control) or 5 ng/ml TGF-β for 36 h (Bars
= 10 µm).
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Constitutive Activation of Activin Receptor-like Kinase 2 in Breast Cancer Cells inhibits Metastatic
Progression and Osteolytic Bone Lesions
Abstract
Transforming growth factor-β (TGF-β) is a crucial player in metastasis of breast cancer
cells to bone. We previously reported that bone morphogenetic protein-7 (BMP-7) can
counteract the effects of TGF-β in vitro and inhibit the progression and formation of
osteotropic MDA-BO2 human breast cancer bone metastasis in vivo. Whether BMP-7
acts directly on the breast cancer cells and/or on the cancer-associated bone stroma has
remained elusive. Here, we demonstrated that activin-like kinase receptor 2 (ALK2) is
the functional BMP-7 type I receptor in MDA-BO2 cells. Subsequently, to restrict BMP-
7-induced actions to MDA-BO2 cells we engineered these cells to ectopically express a
constitutively active variant of ALK2, denoted caALK2. We demonstrate that caALK2
continuously activates the BMP signaling pathway as measured by Smad phosphorylation,
BMP transcriptional reporter activity and target gene responses, and antagonized basal
and TGF-β-induced transcriptional reporter activation. In vivo tumor-induced osteolysis
and metastatic progression was mitigated in mice inoculated with MDA-BO2 cells over-
expressing caALK2 compared to a control cell line. These observations suggest that cell
autonomous activation of caALK2 or BMP7 over-expression in breast tumor cells inhibit
osteolysis and metastatic progression possibly by interfering with the TGF-β-mediated
self-amplifying cycle of bone destruction.
Abbreviations ActR-II, Activin receptor type II; ALK, Activin receptor-like kinase; caALK, consti-
tutively active ALK; BMP, bone morphogenetic protein; BMPR-II, BMP receptor type II; BRE, BMP-
responsive element; caALK2, constitutively active ALK2; EMT, epithelial mesenchymal transition; GFP,
green fluorescent protein; HLH, helix-loop-helix; ID, inhibitor of differentiation/DNA binding; µ-CT,
micro-computed tomography; MET, mesenchymal epithelial transition; P-Smad, phosphorylated Smad;
I-Smad, inhibitory Smad; Smad, small phenotype and mothers against DPP related protein; TGF-β,
transforming growth factor β.
115
Introduction
Women diagnosed with advanced breast cancer are at high risk of developing metastatic
bone disease [1]. Tumor-induced bone remodeling result in severe patient morbidity
[2, 1]. At present, no curative therapies are available for the treatment of bone metastasis
and a better understanding of the underlying mechanisms of metastatic disease and the
interplay between the cancer cells and the bone microenvironment is critically important
in the search for new anti-metastatic therapies.
Bone morphogenetic protein (BMP)-7 is a dimeric cytokine and a member of the
transforming growth factor (TGF)-β family that have pleiotropic functions in develop-
ment, tissue homeostasis and in cancer progression [3]. BMPs signal via assembly of het-
erotetrameric BMP-receptor complexes comprised of type I and type II serine/threonine
kinase receptors [4, 5, 6]. The type I receptors for BMPs include activin-like kinase
(ALK)1, ALK2, ALK3, and ALK6 whereas the type II receptors are BMPRII, ActRII,
and ActRIIB. ALK2 has been described as predominant type I receptor for BMP-7
[5, 6, 7, 8, 9]. Type I receptors are phosphorylated and activated by type II recep-
tors and determine the signaling specificity within the heterotetrameric complex [10].
Upon ALK2 activation receptor-regulated (R-)Smad1, Smad5, and Smad8 can be phos-
phorylated and form heteromeric complexes with the common mediator Smad4. These
transcriptional complexes modulate target gene expression in concert with various co-
factors [5, 11, 12]. Inhibitory Smads (I-Smads), Smad6 and Smad7 antagonize activation
of R-Smads [13, 14, 15].
BMP-7 plays key regulatory roles during early embryogenesis [16, 17, 18, 19]. In a
pathological setting, loss of BMP-7 mRNA expression in primary tumor is associated
with increased bone metastasis and invasiveness of breast cancers cell lines [20]. More-
over, BMP-7 was shown to counteract TGF-β-induced tumorigenic responses in breast
cancer cells in particular through inhibition of TGF-β-mediated epithelial mesenchymal
transition (EMT) and induction of mesenchymal epithelial transition (MET) [17, 20, 21].
The dichotomous roles of TGF-β and BMP-7 on EMT and MET can be explained, at
least in part, by the differential regulation of inhibitors of differentiation/DNA binding
(ID) proteins [22].
Breast cancer has high predilection for the skeleton and once micro-metastatic le-
sions are established they induce osteolytic bone destruction through a vicious cycle of
paracrine signaling between the tumor cells and the bone microenvironment [1, 2, 23].
In brief, cancer cells stimulate osteoclastic progenitor maturation and bone resorption
resulting in release of matrix-bound growth factors such as TGF-β, insulin-like growth
factor and others. These cytokines can then act back on the tumor cells and stimulate
further growth, osteoclastogenesis and bone destruction [1, 2, 21, 23]. The MDA-BO2
breast cancer cell line is an osteotropic sub-clone of the MDA-MB-231 cell line which
gives rise to highly aggressive and osteolytic bone metastasis in immunodeficient mice
[24]. Over-expression of BMP-7 in MDA-BO2 cells or systemic administration of human
recombinant BMP-7 to MDA-BO2 tumor-bearing animals inhibited the metastatic po-
tential and the progression of these breast cancer cells in vivo [20]. Whether the BMP-7
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exerts its effects directly on the cancer cells directly and/or on the cancer-associated
stroma is not known. In this study, we engineered MDA-BO2 cells to over-express a
constitutively active form of, the BMP-7 receptor, ALK2 to restrict BMP-7-induced
responses solely to breast cancer cells. This cell line was characterized in vitro and com-
pared to BMP-7 over-expressing cells in a bone tumor model in vivo. The outcome of
our studies demonstrates that inhibition of de novo formation of bone metastases and
tumor cell-induced osteolysis is mediated primarily through direct effects of BMP-7 on
the cancer cells.
Results
ALK2 is the functional BMP-7 type I receptor in MDA-BO2
cells
We first examined the expression profile of BMP type I and type II receptors in MDA-
BO2 cells by quantitative real-time PCR (Fig. 1A). ALK2 was expressed in these cells
however the expression levels of ALK3 was four fold higher. Some ALK6 was expressed,
whereas ALK1, a type I receptor for BMPs in endothelial cells, was not detected as
expected. The BMPRII was expressed at high levels whereas ActRII and ActRIIB were
detected at lower ratios (Fig. 1A).
The physiological binding property of BMP-7 to cell surface BMP type I receptors of
MDA-BO2 cells was analyzed by affinity labeling with radiolabeled BMP-7 to a mono-
layer of cells. Ligand-receptor complexes were cross-linked and lysates immunoprecipi-
tated with anti-sera for all BMP type I receptors. BMP-7 specifically bound to ALK2
(Fig. 1B). No detectable binding to ALK3 or ALK6 was observed for BMP-7 (Fig. 1B).
Ligand receptor binding triggers trans-phosphorylation of BMP-specific R-Smads;
i.e. Smad1, Smad5, and Smad8 and subsequently heteromeric complex formation with
Smad4 [13]. To ascertain that BMP-7 signals via ALK2, we transiently co-transfected
cells with shRNA plasmids targeting ALK2 and the BMP responsive reporter construct
(BRE-luc) which contains repeated promoter sequences of the BMP target gene ID1
[25]. When endogenous levels of ALK2 were depleted in MDA-BO2 cells both the basal
and the BMP-7-induced reporter activity was significantly inhibited (Fig. 1C). This was
observed with two independent shRNAs for ALK2 and strongly suggests that BMP-7
indeed signals via ALK2 in MDA-BO2 cells.
Mimicking a state of continuous BMP-7 signaling can be achieved through expression
of a constitutively active form of the ALK2 receptor (caALK2). This genetically modi-
fied receptor contains an activating mutation, Q207D, in the GS domain [26]. MDA-BO2
cells with isogenic stable expression of caALK2 were generated by Gateway Flp-In re-
combinase. Cells stably expressing GFP were used as controls along with MDA-BO2
cells over-expressing BMP-7 [20]. The stable caALK2 cells expressed 8 fold more ALK2
compared to physiological levels in control GFP (Fig. 1D) and parental MDA-BO2 cells
(data not shown).
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Figure 4.1: Ectopic of constitutive activate BMP-7 type I receptor, ALK2, in MDA-BO2 cells.
(A) Quantitative real-time PCR analysis of the BMP specific type I receptors ALK1, ALK2, ALK3,
and ALK6 and the type II receptors ActRII, ActRIIB, and BMPRII in MDA-BO2 cells. Relative
gene expression levels were corrected to β-ACTIN using the ￿￿Ct method. Values are presented as
relative mean ± S.D. (B) MDA-MB-231 cells were affinity-labeled with [125I]-BMP-7, cross-linked and
immunoprecipitated with anti-sera to ALK2, ALK3 and ALK6. Proteins were resolved by SDS-PAGE
and radioactivity detected on a Phosphoimager. (C) MDA-BO2 cells were transiently co-transfected
with the BRE-luc reporter and shRNA constructs targeting ALK2. A shRNA plasmid targeting GFP
was used as control. Cells were stimulated with (black bars) or without (white bars) BMP-7 for 16 hours
and the relative luciferase activity determined. The BMP-7-induced BRE-luc activity was significantly
inhibited when shALK2.1 (P≤0.01) or shALK2.2 (P≤0.001) were co-transfected compared to shGFP
control transfected cells. Also, basal reporter activity was inhibited by shALK2.1 compared to shGFP
control transfected cells (P≤0.05). (D) Quantitative real-time PCR analysis of the relative ALK2 gene
expression in GFP control or caALK2 overexpressing MDA-BO2 cells. Data is presented as mean ± S.D
corrected for β-ACTIN expression levels. (E) Immunoblot analysis of P-Smad1/5 in stable MDA-BO2
cell lines. GFP control cells stimulated with BMP-7 for 45 minutes were used as a positive control. A
non-specific protein band was used to control for equal loading. (F) Cells with ectopic expression of
control GFP, BMP-7 or caALK2 were transiently transfected with the BRE-luc reporter and stimulated
with (black bars) or without (white bars) BMP-7 for 16 hours. Basal levels of BRE-reporter activity in
BMP-7 and the caALK2 cells were induced compared to control GFP cells (P≤0.05).
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We next analyzed whether ectopic expression of caALK2 resulted in continuous ac-
tivation of the BMP signaling cascade. Constitutive active ALK2 cells showed high
endogenous levels of P-Smad1/5 compared to the control GFP cell line as observed by
western blot analysis (Fig. 1E lane 4). The amount of phosphorylated Smad1/5 (P-
Smad1/5) was equivalent to the P-Smad1/5 intensity in GFP control cells stimulated
with 500 ng/ml BMP-7 (Fig. 1E lane 2) and slightly higher than P-Smad1/5 levels in
BMP-7 over-expressing cells (Fig. 1E lane 3). When stable cell lines were transfected
with the BRE-luc reporter, significant higher basal luciferase activity was observed in
caALK2 and BMP-7 cells compared to control GFP cells (Fig. 1F). Exogenous addition
of BMP-7 did not further increase the luciferase activity in either caALK2 or BMP-7 over-
expressing cells suggesting that a plateau in BMP signaling is reached by constitutive
receptor activation and BMP-7 expression (Fig. 1F). The amount of BMP-7 produced
by BMP-7 over-expressing cells was estimated by harvesting conditioned medium from
the cells and using this medium in a BRE-luc reported assay. This was estimated to
approximately 200 ng/ml (Fig. S1). Thus, stable isogenic expression of caALK2 con-
tinuously activates the BMP signaling cascade to similar extent as ectopic expression of
BMP-7 in MDA-BO2 cells.
Ectopic expression of caALK2 inhibits TGF-β signaling
Exogenous addition of BMP-7 can inhibit TGF-β mediated signaling and counteract the
induction of downstream responses such as EMT [20, 17]. We hypothesized that ectopic
expression of caALK2 would result in a similar inhibition of the TGF-β pathway. To
explore this, we transiently transfected the three stable MDA-BO2 lines with, CAGA-luc,
a Smad3/4-dependent TGF-β responsive reporter [27].
Basal and TGF-β-induced luciferase activities were significantly reduced in cells ex-
pressing caALK2 (Fig. 2A and B) and similar results were observed in BMP-7 over-
expressing cells (Fig. 2A). Together, these results suggest that the interplay between
BMP-7 and TGF-β signaling pathways is mutually competitive and may depend on for-
mation of mixed Smad complexes [7] or bioavailability of intracellular signaling molecules
such as Smad4 or transcriptional co-activators [28].
Ectopic expression of caALK2 mimics BMP-7-induced gene re-
sponses
Ectopic expression of BMP-7 or caALK2 induces similar profiles of Smad1/5 activation
and BRE-luc reporter activation. The expression levels of the BMP-inducible target
genes ID2, SMAD6, and SMAD7 were greatly induced after 24 hours BMP-7 stimulation
in control GFP cells (Fig. 3). Elevated mRNA levels of ID2 were also observed in
cells over-expressing BMP-7 and caALK2. The expression was comparable to control
cells stimulated with BMP-7 (Fig. 3A). Similar enhanced basal levels of SMAD6 and
SMAD7 mRNA were observed in these lines (Fig. 3B and C). SMAD6 was expressed at
two fold higher levels in caALK2 cells compared to BMP-7 cells (Fig. 3B). Exogenous
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Figure 4.2: Ectopic expression of caALK2 inhibits TGF-β signaling. (A) The stable MDA-BO2
cell lines were transiently transfected with the TGF-β-inducible CAGA-luc reporter and the relative
luciferase activity measured. Autocrine TGF-β activity was inhibited in cells with ectopic expression of
caALK2 (P≤0.01) or BMP-7 (P≤0.001) compared to GFP control cells. (B) GFP control and caALK2
cells were transient transfected with the CAGA-luc reporter and cells were stimulated with (black bars)
or without (white bars) TGF-β for 16 hours. The TGF-β-induced reporter activity was significantly
inhibited in caALK2 cells (P≤0.001) versus control GFP cells.
addition of BMP-7 to the BMP-7 MDA-BO2 cells further enhanced these gene responses
by 2 fold whereas the response in caALK2 cells was saturated (Fig. 3B and C). Thus,
activation of BMP-7 signaling pathways in MDA-BO2 via either over-expression of ligand
or continuous activation of the receptor results in comparable target gene responses.
Figure 4.3: Target gene responses in cells over-expressing GFP, caALK2 or BMP-7. Quantita-
tive real-time PCR analysis of (A) ID2, (B) SMAD6, and (C) SMAD7 in cells stimulated with (black
bars) or without (white bars) BMP-7 for 24 hours. Data is presented as the relative gene expression
compared to GAPDH as a mean of three measurements ± S.D.
We next examined if expression of either BMP-7 or caALK2 affects the viability of
MDA-BO2 cells in vitro. Viability profiles for the control GFP, BMP-7, and caALK2
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cells were monitored for four consecutive days and similar growth kinetics were observed
for the three cell lines (Fig. S2). Furthermore, no differences in growth or sizes of colonies
were found in anchorage-independent growth assays with the three cell lines (data not
shown).
Constitutive activation of ALK2 inhibits osteolysis and metastatic
progression in vivo
Bone metastases from breast cancers are typically osteolytic as a result of the establish-
ment of a vicious cycle of tumor-induced osteoclastic bone resorption and tumor pro-
gression. The net results being osteolysis and enhanced release of growth factors stored
in the bone matrix, which can then act back on the cancer cells [1, 23]. This ultimately
results in dramatic alterations in the micro-architecture of the bone and extensive loss of
mineral content. We previously found that BMP-7 suppress the incidence and progres-
sion of metastatic bone disease [20, 29]. In order to determine if the inhibitory actions of
BMP-7 is a result of direct effects of BMP7 on the breast cancer cells and/or mediated
indirectly via the surrounding bone-marrow stroma, we compared the growth in bone
of cells over-expressing BMP-7 versus cells over-expressing caALK2 in MDA-BO2 cells
in vivo. Alternatively, MDA-BO2 cells were inoculated into the systemic circulation of
immunodeficient mice via the left heart ventricle giving rise to osteolytic bone metas-
tases [20, 29, 30]. Metastatic progression was followed in time by bioluminescent imaging
(BLI) and osteolytic lesions were detected by radiography and/or micro-computed to-
mography (µ-CT) scanning as areas of low mineral density at the end of the experiment
[30, 31].
For the intra-osseous tumor growth model, series of longitudinal and transverse µ-CT
and radiographs were compared to assess the extent of tumor-mediated osteolysis in the
three experimental groups (Fig. 4). Animals injected with caALK2 or BMP-7 over-
expressing tumor cells displayed significantly less bone destruction compared to mice
inoculated with control MDA-BO2 GFP cells. (P=0.04 and P=0.017 for caALK2 and
BMP-7 ectopic expressing cells, respectively; Fig. 4A and B). The bone density was
measured by transverse image analysis of the proximal tibiae at one fixed position and
given as the % area covered by mineralized bone. The µ-CT volume measurements were
significantly reduced in MDA-BO2 GFP xenografted animals compared to non-tumor
bearing tibiae (P≤0.001), as expected (Fig. 4C). The radiographic observations were
further supported by morphometric analysis by Masson-Goldner histological staining of
bone sections (Fig. 4D). This revealed extensive bone loss and complete replacement
of the bone marrow with breast cancer cells in bone sections from mice inoculated with
MDA-BO2 GFP cells. Osteolytic bone destruction was again significantly less in mice
inoculated with both BMP-7 and caALK2 expressing cells (Fig. 4C and D).
We next used the experimental in vivo model of bone metastasis, which recapitulates
later stages of metastatic progression namely, survival in the blood stream, extravasation,
bone marrow colonization and establishment of bone metastases [32, 31, 20]. Animals
were injected with stably expressing GFP or caALK2 MDA-BO2 cells and metastatic
121
Figure 4.4: Active BMP signaling in MDA-BO2 cells inhibits osteolytic bone resorption.
(A) Representative µ-CT images of the longitudinal plane and the corresponding transversal sections
acquired below the growth plate of non-injected tibiae or mice injected with GFP control, caALK2 and
BMP-7 MDA-BO2 cells. Micro-CT scans were acquired at the end of the experiment 45 days after tumor
cell inoculation. Mice injected with GFP control cells display extensive tumor-induced osteolysis and
complete loss of normal bone architecture (arrows indicate osteolytic lesions). Animals injected with
caALK2 or BMP-7 over-expressing cells display significantly less osteoclastic bone destruction. This is
quantified in the figure bone surface area. Abbreviations: F, fibula; T, tibia. (B) Quantification of the
tumor burden and (C) percentage bone volume area on µ-CT images (n=6) measured by binary image
analysis. The tumor burden and osteolytic bone destruction were significantly higher in GFP control
MDA-BO2 versus BMP-7 and caALK2 MDA-BO2 inoculated mice ∗∗∗P≤0.001 and ∗P≤0.05 in caALK2
and BMP-7 MDA-BO2 ￿P≤0.05 versus GFP MDA-BO2 inoculated mice. Data is presented as mean ±
S.D. (D) Histomorphometric analysis of proximal tibiae. Masson’s-Goldner trichrome staining was used
to visualize mineralized bone. Massive loss of cortical and trabecular bone is observed in control GFP
injected animals. Images were captured at 4 x magnification. Abbreviations: B, bone; T, tumor.
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Figure 4.5: Ectopic expression of caALK2 in MDA-BO2 cells inhibits breast cancer metastasis.
(A) In vivo BLI at day 35 of three representative mice injected with MDA-BO2 luc cells stably expressing
GFP control or caALK2. Dorsal images are shown. (B) Average total flux of BLI from long bones of
each experimental group followed in time. MDA-BO2 GFP (black square, black line) and caALK2
(grey circle, grey dotted line). Asterisks indicate statistically significant difference in total flux at day
35 between GFP MDA-BO2 and caALK2 MDA-BO2 long bone metastases ∗∗∗P≤0.001. (C) Average
number of metastases per animal in each experimental group. Significant less metastases are observed
in the animals inoculated with caALK2 versus GFP control cells at day 35 ∗P≤0.05. (D) Representative
radiographies of GFP (left) and caALK2 (right) inoculated mice at day 35. (E) Quantification of the
average area of osteolytic lesion measured on radiographies on hind legs of mice with bone metastases.
Results are expressed at mean relative area ± S.E.M. ∗P≤0.05 compared to GFP MDA-BO2 inoculated
mice. (F) Histology of tibiae with metastases. Near complete loss bone architecture is observed in
control GFP MDA-BO2 injected animals. Images were acquired at 4 x magnification. Abbreviations:
B, bone; GP, growth plate; T, tumor.
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progression was assessed by BLI (Fig. 5A and B). Tumor burden in long bones (Fig. 5B)
was significantly decreased in mice inoculated with caALK2 MDA-BO2 cells compared
to GFP control MDA-BO2 tumor-bearing mice (P≤0.001). Also, the average number of
metastasis at the end of the experiment was significantly reduced in caALK2 MDA-BO2
inoculated mice compared to GFP MDA-BO2 metastases-bearing animals (P≤0.05) (Fig.
5C). In line with these findings, mice inoculated with the caALK2 over-expressing cells
displayed less osteolytic lesions (Fig. 5D and E) compared to mice with GFP control
MDA-BO2 bone metastases (P≤0.05) as evaluated by radiography. Histomorphometric
analysis further confirmed these findings (Fig. 5F). Mice inoculated with GFP control
cancer cells displayed a near complete loss of normal bone architecture and tumor cells
had largely replaced the bone marrow.
To verify that tumor cells maintained the expression of BMP-7 or caALK2 in vivo
tumor cells derived from bone tumors or metastases were analyzed by quantitative real-
time PCR (Fig. S3). BMP-7 and caALK2 over-expression was retained to similar levels
as in the parental cell lines. In addition, functionality of caALK2 in bone metastases
was confirmed by immunohistological staining of P-Smad1. Enhanced nuclear P-Smad1
staining was observed in caALK2 expressing sections compared to control GFP metas-
tases (Fig. 6).
Taken together, our observations suggest that the inhibitory action of BMP-7 on
tumor growth and metastatic progression is mediated via direct effects on breast cancer
cells.
Figure 4.6: Immunohistological staining of P-Smad1 in breast cancer metastasis (A) P-Smad1
immunostaining of GFP and caALK2 overexpressing tumor metastasis. (B) Image quantification of P-
Smad1 staining in metastatic bone sections. Significant more P-Smad1 staining is observed in caALK2
versus GFP control bone metastases (P≤0.001). Error bars indicate mean ± S.D.
Discussion
Skeletal metastases are observed in the majority of breast cancer patients diagnosed
with advanced disease [33, 34]. Evidence is mounting that the formation and progres-
sion of skeletal metastasis is critically dependent on tumor-induced osteoclastic bone
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destruction, which requires a complex interplay of cancer cells and the bone stromal
microenvironment. [1, 2, 23, 31]. TGF-β is a major inducer of this vicious cycle of skele-
tal metastasis and understanding the multifaceted mechanisms and the role of TGF-β
and BMP signaling herein is critically important for the development of anti-metastatic
therapies.
We previously showed that over-expression of BMP-7 in osteotropic breast cancer
cells or systemic administration of human recombinant BMP-7 to tumor-bearing animals
inhibit de novo formation and progression of osteolytic metastasis [20, 29]. However,
whether BMP-7 confers these anti-metastatic effects by acting directly on the cancer
cells and/or via the bone microenvironment has remained elusive.
Here, we demonstrate that BMP-7 specifically binds and signals via the type I recep-
tor ALK2 in MDA-MB-231/BO2 cells. We engineered MDA-BO2 cells to stably express
a constitutively active form of ALK2 [26]. This enabled us to study ligand-independent
BMP-7 signaling confined to the cancer cells and compare to BMP-7 over-expressing
MDA-BO2 cells which in addition secrete ligands into the surrounding microenvironment.
Ectopic expression of caALK2 in MDA-BO2 cells exhibited sustained phosphorylation
of Smad1/5/8 and elevated BMP-mediated transcriptional activity, thus mimicking a
state of continuous BMP-7 signaling in the cancer cells. Furthermore, BMP-responsive
target genes such as ID2, Smad6, and Smad7 were highly elevated in caALK2 MDA-BO2
cells. Autocrine and TGF-β-induced transcriptional reporter activity was mitigated by
over-expression of caALK2 or BMP-7, as was previously observed when MDA-BO2 cells
were co-stimulated with BMP-7 and TGF-β [20, 29].
We next compared the metastatic ability and intra-bone tumor growth of these cell
lines in vivo. Forced expression of caALK2 or BMP-7 in MDA-BO2 cells resulted in
significantly decreased tumor-induced bone resorption. In addition to intra-bone tumor
growth, over-expression of caALK2 strongly inhibited the development of bone metas-
tases in nude mice after intra-cardiac inoculation. Also, the number of metastasis was
reduced and osteolytic lesion area decreased. These findings are in line with our previ-
ously reported observations with BMP-7 over-expressing MDA-BO2 cells or recombinant
BMP-7 treatment of mice with breast cancer metastasis [20].
Together, these results suggest that de novo bone metastasis formation and subse-
quent osteolytic bone destruction is regulated by tumor cell autonomous signaling. The
antagonistic actions of over-expressing either caALK2 or BMP-7 on TGF-β signaling
seem to play an important anti-metastatic role. Inhibition of bone metastasis formation
and osteolytic progression was previously reported when TGF-β signaling was blocked
through ectopic expression of a dominant negative TGF-β type II receptor [23] or by
systemic treatment with kinase inhibitors to ALK5 [35, 36, 37].
Though the exact downstream mediators which are responsible for the dichotomous
roles of BMP-7 and TGF-β in metastasis remain unknown, it is thought to be, in part,
dependent on the differential regulation of ID proteins [22]. TGF-β is known to repress
ID expression, whereas BMPs induce and stabilize expression of ID genes [22, 38]. We
found that both ID1 promoter activity and ID2 expression were enhanced in caALK2
cells. Conversely, ID1 and ID3 have also been identified as prime mediators of lung
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metastases in MDA-MB-231 cells [39] and targeted silencing of ID1 in 4T1 breast cancer
cells inhibited lung metastatic spread of 4T1 cells [40]. Thus, mechanisms of metastasis
might be distinct depending on the route of administration and the specific cell subtype
applied. To elucidate the underlying mechanisms of inhibition of metastatic bone disease
by which active BMP signaling inhibits osteolysis we examined a set of bone-metastatic
genes reported to mediate different steps of the metastatic cascade [23, 41, 42]. However,
we found no difference in the expression levels of IL-11, CTGF or PTHrP in caALK2
and BMP-7 over-expressing cells compared to GFP control MDA-BO2 cells.
We further show that Smad6 and Smad7 were significantly up-regulated in caALK2
and BMP-7 over-expressing cells indicative of enhanced proteasomal degradation of type
I receptors and R-Smads [43, 44, 45]. Sustained up-regulation of these genes could have
dramatic effects on TGF-β and BMP signaling in the tumor cells. Over-expression of
Smad7 in melanoma and breast cancer cells was recently shown to inhibit the formation of
metastasis [14, 15]. We speculate that since the BMP signaling pathway is continuously
activated, by either caALK2 or BMP-7, the potential inhibitory actions of Smad7 may
be more pronounced on TGF-β signaling compared to the effects on BMP-7 signaling
pathway. In order to elucidate this, knockdown studies of Smad7 in cells ectopically
expressing caALK2 or BMP-7 would have to be performed.
In a recent report, continuous activation of ALK3, a receptor for BMP-2 and BMP-
4 [46], was shown to mediate invasion and metastasis of MDA-MB-231 breast cancer
cells. This pro-metastatic function of caALK3 could be blocked by over-expression of a
mutated dominant negative ALK3 receptor [47]. We specifically show that BMP-7 signal
via ALK2 in MDA-BO2 cells and that over-expression of caALK2 gives rise to a less
metastatic phenotype in vivo. Thus, active BMP-7 signaling in tumor cells distinctively
induce anti-tumorigenic properties in these human breast cancer cells. Together, these
observations highlight the importance of discriminating between different BMPs when
characterizing their functions.
In summary, we demonstrate that continuous activation of BMP-7 signaling via ec-
topic expression of caALK2 or BMP-7 ligand can inhibit tumor-induced osteolysis and
progression of breast cancer bone metastases. Our results suggest that therapeutic tar-
geting of TGF-β signaling and enhancement of BMP-7 signaling can prevent progression
of skeletal metastases. We are currently analyzing potential downstream target genes of
TGF-β and BMP-7 signaling that are affected by active BMP-7 signaling. Identifying
such genes could potentially allow us to target the pro-metastatic function of TGF-β or
augment the anti-metastatic activities of BMP-7 signaling.
Materials and Methods
Cell culture and reagents
The human breast cancer cell lines MDA-MB-231 luc and MDA-MB-231/BO2 FRT luc cells
(referred to as MDA-BO2) were cultured as previously described [20, 48]. Human recombinant
BMP-7 (RD Systems) was used at 500 ng/ml unless otherwise indicated. Human recombinant
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TGF-β3 was used at 5 ng/ml and obtained from K. Iwata (OSI Pharmaceuticals, Inc., Melville
NY, USA). Antibodies recognizing BMP type I and type II receptors are described in [8] and
antibody to phosphorylated Smad 1/5 (P-Smad1/5) is described in [11]. Lentiviral shRNA
constructs targeting ALK2 were TRCN 0000 000 442 and TRCN 0000 000 444 (Sigma-Aldrich).
The non-targeting control lentiviral shRNA plasmid was SCH002 (Sigma-Aldrich).
Cloning and generation of caALK2 over-expressing cell line
The caALK2 plasmid was kindly provided by Dr. K. Miyazono [26]. Constitutive active ALK2
was enzymatically cleaved from pENTR backbone and inserted into the pEF5/FRT/V5 vector
by Gateway technology (Invitrogen). MDA-BO2/luc Flp-In cells were transiently cotrans-
fected with the pOG44 Flp recombinase expression plasmid and the pEF5/FRT/V5/caALK2
construct and selected with antibiotics to generate stable isogenic caALK2 expressing cells [20].
[125I]-BMP-7 binding assay
Iodination of BMP-7 was performed according to the chloramine T method and cells were
affinity-labeled with the radioactive ligand (Amersham) as previously described [49, 5, 8]. In
brief, a monolayer of cells were incubated with [125I]-BMP-7 for 3 hours on ice and cross-linked
with 54 mM disuccinimidyl suberate (DSS) and 3 mM bis (sulfosuccinimidyl) suberate (BS3,
Pierce). Cell lysates were incubated with specific anti-sera for type I and type II receptors
for 3 hours and immune complexes were precipitated with proteinA Sepharose (Amersham).
Samples were boiled in SDS sample buffer and separated by SDS-PAGE. Gels were dried and
scanned with the STORM imaging system (Amersham).
Quantitative real-time PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen) and first strand cDNA synthesis
and real-time PCR performed as previously described [50]. Samples were run in triplicates
for each primer set and the relative gene expression levels were assessed as the threshold cycle
(Ct) values of the target and reference gene normalized for GAPDH or ACTIN. Values are
presented as mean ± S.D. The following primers were used; ID2, forward: 5’-TCA GCC TGC
ATC ACC AGA GA-3’ and reverse: 5’-CTG CAA GGA CAG GAT GCT GAT -3’. SMAD6
forward: 5’-TCT CCT CGC GAC GAG TAC AAG-3’ and reverse: 5’-GGA GCA GTG ATG
AGG GAG TTG-3’. SMAD7 forward: 5’-AGA GGC TGT GTT GCT GTG AAT C-3’ reverse:
5’- GCA GAG TCG GCT AAG GTG ATG-3’.
Cell transfection and cell viability assay
Cells were transiently transfected with BRE renilla luciferase [25] or the CAGA renilla-luc
[27] reporter constructs using FugeneHD (Roche) according to the manufacturer’s protocol.
The following day, cells were stimulated 15 hours (or after three days for shRNA experiments)
with the respective ligand. Cells were washed, lysed and the relative renilla/firefly luciferase
activity measured [50, 20]. Transfection was done in triplicate and representative experiments
are shown. For shRNA co-transfection assays, a ratio of 1:6 was used of BRE-luc versus shRNA.
Cell viability was measured performed as previously described [32, 50].
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Western blot analysis
Cells were stimulated with BMP-7 for 45 minutes, washed with PBS and lysed in SDS-sample
buffer. Proteins were separated on SDS-PAGE and subjected to western blotting as previously
described [50].
In vivo intra-bone tumor growth and bone metastasis models
Six week old female BALBc nude mice (Charles River) were anesthetized with isofluorane and
inoculated with 100.000 freshly harvested MDA-BO2-luc cells suspended in 10 µl sterile PBS
(n=5 per group). The surgical procedure was as follows; an incision was made just below the
knee and two holes were drilled in the longitudinal plane of the proximal diaphysis using a 27G
needle. Tumor cells were then directly inoculated into the bone marrow cavity and the wound
closed with sutures [20]. For the bone metastasis model 1x105 freshly harvested cells in 100 µl
PBS were inoculated into the left heart ventricle (n=10 per group) [20]. Injections were done
with 27G syringes. Tumor growth progression was followed weekly by bioluminescent imaging
on the IVIS-100 (Caliper Life Sciences). All animal experiments were approved and carried
out according to the guidelines provided by the local animal welfare committee.
Radiography and µ-CT imaging
Radiographies were acquired as described in [20] and µ-CT scanning was performed with
Skyscan 1076 micro-CT (Skyscan) on fixed tibial samples. Acquisition parameters were as
follows; 750 ms exposure, 0.9 degree rotation at a source voltage of 40kV. 3D scans were recon-
structed using the NRecon and Dataviewer software from Skyscan. Series of tibial longitudinal
and transversal plane sections were analyzed. Tibial cross-sections were quantified by binary
image analysis and presented as the percentage cone comprising area in a given image.
Immuno- and histochemical analysis
Bone tumor sections were imbedded in paraffin and sectioned at 5-6 µm. Histological Masson’s-
Goldner staining was performed as previously described [20, 30]. The relative tumor burden
and area of osteolytic bone resorption were quantified by image analysis with ImageJ software.
Statistical analysis
All results are expressed as the mean ± S.E.M unless otherwise stated. One-way ANOVA
followed by Bonferronis multiple comparison test and two-tailed Students t-test was used where
applicable. P≤0.05 was considered to be statistically significant.
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S.E. Papapoulos, and M.G. Cecchini. Interference with the microenvironmental support impairs
the de novo formation of bone metastases in vivo. Cancer Res., 65(17):7682–7690, September 2005.
[32] M. Deckers, M. van Dinther, J. Buijs, I. Que, C. Ĺ’owik, G. van der Pluijm, and P. ten Dijke.
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Supplemental material
Figure 4.7: Figure S1. BMP secretion in conditioned medium from BMP-7 over-expressing
cells. (A) Culture medium was collected from BMP-7 over-expressing cells two days after stimulation
and added to MDA-BO2 cells transfected with BRE-luc reporter. A positive control was treated with
200 ng/ml BMP-7 (black bar). Data is presented at mean ± S.D of triplicate samples.
Figure 4.8: Figure S2. Tumor cell proliferation in vitro. Cell viability of stable MDA-BO2 cell
lines measured for four consecutive days. The relative growth rates of GFP control (black square),
BMP-7 (grey triangle), and caALK2 over-expressing cells (grey open circle) is presented. Error bars
indicate mean ± S.D. of four measurements, a representative experiment is shown.
133
Figure 4.9: Figure S3. Continuous over-expression of BMP-7 or caALK2 in vivo. The relative
expression level of BMP-7 (A) or ALK2 (B) compared to GAPDH determined by quantitative real-time
PCR in MDA-BO2 cell clones (cl) established from bone tumors and metastases. Error bars indicate
mean ± S.D.
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Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces
renal fibrosis in db/db mice.
Abstract
Progressive kidney fibrosis precedes end-stage renal failure in up to a third of patients
with diabetes mellitus. Elevated intra-renal transforming growth factor-β (TGF-β) is
thought to underlie disease progression by promoting deposition of extracellular matrix
and epithelialmesenchymal transition. GW788388 is a new TGF-β type I receptor in-
hibitor with a much improved pharmacokinetic profile compared with SB431542. We
studied its effect in vitro and found that it inhibited both the TGF-β type I and type II
receptor kinase activities, but not that of the related bone morphogenic protein type II
receptor. Further, it blocked TGF-β-induced Smad activation and target gene expression,
while decreasing epithelial- mesenchymal transitions and fibrogenesis. Using db/db mice,
which develop diabetic nephropathy, we found that GW788388 given orally for 5 weeks
significantly reduced renal fibrosis and decreased the mRNA levels of key mediators of
extracellular matrix deposition in kidneys. Our study shows that GW788388 is a potent
and selective inhibitor of TGF-β signalling in vitro and renal fibrosis in vivo.
Abbreviations
ActRII, activin type II Receptor; ALK, activin receptor-like kinase; caALK, constitutively active ALK;
β-gal, β-galactosidase; BMP, bone morphogenic protein; BMPRII, BMP type II receptor; BRE, BMP
responsive element; COL, collagen; CTGF, connective tissue growth factor; ECM, extracellular matrix;
EMT, epithelial to mesenchymal transition; FN, fibronectin; GAPDH, glyceraldehyde-3-phosphate de-
hydrogenase; GW788388, 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl) pyridin-2-yl)-N-(tetrahydro-2Hpyran-
4-yl) benzamide; MMP, matrix metalloproteinase; NMuMG, namru murine mammary gland; PAI-1,
plasminogen activator inhibitor 1; PAS, picric acid stain; PSmad, phosphorylated Smad; RCC4, renal
cell carcinoma; RT-PCR, reverse transcriptase polymerase chain reaction; SB431542, 4-(5-benzo(1,3)
dioxol- 5-yl-4-pyridin-2-yl-1H -imidazol-2-yl)-benzamide; Smad, small phenotype and mothers against
DPP related protein; α-SMA, α-smooth muscle actin; TGF-β, transforming growth factor-β; TβRII,
TGF-β type II receptor; TIMP, Tissue inhibitor of metalloproteinase; VHL, von Hippel Lindau.
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Introduction
Diabetic nephropathy leads to end-stage renal failure in 20 to 30% of patients with type
1 or type 2 diabetes mellitus[1].1 The multifunctional cytokine, transforming growth
factor-β (TGF-β), is elevated in patients with diabetic nephropathy and is likely a prime
mediator in the progression of renal disease [2, 3].
Specimens from patients with diabetic nephropathy show elevated TGF-β mRNA and
protein levels in glomeruli and the tubulointerstitium [4]. Also, urinary and serum levels
of TGF-β are significantly increased in diabetes patients [5]. In experimental animal
models of type 1 and type 2 diabetes, similar patterns of increased TGF-β expression
and secretion have been observed [6]. Nuclear accumulation of downstream TGF-β
effector proteins was observed in diabetic kidneys. Furthermore, elevated levels of the
TGF-β type II receptor (TβRII) have been reported in diabetic mice compared with
non-diabetic controls [7].
One of the mechanisms by which TGF-β induces fibrogenesis is through stimulation
of extracellular matrix (ECM) proteins and inhibition of matrix degradation. Expres-
sion of key matrix components is enhanced upon TGF-β treatment, both in glomerular
mesangial cells and renal tubular epithelial cells [8, 9, 10]. These factors include fi-
bronectin (FN), type I collagen (COL-1), type III collagen (COL-III), type IV collagen
(COL-IV) and laminin [11]. TGF-β further stimulates ECM accumulation through en-
hancing expression of connective tissue growth factor, which in turn induces FN and
COL-III expression [12]. Also, activated TGF-β suppress the activity of matrix metallo-
proteinases [13] through increased expression of tissue inhibitor of metalloproteinases and
plasminogen activator inhibitor 1 (PAI-1) [14]. Thus, TGF-β promotes renal fibrogenesis
by increasing the synthesis of ECM components and inhibiting matrix degradation.
An additional cellular pathomechanism whereby TGF-β promotes fibrosis is through
the mediation of epithelial to mesenchymal transition (EMT), a process whereby po-
larised epithelial cells are transformed into highly migratory fibroblastoid cells. Epithelial
cells lose polarity, epithelial markers, and cellcell contact. The cells undergo cytoskeletal
remodelling and gain mesenchymal markers essential for cell-ECM association. The net
result being enhanced cell motility and invasiveness [15, 16]. In renal fibrosis, the patho-
logical significance of tubular EMT has become increasingly recognised. Epithelia can
contribute to the ECM overproduction by creating new fibroblasts through the induction
of EMT [17].
TGF-β and the superfamily members, activins and bone morphogenic proteins (BMPs),
signal through related type I and type II transmembrane serine/threonine kinase recep-
tors. The kinases act in sequence, with the ligand-specific type I receptor acting as a
substrate for the type II receptor. In most cell types, TGF-β signals via the TGF-β
type I receptor also termed activin receptor-like kinase (ALK)5 [18]. In endothelial cells,
however, TGF-β signals via ALK1 and ALK5 [19]. In contrast, BMP signals through
ALK2, ALK3, or ALK6 and activin, and nodal through ALK4 and ALK7 [20, 21]. For
TGF-β/ALK5 and activin, the signal is transduced into the cytoplasm through phos-
phorylation of the receptor-regulated Smads (R-Smads), Small phenotype and mothers
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against DPPrelated protein (Smad)2, and Smad3. For TGF-β/ALK1 and BMP, the
signal is via phosphorylation of the R-Smads, Smad1, 5, and 8 [22]. Phosphorylated and
activated R-Smads dissociate from the receptor complex and associate with Smad4 in a
heteromeric manner. The activated complexes shuttle to and accumulate in the nucleus.
Here they regulate expression of a large array of genes in a cell-type-specific and ligand
dose-dependent manner [23].
To directly address the therapeutic potential of TGF-β inhibitors in renal disease,
small-molecule competitive antagonists of the ALK5 kinase activity have been developed.
These inhibitors interact with the ATP-binding site, thereby preventing phosphorylation
of Smad proteins [24, 25]. The commonly used ALK5 inhibitor, 4-(5-benzo(1,3)dioxol-5-
yl-4-pyridin-2-yl-1H-imidazol-2-yl)-benzamide (SB431542), is an ATP competitive kinase
inhibitor [26]. Another mechanism for abrogating TGF-β signalling has been through
long-term treatment with monoclonal anti-TGF-β antibody. In diabetic rodents, this
effectively prevented glomerulosclerosis and renal insufficiency [7, 27, 28, 29]. Also,
antisense TGF-β oligonucleotides were found to reduce kidney weight and expression
of matrix components in diabetic mice [30]. Recently, a soluble fusion protein of the
TβRII was reported to reduce albuminuria in a chemically induced model of diabetic
nephropathy in rats [31].
A limited number of studies have been reported on the use of small-molecule inhibitors
of TGF-β signalling in vivo [32, 33]. SB525334 was shown to significantly reduce pro-
collagen 1a(I), in rat kidneys, in an induced model of nephritis [34]. Also the inhibitor
IN-1130 reduced obstructive nephropathy in rats [35]. These data provide a strong
foundation for using type I receptor kinase inhibitors in clinical testing.
Recently, 4-(4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin- 2-yl)-N-(tetrahydro-2Hpyran-
4-yl) benzamide (GW788388) was developed, as an alternative to the ALK5 inhibitor,
SB431542, with better in vivo exposure (Figure 1). GW788388 is orally active and has
a good pharmacokinetic profile, with an elimination half-life of 1.3 h and a systemic
plasma clearance of 20 ml/min/kg in rats. It was previously shown to reduce the fibrotic
response in a chemical induced model of fibrosis in rats and improve liver histology [32].
In this study, we further characterised the potency and selectivity of this novel in-
hibitor, GW788388. We show that this compound effectively blocks both the ALK5
and to some extent the TβRII. In renal epithelial and cancer cell lines, we assess the
inhibitory effects on TGF-β-mediated biological responses such as EMT and fibrogen-
esis. We examine the effect of blocking TGF-β signalling on renal fibrosis and kidney
function in the db/db mouse model of spontaneous diabetic nephropathy, resembling
the pathogenic phenotype observed in patients with type 2 diabetes mellitus. We show




GW788388 is a selective inhibitor of ALK5 and TβRII
Structures of GW788388 and SB431542, two ATP competitive inhibitors of the kinase
domain of ALK5 are shown in Figure 1a. In a biochemical binding assay, using the
intracellular kinase domain of ALK5, GW788388 was found to have an IC50 for GST-
ALK5 of 0.018 ± 0.08 TGF-µM [32]. To test the specificity of GW788388, we performed
an in vitro kinase assay on full length receptors. Human embryonic kidney 293T cells
were transiently transfected with expression plasmids encoding constitutively active ALK
(caALK) 5, TβRII, BMP type II receptor (BMPRII) or activin type II receptor (ActRII).
Receptors were immunoprecipitated and challenged with [γ32P]-labelled ATP and 10 µM
of compounds. GW788388 potently inhibited autophosphorylation of ALK5, TβRII and
to some extent the ActRII (Figure 1b). The compound had no effect on the BMP type
II receptor kinase activity.
To address if GW788388 was cytotoxic, we treated cells with a dilution range of the
compound and measured cell viability after 72 hours. GW788388 showed no toxicity
in Namry murine mammary gland (NMuMG) (Figure 1c), MDA-MB-231, renal cell
carcinoma (RCC)4, or U2OS cells (data not shown) when treated with dilutions from 4
nM to 15 µM. Similar results were obtained with the SB431542 inhibitor (Figure 1c).
GW788388 inhibits TGF-β-induced Smad2 phosphorylation and
Smad2/3 nuclear translocation
Since GW788388 could block the kinase activity of ALK5 and TβRII, we next studied
the inhibitory effect on TGF-β, activin, and BMP-induced R-Smad phosphorylation and
nuclear translocation. GW788388 inhibited TGF-β-induced Smad2 phosphorylation in a
dose-dependent manner in NMuMG (Figure 2a; Figure S1a), MDA-231-MB (Figure 2b),
and renal cell carcinoma (RCC4)/von Hippel Lindau (VHL) (data not shown). TGF-β-
mediated Smad1/5 phosphorylation, which requires ALK5 and TβRII, was also inhibited
by GW788388 (Figure 2a and b). In T47D cells, GW788388 and SB431542 inhibited the
activin-induced phosphorylation of Smad2 (Figure 2c).
Upon phosphorylation, R-Smads form complexes with Smad4 and accumulate in the
nucleus. TGF-β-induced Smad2/3 nuclear translocation was dose-dependently inhibited
when NMuMG cells were treated with GW788388 (Figure 2d). We tested if GW788388
inhibited the BMP signalling cascade by analyzing the effect of the compound upon
BMP-induced phosphorylation of Smad1/5. As shown in Figure 2e, GW788388 had no
inhibitory effect on Smad1/5 phosphorylation by BMP. SB431542 was shown to have
some inhibitory effect on the mitogen-activated protein kinase p38α at 10 µM.25 We
therefore tested whether GW788388 could inhibit sorbitol-activation of stress-induced
kinases such as the mitogen-activated protein kinases p38 and ERK 1/2. GW788388
had no inhibitory effect on these mitogenactivated protein kinases (data not shown).
Thus, GW788388 selectively inhibits TGF-β and activin Smad signalling and not the
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Figure 5.1: GW788388 inhibits both ALK5 and TβRII. (A) Chemical structures of
GW788388, 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl) pyridin-2-yl)-N-(tetra-hydro-2Hpyran- 4-yl) benza-
mide and SB431542, 4-(5-benzo(1,3) dioxol- 5-yl-4-pyridin-2-yl-1H -imidazol-2-yl)-benzamide. (B) Ef-
fect of GW788388 and SB431542 on autophosphorylation of caALK5, TβRII, ActRII and BMPRII
kinase activity. HEK293T cells were transfected with plasmids encoding full length actively signalling
receptors. These were immunoprecipitated and the in vitro kinase assays were performed with gamma
32P-labelled ATP in the presence of 10 µM GW788388 (GW) or 10 µM SB431542 (SB). (C) Cell viabil-
ity assay. NMuMG cells were treated with dilutions of GW788388 (squares) and SB431542 (triangles)
for 72 hours. Viability was measured with MTS assay. Data is presented as % inhibition compared to
vehicle control. Bars represent mean ±s.e.m.
closely related BMP-signalling cascade.
GW788388 selectively inhibits ALK4, ALK5 and ALK7
To further confirm the selectivity of GW788388, U2OS cells were transiently trans-
fected with expression plasmids encoding the constitutively active full-length receptors
caALK2, caALK3, caALK4, caALK5, caALK6, and caALK7 [36]. These mutation-
ally active receptors signal independently of ligand and their type II receptors. They
were cotransfected with the corresponding luciferase reporter constructs. The TGF-
β-inducible reporter CAGA 12-Luc contains Smad-responsive elements from the PAI-1
promoter, which specifically bind Smad3/Smad4 and drive the luciferase reporter gene
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Figure 5.2: GW788388 inhibits TGF-β-induced Smad activation dose-dependently. NMuMG
(A) and MDA-MD-231 cells (B) were treated with GW788388 (GW) or SB431542 (SB) in the presence
or absence of TGF-β for 1 hour. Protein expression of PSmad2, PSmad1/5 and Smad2/3 was analysed
by western blot analysis. β-Actin served as a loading control. (C) Immunofluorescent staining of Smad
2/3 in NMuMG cells treated with vehicle or GW788388 ± TGF-β for 1 hour. Images were captured
with confocal microscopy. (D) Western blot analysis of U2OS cells treated with GW788388±BMP6 for
1 hour. Control denotes non treated cells and DMSO was used as vehicle.
[37]. The BMP-inducible luciferase reporter, BMP-responsive element-Luc, contains a
BMP-responsive elements from the inhibitor of DNA-binding 1 promoter [38].
GW788388 inhibited the TGF-β response, very efficiently, by blocking signalling
through caALK5, caALK4, and caALK7 in a dose-dependent manner (Figure 3a). The
SB431542 inhibitor was used for comparison and similar results were obtained with all
caALKs (data not shown). In agreement with the phosphorylation data, GW788388 had
no inhibitory effect on the constitutively active BMP receptors (Figure 3b). In addition,
TGF-β and activin (Figure S1b) but not BMPinduced reporter activity was blocked by
GW788388 (data not shown). Thus, GW788388 is a selective inhibitor of the TGF-β
type I receptors ALK5, ALK4, and ALK7.
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Figure 5.3: GW788388 inhibits ALK5, ALK4 and ALK7 in a dose-dependent manner and has
no effect on ALK2, ALK3 and ALK6. (a) U2OS cells were transfected with caALK4, caALK5 or
caALK7 together with the TGF-β specific luciferase reporter construct CAGA12-luc. Cells were treated
with doses of GW788388 (GW) or vehicle. (b) U2OS cells were transfected with caALK2, caALK3 or
caALK6 together with the BMP responsive BRE-luciferase reporter. Measurements are presented as
luciferase activity normalised to β-gal activity. Error bars indicate mean ±s.e.m. of three measurements,
one representative experiment is shown.
GW788388 inhibits TGF-β-induced EMT and growth inhibition
In epithelial cells, the TGF-β-mediated growth inhibitory response and EMT are two
cellular processes that have been extensively explored. The NMuMG cells are a widely
used in vitro model system for studying these TGF-β-mediated responses [39]. To test
if GW788388 could inhibit the TGF-β-induced growth inhibitory response, we measured
cell proliferation with serial dilutions of GW788388. As shown in Figure 4a, increas-
ing concentrations of GW788388 inhibits TGF-β-induced growth inhibition. These re-
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sults were further supported by light microscopy images, demonstrating detachment of
NMuMG cells from the tissue culture surface in response to TGF-β treatment, sugges-
tive of programmed cell death (Figure 4b). Thus, GW788388 blocked TGF-β mediated
growth arrest.
With phase-contrast microscopy, we observed the transition of the cells from an
epithelial to a fibroblastoid phenotype upon stimulation with TGF-β for 48 h (Figure
4b). In cells stained by immunofluorescence with epithelial and mesenchymal markers,
we observed actin stress fiber formation (Figure 4c), loss of E-cadherin expression at
cell-cell junctions, and gain of N-cadherin expression (data not shown) in response to
TGF-β treatment. This EMT response, mediated by TGF-β, was completely inhibited
with GW788388 (Figure 4b and c).
We confirmed these visual observations by analyzing protein and mRNA expression
by western blot analysis and semi-quantitative reverse transcriptase-polymerase chain
reaction. In NMuMG and RCC4/VHL cells, we analyzed the changes in the expres-
sion of epithelial and mesenchymal markers after 48 h of TGF-β stimulation (Figure 5).
E-cadherin protein expression was reduced upon TGF-β treatment, whereas the expres-
sion of the mesenchymal markers N-cadherin and α-smooth muscle actin was increased
(Figure 5a and b). GW788388 attenuated these TGF-β-induced EMT responses. The
inhibitory effect of GW788388 was also observed on mRNA levels of critical TGF-β tar-
get genes involved in EMT, such as E-cadherin, FN, and the transcriptional repressor
of E-cadherin, SNAIL (Figure 5c). In conclusion, GW788388 blocks the TGF-β-induced
growth inhibitory and EMT response.
GW788388 inhibits the TGF-β-induced fibrotic responses in vitro
Since GW788388 inhibited important TGF-β-induced target gene responses required
for EMT, we sought to examine whether the drug also could inhibit TGF-β responses
involved in ECM remodelling. We investigated this by quantitative RT-PCR and western
blot analysis. We found that GW788388 could prevent the TGF-β-induced up-regulation
of CTGF, PAI-1, and COL-I mRNA expression in the renal epithelial cells RCC4/VHL
(Figure 6a) and FN in NMuMG cells (Figure 5c). On protein levels, we confirmed that
GW788388 blocks the TGF-β-induced expression of COL-I and FN (Figure 6b). Thus,
GW788388 inhibits the TGF-β-mediated expression of important players in fibrogenesis
both on mRNA and protein levels.
GW788388 potently attenuates renal fibrosis in vivo
We have demonstrated that GW788388 is a potent inhibitor of TGF-β signaling in several
in vitro models. We next sought to examine the effects of GW788388 in vivo. First,
we compared the i.v. pharmacokinetic profiles of GW788388 compared to SB431542, in
Sprague-Dawley rats. Clearance was 34 ± 12.2 ml/min/kg for GW788388 versus 37.5 ±
13.5 ml/min/kg for SB431542. The half-life of GW788388 was 4.1 ± 1.8 hours versus
28.5 ± 16.1 minutes for SB431542 (data not shown). Hence, GW788388 is far more
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Figure 5.4: GW788388 inhibits TGF-β-mediated EMT and apoptosis. NMuMG cells were
treated with GW788388, the vehicle control DMSO and TGF-β where indicated, for 48 hours. (A)
NMuMG cell proliferation measured after 72 hours drug stimulation with dilution series of GW788388
(GW) (squares) and SB431542 (SB) (triangles) in the presence (closed symbols) or absence (open
symbols) of TGF-β. Metabolically active cells were measured with a cell proliferation/viability assay.
Bars represent means of three independent measurements ±s.e.m. (B) Phase contrast images of TGF-
β-induced EMT. (C) Immunofluorescent staining of actin stress fibre formation. Images were captured
with confocal microscopy.
suitable for in vivo applications than SB431542.
The db/db mouse model of spontaneous diabetic nephropathy was chosen for further
in vivo characterisation of GW788388. Six month old mice were used, with advance
stage renal disease, significant glomerular changes and elevated albuminuria [40]. Mice
were treated for 5 weeks with oral administration of 2 mg/kg/day of GW788388. No
adverse side-effects were observed with the treatment.
Figure 7a shows diabetic mouse kidneys stained with Masson’s Trichrome stain. Col-
lagen deposits are observed in blue. Robust collagen deposits were seen in glomeruli and
minimal to mild glomeropathy was evident in most diabetic animals (left panel). Treat-
ment with GW788388 at 2 mg/kg/day resulted in a reduced collagen staining (Figure
145
Figure 5.5: TGF-β-induced EMT is inhibited by GW788388. Western blot analysis of epithelial
and mesenchymal protein markers in RCC4/VHL (A) and NMuMG (B) cells after 48 hours drug and
TGF-β stimulation. Control is DMSO treated cells. β-Actin was used as a loading control. (C) RT-
PCR semiquantitative analysis of SNAIL, PAI-1, E-Cadherin and FN in NMuMG cells after GW788388
(GW) or SB431542 (SB) treatment and TGF-β stimulation for 48 hours. GAPDH was included as
loading control. Control depicts non treated cells and DMSO vehicle treated cells.
7a right panel). Glomerulopathy was assessed independently on PAS stained sections,
scored blinded. Diabetic mice had significant glomerulopathy marked by mesangial ma-
trix expansion, mesangial hypertrophy, proliferation and glomerular basement membrane
thickening. This was significantly reduced when treated with GW788388 (Figure 7b).
Urinary albumin excretion was additionally measured and corrected for creatinine con-
centrations. In diabetic mice urinary albumin levels were significantly elevated (Figure
7c). GW788388 appeared to decrease urinary albumin concentrations, although not sta-
tistically significant, suggesting that the underlying glomerular dysfunction persisted in
the treated animals. To confirm that the observed changes, in glomerulopathy and the
trend for reduced albuminuria, correlated with inhibition of TGF-β target genes in vivo
RNA was extracted from kidneys and the levels of matrix mRNAs examined. FN, COL-I,
PAI-1 and COL-III expression levels were significantly increased in diabetic mice as com-
pared to their lean littermates (Figure 7d). Treatment with 2 mg/kg/day of GW788388
significantly reduced the mRNA levels of PAI-1, COL-I and COL-III to nearly the same
levels as seen in the non-diabetic lean littermates. Taken together, these results indicate
that GW788388 attenuates TGF-β signalling in vivo and effectively reduces hallmarks
of fibrogenesis in mice suffering from late stage diabetic nephropathy.
146
Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces
renal fibrosis in db/db mice.
Figure 5.6: GW788388 inhibits the TGF-β-induced fibrotic response in vitro. (A) The effect
of GW788388 (GW) on TGF-β-induced mRNA expression of the ECM genes PAI-1, COL-1αI and
CTGF were analysed by real time Q-PCR. RNA was extracted from RCC4/VHL renal epithelial cells
stimulated with drug ± TGF-β for 48 hours. GAPDH was used as a reference housekeeping gene.
Results are presented as means ± SD of three measurements, the experiment was repeated twice. (B)
GW788388 inhibits TGF-β-induced FN and COL-I on protein level, β-actin was used as a loading
control. Controls were treated with DMSO.
Discussion
TGF-β is suggested to be a key factor in the generation of tissue fibrosis [8, 28, 29, 41].
In the diabetic kidney, TGF-β plays an important role in early and late manifestations
of nephropathy such as renal hypertrophy and mesangial matrix expansion [7]. These
pathomechanisms result in destruction of functional renal tissue and eventually loss of
renal function. Blocking TGF-β signalling is therefore considered a promising thera-
peutic approach in the treatment of renal disease. We studied a new TGF-β inhibitor,
GW788388 (results are summarised in Figure 8).
We show that GW788388 effectively inhibits TGF-β-mediated responses in vitro by
blocking the kinase activity of both the type I and the type II receptors. Importantly,
we show that oral administration of GW788388 to diabetic mice significantly reduces
glomerulopathy in kidneys and attenuates expression of key components involved in
fibrosis. These results encourage further studies to therapeutically target the TGF-β
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Figure 5.7: GW788388 attenuates renal fibrosis in db/db mice. GW788388 was orally adminis-
tered to db/db mice for 5 weeks at 2 mg/kg/day. (A) Masson’s Trichrome stained kidney sections. Rep-
resentative images are shown for db/db control (left panel) and db/db mice treated with 2 mg/kg/day
GW788388 (right panel). Blue stain indicates heavy collagen presence indicative of glomerulosclerosis.
(B) Glomerulopathy blinded scores of PAS stained kidney sections. 40 tufts were scored/animal and
the mean score ± s.d were tabulated for each animal. ∗∗P≤0.001versusleancontrol(n = 10),∗P≤0.01
versus vehicle treated db/db mice (DB) (n=12). 2 mg/kg/day dose of GW788388 (2mg DB) (n=7).
(C) Urinary albumin levels corrected for creatinine excretion. Lean controls (n=10), db/db control
(DB) (n=11) and treated with 2 mg/kg/day (2mgDB) (n=6). (D) GW788388 reduced the expression of
TGF-β-induced extracellular matrix target genes in vivo. RNA extracted from kidneys and analysed by
real time PCR of lean controls (n=11), db/db control mice (n=12) and mice treated with 2 mg/kg/day
(n=7). Bars represent mean ± s.e.m.
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pathway in order to treat renal diseases.
GW788388 was identified as an orally active ALK5 inhibitor with much improved
in vivo properties compared to SB431542 [24, 32]. In order to study the specificity of
the compound we performed an in vitro kinase assay with 32P-ATP. We found that
GW788388 potently inhibits both the ALK5 and the TβRII kinase receptor activity
but not the BMPRII. This contrasts what is seen for the related inhibitor, SB431542
[19, 22]. As a consequence of inhibiting the TGF-β receptors, we found that TGF-
β-induced Smad2 phosphorylation and nuclear accumulation were potently blocked by
GW788388. The specificity of GW788388 was further tested on all seven activated ALKs
with reporter assays. We show that the compound could inhibit ALK5 along with the
structurally similar receptors i.e. ALK4 and ALK7. GW788388 did not inhibit ALK2,
ALK3 and ALK6. Previous studies using other TGF-β type I receptor inhibitors have
shown similar results [34, 42, 43] the main distinction being that GW788388 also reduce
the TβRII kinase activity.
TGF-β induces a growth inhibitory and an EMT response in NMuMG cells [39, 44].
We show that GW788388 dose-dependently inhibits these TGF-β responses. The TGF-
β-mediated up-regulation of target genes, involved in excess ECM deposition is well
described. Treating renal epithelial cells with TGF-β mimics the fibrotic response seen in
renal disease, where mRNA levels of PAI-1 and COL-I are increased by TGF-β treatment
[27]. In our hands, GW788388 could prevent the TGF-β-mediated up-regulation of
CTGF, PAI-1 and COL-I RNA levels and FN and COL-I on protein levels in the renal
epithelial cell line RCC4/VHL. Recently, SNAIL was described to directly induce renal
fibrosis and strong expression was found in fibrotic human kidney sections [45]. With
GW788388, we could block SNAIL mRNA expression in epithelial cells. Taken together,
these data indicate that GW788388 selectively and efficiently inhibits TGF-β-mediated
responses in vitro.
Since GW788388 inhibits important components in the TGF-β-induced fibrotic re-
sponse in cell models, we hypothesised that GW788388 could reduce markers of fibrosis in
a mouse model of diabetic nephropathy. Our aim was to examine if TGF-β receptor inhi-
bition could be effective in older mice with established renal disease, as would be observed
in patients presenting with impaired renal function. We show that oral administration of
GW788388 for 5 weeks in 6 month old db/db mice significantly attenuated glomerulopa-
thy in mouse kidneys. This correlated with reduced mRNA expression of critical factors
in ECM remodelling, namely PAI-1, collagen I, and collagen III by GW788388. These
results are in agreement with the oral application of GW788388 to rats with chemical
induced liver fibrosis [32] and with db/db mice treated with neutralizing anti-TGF-β
antibodies [7].
Despite ALK5 inhibition having inhibitory effects on fibrogenesis and histological
glomerulopathy, the effects on kidney function were not significant. Only a trend for
a reduction in urinary excretion of albumin was observed. This suggests that longer
treatments may be necessary to reverse the effects of fibrosis. Moreover, it is not clear
if ALK5 inhibition would address the underlying glomerular pathology leading to al-
buminuria in the first instance. To address this hypothesis, treatment would need to
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be started earlier before any albuminuria is observed. Thus, for ALK5 inhibition alone
to be fully effective against a change in glomerular permeability, we hypothesise that
earlier and longer treatment periods are needed in order to inhibit tissue remodelling
within the kidney and allow restoration and/or preservation of glomerular morphology
and function.
All together, these data provide a strong foundation for using TGF-β receptor kinase
inhibitors in a clinical setting. Renal disease progresses slowly and halting this process
with a TGF-β receptor inhibitor will presumably require chronic treatment. However,
TGF-β is a pleiotropic cytokine which modulates a broad array of processes. The chal-
lenge in using TGF-β receptor inhibitors for anti-fibrotic treatment will be to balance
the disease related fibrotic actions against the immune modulatory and tumour suppres-
sor functions of TGF-β. Also, all ALK5 kinase inhibitors reported to date inhibits the
kinase activity of the ALK4 and ALK7 [20, 24, 33, 43, 46] and GW788388 to some ex-
tend the ActRII. Long-term treatment may therefore affect activin and nodal dependent
signalling.
In summary, we have demonstrated that GW788388 can inhibit TGF-β signalling in
vitro and attenuate renal fibrosis in vivo (Figure 8). By blocking the action of the ALK5
and TβRII kinase receptors TGF-β-induced growth arrest, EMT and ECM deposition
was inhibited in vitro. Through oral administration of GW788388 to db/db mice for
5 weeks, we were able to reduce glomerulopathy and prevent the TGF-β-mediated up-
regulation of excess renal ECM deposition. Thus, we could reduce renal fibrosis in
a mouse model for advanced diabetic nephropathy. Our results suggest that TGF-β
receptor kinase inhibition should attenuate fibrogenesis and improve the fibrotic outcome
for patients suffering from diabetic nephropathy. Whether prolonged or earlier treatment
might restore or prevent declines in renal function and not just fibrosis remain to be
determined.
Materials and Methods
Cell culture and reagents
The human breast carcinoma MDA-MB 231, the human osteosarcoma U2OS and the monkey
kidney COS cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with
10% fetal bovine serum, 100 U/ml penicillin and 50 µg/ml streptomycin. The human renal
carcinoma cell line (RCC4) stably transfected with plasmid expressing the von Hippel Lindau
(VHL) protein, was maintained in medium as above with neomycin. The murine breast ep-
ithelial cells, NMuMG were maintained in DMEM as above with 10 mg/ml insulin [44]. Cell
lines were cultured at 37 ◦ in 5% CO 2. SB431542 was from Tocris. Compounds were dissolved
in DMSO. We used 5 ng/ml TGF-β3, 100 ng/ml BMP6 and 50 ng/ml activin a. Antibodies
recognizing phosphorylated Smad2 (PSmad2) and phosphorylated Smad 1/5 (PSmad1/5) are
described in [47] and TβRII antibody in [18]. Smad2/3, N-cadherin and E-cadherin antibodies
were from BD transduction laboratories. Collagen type I antibody from Southern Biotechnol-
ogy. FN antibody from Abcam. β-Actin (AC-15), α-smooth muscle actin (1A4) and FLAGM2
antibodies from Sigma. Hemagglutinin antibody was from Roche.
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Cellular assays, immunodetection and RNA extraction
Immunofluorescence, western blotting, in vitro kinase assay, cell proliferation assays, transfec-
tion and transcriptional reporter gene assay were done as previously reported [19, 36, 37, 38, 39,
48]. RNA extraction RT-PCR and Q-PCR were described in [32, 44]. For detailed description
of these methods see Supplementary Methods.
Histopathology
Kidneys were fixed in 10% formalin. Sections were stained with picric acid stain (PAS) and
Masson’s Trichrome at Research Pathology Services Incorporated (New Britain, PA). Stained
sections were submitted to Pathology Associates, Incorporated for assessment of glomerular
changes. Scoring system is outlined in Supplementary methods.
Animal experiments
Intravenous pharmacokinetics profiles were determined in Sprague-Dawley rats, using a crossover
design on four separate study days (see Supplementary Methods). Male C57BLKS/JLepr db/db
mice were used as a model for type 2 diabetes mellitus [40] (Jackson laboratory). Animals re-
ceived GW788388 at 2 mg/kg/day mixed with powdered rodent chow, water ad libitum. After
5 weeks of drug treatment, a 24 hour urine collection was performed by individual housing in
metabolic cages. Albumin concentrations corrected for creatinine were determined (Nephrat
II enzyme-linked immunosorbent assay kit). Kidneys were snap-frozen for RNA analysis or
fixed for histology. Plasma drug levels determined by HPLC/MS/MS. GW788388 was isolated
from 50 µl of plasma (Sciex API 365). End plasma concentration was 10.4 ± 1.2 nM and urine
concentration 0.9 ± 0.3 µM. All experimental procedures conformed to the Guide for the Care
and Use of Laboratory Animals published by US Institutes of Health (NIH Publication No.
85-23, revised 1996) and were approved by the Institutional Animal Care and Use Committee.
Statistical Analysis
The experiment was completely randomised. One-way analysis of variance was performed with
Bonferroni’s multiple comparison test. P≤0.05 was considered to be statistically significant.
Mean is presented either as ± s.e.m or ± s.d.
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Supplementary information
Figure 5.9: Supplementary Figure S1. TGF-β-induced Smad2 phosphorylation and activin-
induced CAGA-luciferase activity are inhibited in a concentration-dependent manner. (A)
Western blot analysis of Smad2 phosphorylation in NMuMG cells after 1 hour TGF-β stimulation.
Smad2 phosphorylation is blocked with nanomolar concentrations of GW788388. (B) Activin a-induced
CAGA-luciferase activity is inhibited by SB431542 and GW788388. Transiently transfected U2OS cells
were stimulated with activin overnight and luciferase activity measured, corrected for β-gal activity.
Error bars denote ± s.e.m of three measurements.
Supplementary methods
Transfection and reporter gene assay.
Transient transfection of cells were carried out using Lipofectamine (Invitrogen) [39]. Human
constitutive active ALK (caALK) 1, 2, 3, 4, 5, 6, and -7 plasmids and the CAGA12 or the
BRE luciferase reporter constructs have previously been described [36, 37, 38]. We measured
on the Wallac 1420 VICTOR3.
RNA extraction, RT-PCR and Q-PCR.
Cells were treated with GW788388, SB431542 or DMSO and TGF-β the day after plating.
Total RNA was isolated using the RNeasy kit (Qiagen). RT-PCR was performed for PAI-1,
SNAIL, FN, E-cadherin and glyceraldehyde-3- phosphate (GAPDH) as previously described
[44]. RNA was extracted from mouse kidneys and Q-PCR was performed using the ABI Prism
6700 Workstation [32]. RpL-32 or GAPDH were used as housekeeping genes.
In vitro kinase assay, cell viability assay and western blotting.
The kinase assay was performed as described in [7]. In brief, cells were transfected with
caALK5, TβRII, BMP type II receptor (BMPRII) or the Activin type II receptor (ActRII). Im-
munoprecipitated receptors challenged with 14.8 kBq/ml [γ-32P]-ATP and 10 µM compounds.
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Oral administration of GW788388, a kinase inhibitor of the TGF-β type I and type II receptors, reduces
renal fibrosis in db/db mice.
Cell viability and proliferation assays were done according to the manufactures instructions
(CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, The Netherlands).
Viability and proliferation were measured after 72 hours drug treatment in the presence or
absence of TGF-β. Western blot analyses were performed using standard techniques [39].
Immunofluorescence.
Cells were seeded on coverslips and treated with GW788388 and TGF-β where indicated, for
1 or 48 h as previously described [39, 44]. Images were captured with confocal microscopy.
Histopathological scoring.
Stained sections were independently assessed for glomerular changes. Scoring was done on
approximately 40 glomerular tufts (representing essentially all of the glomeruli present in a
typical section) from each animal using the following categorical criteria for each glomerulus:
0 - well-defined glomerular tuft with essentially no significant accumulations of PAS positive
mesangial matrix; 1 - slight, focal increases in PAS positive mesangial matrix or thin bands of
increased PAS positive matrix running along the core of the glomerular tuft; 2 - Multiple small
foci of increased mesangial matrix or thicker more dense bands of matrix; 3 - Increased matrix
to the extent that some lobules of a glomerular tuft can be considered sclerotic. Mesangial cells
may be increased in these areas; 4 - significant increases in mesangial matrix and frequently
increased numbers of mesangial cells involving the entire glomerular tuft.
Pharmacokinetic profiling in vivo.
Intravenous pharmacokinetics profiles were determined in Sprague-Dawley rats, using a crossover
design on four separate study days. Femoral vein catheters implanted for infusion of test com-
pounds at least three days prior to the start of the study. On day one, animals received
GW788388 (6 µmol/kg target dose) or SB431542 (2 µmol/kg target dose) by 30 minutes i.v.
infusion (4 mL/kg). The dose (pH = 3.5), contained 3% DMSO prepared in 20% aqueous
encapsin (Cerestar USA Inc., Hammond, IN). For SB431542 the dose solution was prepared in
10% PEG 400 and isotonic saline (pH = 3.5-4.0) and contained 1.0% DMSO.
Chapter 6
Summary and Discussion
Since the discovery of TGF-β nearly three decades ago [1, 2, 3, 4] tremendous scien-
tific effort has led to a sophisticated understanding of the multifunctional actions of this
pleiotropic cytokine. TGF-β regulates a myriad of processes in normal tissues and in
cancer pathogenesis a characteristic is the frequent loss of TGF-β-induced growth arrest
and abnormal secretion of this cytokine (reviewed in [5, 6, 7, 8, 9]). The pathogenic
branch of TGF-β signaling is an attractive target for therapeutical intervention. How-
ever, in order to specifically direct therapy to this arm of TGF-β signaling a deeper
understanding of its cellular actions and intercellular signal transduction pathways in
specific contextual settings is crucial. Several studies are presented in this thesis, which
are aimed at unraveling the mechanisms by which TGF-β is involved in the pathogenesis
of breast cancer, breast cancer bone metastasis and in renal fibrosis.
The key findings presented in this thesis are:
1. The intracellular TGF-β effector proteins, Smad2 and Smad3, play differential
roles in breast cancer bone metastasis. Smad2 mediates anti-angiogenic properties
whereas Smad3 contributes with pro-angiogenic effects in vitro and in human breast
cancer bone metastasis (chapter 2).
2. HMGA2 was identified as a Smad4-dependent TGF-β target gene in breast cancer
cells. This factor is required for TGF-β-induced EMT of epithelial cells. Ectopic
expression of HMGA2 results in a down-regulation of E-cadherin, which is mediated
via enhanced expression of its transcriptional repressors Snail1, Snail2/Slug and
Twist (chapter 3).
3. TGF-β-induces EMT, growth arrest and initiates specific gene responses in epithe-
lial cells. The actions of TGF-β can be inhibited by administration of the ALK5
and TβRII antagonist GW788388 (chapter 5).
4. Expression of constitutively active ALK2, a BMP-7 type I receptor, in osteotropic
breast cancer cells impairs tumor-induced osteolysis in an intra-bone tumor growth
model (chapter 4).
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5. Constitutive activation of the BMP-7 receptor, ALK2, in breast cancer cells led
to the findings that the anti-metastatic actions of BMP-7, in breast cancer bone
metastasis can occur via direct effects on the tumor cells. This mediates paracrine
signaling in cells of the bone and tumor-associated microenvironment. We spec-
ulate that enhanced BMP signaling can counteract TGF-β in cancer cells hereby
disturbing the vicious cycle of bone metastasis (chapter 4).
6. When the TGF-β inhibitor GW788388 was orally administered to diabetic db/db
mice with advanced nephropathy, GW788388 significantly reduced renal fibrosis
and decreased expression of key mediators of fibrosis in kidneys (chapter 5).
The significance of these observations and how we can relate them to the field of
TGF-β research and potentially lead to clinical applications will be discussed in the
following. A simplified schematic overview of our findings is given in figure 6.1.
6.1 Modulation of the TGF-β signaling pathway
TGF-β may exert dual roles in carcinogenesis. Acting at first as a tumor suppressor,
in premalignant stages of tumorigenesis, via inhibition of proliferation and induction of
apoptosis. At later stages of disease, TGF-β can shift to being a tumor promoter (re-
viewed in [5, 6, 7]). Frequently in cancer there is a loss of the TGF-β cytostatic responses
and the switch to a tumor promoting role of TGF-β. Concomitantly, high dose secretion
of active TGF-β is often observed in carcinomas. The net result being tumor progres-
sion and possibly metastasis (reviewed in [5, 8, 9]). The molecular determinants which
mediate this switch remain poorly understood [10]. However, dissecting the individual
steps of the metastatic cascade has led to pivotal findings and the mechanistic of breast
cancer metastasis are gradually being unveiled.
Smad2, Smad3, HMGA2 downstream mediators of TGF-β sig-
naling
We studied several aspects of the pro-tumorigenic functions of TGF-β in breast can-
cer cells and in breast cancer metastasis models in vivo. It was previously shown that
knockdown of Smad4 inhibits the formation and progression of bone metastasis of MDA-
MB-231 cells [11, 12]. However, Smad4 is a central regulator of both TGF-β and BMP
signaling. In chapter 2 we describe a comparative analysis of the two direct down-
stream mediators of TGF-β signaling Smad2 and Smad3. The function of these signaling
molecules were analyzed in the highly invasive and osteotropic breast cancer cells the
MDA-MB-231. Smad2 or Smad3 expression was genetically knocked down by lentiviral
transduction of microRNAi (miR RNAi).
When analyzing the effect of eliminating these TGF-β effector molecules we found that
key metastatic TGF-β target genes [13] were critically dependent on Smad3 and not
Smad2 (see figure 6.1). These genes include IL-11, PAI-1 and CTGF. That Smad3 is
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Figure 6.1: Modifying the TGF-β signaling pathway
We modified TGF-β signaling and downstream responses through several mechanisms in NMuMG and
MDA-MB-231 breast cancer cells. By lentiviral transduced microRNAi we eliminated the expression
of either Smad2 or Smad3. Smad2 and Smad3 were shown to play specific roles in MDA-MB-231
breast cancer cells. Smad3 was necessary for TGF-β inducible gene responses of IL-11, CTGF, PAI-1
and VEGF-A. In contrast, loss of Smad2 enhanced VEGF mRNA expression (left side of figure). We
studied the function of HMGA2 a direct target gene of TGF-β and found HMGA2 to be dependent on
Smad3 and Smad4 in MDA-MB-231 cells and on Smad2, Smad3, and Smad4 in NMuMG cells. Enhanced
HMGA2 expression significantly induced the expression of the E-cadherin repressors Snail1, Snail2 and
Twist. Furthermore, expression of Id2 was repressed when HMGA2 was overexpressed. Thus, ectopic
expression of HMGA2 induce EMT of NMuMG cells independent of TGF-β and loss of HMGA2 inhibits
TGF-β mediated EMT (middle part of figure). Continuous activation of the BMP-7 receptor caALK2
was shown to counteract TGF-β signaling in MDA-BO2 cells as observed in transcriptional reporter
assays (right side of figure).
the major regulator of TGF-β target genes is in line with several other previous reports
[10, 14, 15, 16, 17]. Also, specific knockout of Smad2 or Smad3 in hepatocytes identified
Smad3 as the main transcriptional inducer or repressor downstream of TGF-β [10].
We further analyzed the effect of knockdown on the migratory properties of breast
cancer cells. MDA-MB-231 cells readily migrate in response to TGF-β and this can be
inhibited by administration of an ALK5 kinase inhibitor (chapter 2, [18]). We found that
depletion of either Smad2 or Smad3 was sufficient to inhibit TGF-β-induced migration
of MDA-MB-231 cells.
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To specifically determine the actions of TGF-β in metastasis we used the Smad2 and
Smad3 knockdown cells in a breast cancer metastasis model where cells are inoculated
into the left heart ventricle and metastasize to bone [12]. Knockdown of Smad2 resulted
in enhanced progression of metastasis compared to control and Smad3 knockdown tumor-
bearing animals. In contrast, Smad3 knockdown cells displayed delayed growth kinetics
in the early phases of the experiment. These findings were directly correlated with
differential roles of Smad2 and Smad3 in tumor-induced angiogenesis (see figure 6.1 and
6.2). VEGF secretion was significantly enhanced in MDA-MB-231 cells depleted for
Smad2. In Smad3 knockdown cells, VEGF-A expression and secretion were no longer
induced by TGF-β.
To further examine this, we visualized and quantified the newly formed capillary
networks in bone tumor metastasis by immunohistochemical CD31 staining. Strikingly,
Smad2 knockdown metastasis showed a four fold increase in CD31 staining and the
micro vascular density was significantly enhanced compared to Smad3 knockdown and
control metastasis. Thus, Smad2 may inhibit tumor-induced angiogenesis by negatively
regulating tumor-cell secretion of VEGF into the bone microenvironment. Smad3, on
the contrary, induce angiogenesis by stimulating production of angiogenic factors (like
VEGF) and chemotactic factors, which mediate the recruitment of inflammatory cells
(see figure 6.2).
In agreement with our findings, Smad2 was found to mediate secretion of factors
with anti-angiogenic properties, whereas Smad3 induced the secretion of pro-angiogenic
factors in tubular epithelial cells [19].
A study by Ju et al. [10] clearly demonstrated differential roles of Smad2 or Smad3 in
conditional knockout (KO) hepatocytes. Smad2KO cells displayed enhanced migratory
potentials and spontaneously underwent mesenchymal transition suggesting that Smad2
is required to maintain a stable epithelial morphology [10]. In contrast, TGF-β was
unable to induce EMT in Smad3KO cells. Moreover, Smad3 was found to be an essential
mediator of apoptosis and TGF-β-induced G1 cell cycle arrest whereas in Smad2KO cells
cyclinD1 and c-Myc were up-regulated [10]. Thus, Smad2 and Smad3 exert distinct roles
in TGF-β-mediated cell cycle regulation in hepatocytes. In our breast cancer model we
found that Smad2 knockdown cells proliferated slightly slower in vitro than control and
Smad3 knockdown cells. However, we cannot exclude effects on apoptosis or survival
since proliferation was analyzed in a cell viability assay. It would be interesting to
examine the proliferative capacities of Smad2 miR RNAi cells versus control and Smad3
miR RNAi cells in our bone metastases sections with immunohistochemical markers for
apoptosis and proliferation.
When analyzing TGF-β-induced responses in hepatocytes all genes examined were
shown to be dependent on Smad3 [10]. Similarly, we found that most TGF-β-responsive
genes were regulated by Smad3 not Smad2. Many of these genes were also dys-regulated
in MDA-MB-231 Smad4 knockdown cells [11, 12]. However, even though many pro-
metastatic genes lost their responsiveness to TGF-β in both Smad3 and Smad4 knock-
down cells loss of Smad4 gave rise to a much less severe metastatic phenotype in vivo.
Metastasis-free survival was significantly enhanced when Smad4 was depleted and the
6.1 Modulation of the TGF-β signaling pathway 161
Figure 6.2: Smad2 and Smad3 play distinct roles in breast cancer bone metastasis.
Model of the opposing roles of Smad2 and Smad3 i osteotropic MDA-MB-231 cells. Knock down of
Smad3 (left panel) results in loss of TGF-β-inducible gene responses of critical metastatic inducers such
as IL-11, CTGF, PAI-1, VEGF-A and HMGA2. When Smad3 knockdown cells were used in a bone
metastatic model prolonged latency in metastatic growth was observed. In contrast, when Smad2 was
eliminated (right panel) enhanced expression and secretion of VEGF was observed. This translated
into enhanced metastatic potential of these cells in vivo and significantly enhanced tumor-induced
angiogenesis. Together, these observations support a role for Smad2 as a tumor suppressor and Smad3
as a tumor promoter in breast cancer cells.
frequency of bone metastasis was reduced by 75% [11, 12]. In animal injected with
Smad3 knockdown cells we observed a clear latency in tumor progression in the early
phase of metastatic progression compared to control and Smad2 inoculated animals.
Since Smad4 is a common transcription factor shared by both TGF-β and BMP these
observations could suggest that abrogation of both signaling pathways result in a more
efficient blockade of metastasis compared to only eliminating Smad3.
The molecular determinants that mediate the functional switch, which transform
TGF-β from being a tumor suppressor to a tumor promoter remain poorly understood.
We hypothesize that loss of Smad2 (genetic or epigenetic) during tumorigenesis may
increase the metastatic potential, whereas loss of Smad3 could decrease the metastatic
behavior of breast tumor cells (chapter 2, [10]). This is in line with findings in patients
with stage II breast cancer where loss of P-Smad2 staining is correlated with shorter
overall survival [20]. Thus, it is possible that the functional switch may be determined
by changes of the relative balance of Smad2 (anti-metastatic signaling) and Smad3 (pro-
metastatic signaling) in malignant cells (see figure 6.2) hereby affecting their distinct
properties on the microenvironment [10]. It would therefore be of great interest to per-
form a more detailed genetic analysis of the exact roles of Smad2 and Smad3 both in
response to TGF-β and in non-induced conditions and to analyze the impact of knock-
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down or either Smad2 or Smad3 on the tumor-associated stroma in bone metastasis in
further detail.
Thus, our findings suggest that Smad2 and Smad3 play distinct roles in mammary
cancer metastasis. In hepatocytes, Smad2 knockout cells spontaneously acquired mes-
enchymal features with a pro-migratory phenotype [10]. Smad3, on the other hand,
was necessary for TGF-β-induced EMT and migration [10]. Also, keratinocyte-specific
knockout of Smad2 displayed clear mesenchymal characteristics [21]. Together, these
studies suggest that Smad2 is necessary to maintain a stable epithelial phenotype and
that the two TGF-β R-Smads have distinct functions in several cellular systems. The
breast cancer model used in our study is not suited for studying aspects of EMT as
MDA-MB-231 cells display partial hypermethylation of the E-cadherin promoter [22].
Moreover, we employ intracardiac inoculation of the cancer cells and hereby circumvent
the critical steps of EMT.
EMT facilitates cell movement and the generation of new tissues in embryogenesis.
In a cancer setting, gain of mesenchymal characteristics allow tumor cells to disseminate
and intravasate and hereby escape from the primary tumor as extensively described in
chapter 1 (reviewed in [5, 23, 6, 24]). The downstream mediators of TGF-β Smad2,
Smad3 and Smad4 have all been extensively studied in normal epithelial cell models.
Homozygous deletion of Smad2 triggered complete EMT in skin tumors [21]. In contrast,
over-expression of activated Smad2/3 was shown to increase cell motility in a squamous
skin tumorigenesis models [25]. In line with these findings, Valcourt et al. showed that
ectopic expression of either Smad2 and Smad3, in combination with Smad4 could induce
EMT in NMuMG cells [26]. In these cells, loss of Smad3 or Smad4 by RNAi completely
abrogated TGF-β-induced EMT [17, 12]. Moreover, overexpression of the antagonist of
TGF-β signaling, Smad7, in NMuMG cells blocked TGF-β-mediated EMT [26].
The discovery of HMGA2 as being a direct target gene of TGF-β and necessary for
TGF-β-mediated EMT of mammary epithelial cells is described in chapter 3 (see figure
6.3). We found that knockdown of Smad4, in NMuMG cells blocked TGF-β-induced up-
regulation of Hmga2. In MDA-MB-231 cells, knockdown of either Smad3 or Smad4 could
block TGF-β-mediated HMGA2 mRNA induction. When HMGA2 was over-expressed
this alone could drive the EMT response through direct up-regulation of the E-cadherin
repressors, i.e. Snail1, Snail2 and Twist. In addition, ID2, another key player in EMT,
which expression is reduced in response to TGF-β [27], was down-regulated in HMGA2
over-expressing cells. Furthermore, NMuMG cells depleted for HMGA2 by RNAi no
longer undergo EMT in response to TGF-β. Together these findings establish a strong
role for HMGA2 as a mediator of EMT, which is directly induced by TGF-β [28].
In correlation with these observations, it was shown that HMGA2 is highly up-
regulated during embryogenesis in cells which have not yet undergone overt differen-
tiation [29, 30]. In normal tissues, the expression of HMGA2 is lost and various tumor
types abundantly re-express HMGA2, which is correlated with enhanced malignancy or
metastatic potential [29, 31]. Together, these findings suggests that HMGA2 indeed
could be a key pro-tumorigenic mediator downstream of TGF-β.
We persistently tried to study the role of HMGA2 in the MDA-MB-231 breast can-
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Figure 6.3: HMGA2 induce the expression of E-cadherin repressors resulting in EMT.
TGF-β up-regulate HMGA2 via Smad-dependent mechanisms. Ectopic HMGA2 expression significantly
induced the mRNA expression of Snail1, Snail2 and Twist which functions as critical E-cadherin re-
pressors. In addition, HMGA2 could repress the expression of Id2. Thus, ectopic expression of HMGA2
induce EMT of NMuMG cells independent of TGF-β as observed on morphological and EMT marker
level.
cer bone metastasis model. This was done by knock down of HMGA2 expression by
shRNAi and analyzing the effect in various tumorigenic assays. HMGA2 knockdown
cells displayed reduced capacity to invade and migrate in matrigel coated transwell
chambers (Thuault unpublished observations). No differences were observed in other
in vitro models such as anchorage-independent growth or proliferation assays. When
HMGA2 knockdown cells were used in our in vivo metastasis model we did not observe
any differences in metastasis formation and progression between control cells and cells
silenced for HMGA2. Despite technical difficulties in conducting these experiments we
hypothesize that HMGA2 is important in a primary tumor setting where EMT is needed
for migration and invasion to distant sites. This is in line with findings in squamous car-
cinomas where HMGA2 is observed at the invasive front in carcinoma tissue where tumor
cells migrate into the connective tissue [31]. However, in later stages of the metastatic
cascade HMGA2 may not be necessary for the establishment and progression of breast
cancer bone metastasis.
We studied the knock down of HMGA2 in osteotropic MDA-MB-231 cells a highly
metastatic cell line, which displays complete loss of E-cadherin [22]. This metastasis
mode circumvents critical steps of EMT since the main pro-tumorigenic function of
HMGA2 is the induction of the E-cadherin repressors this may explain the outcome of
our preliminary in vivo study using cells in which there is no E-cadherin present to be
repressed. HMGA2 may therefore be irrelevant in the later stages of tumorigenesis in
MDA-MB-231 cells. Olmeda et al. showed that knock down of the E-cadherin repres-
sor SNAIL in MDA-MB-231 could inhibit orthotopic growth in vivo [32]. This might
have been a superior model for studying the effect of HMGA2 depletion or overexpres-
sion. Alternatively we could have used immortalized human mammary epithelial cells
as described by Onder et al. who recently used this cell line to examine the function of
E-cadherin in breast cancer [33]. Otherwise, the murine epithelial breast cancer line 4T1
which express E-cadherin and give rise bone-tropic metastasis could have been a better
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suited model for these studies [34].
Counteracting TGF-β signaling by continuous activation of ALK2
Metastatic cancer affects millions of people worldwide yet the majority of patients with
cancer metastasis remain incurable [6, 35]. Cancer research have largely been focussed
on the cells from which a given cancer originates in a primary tumor setting. However,
tumor growth depends on interactions between multiple inter-dependent cell types [36].
How the microenvironment and tumor-infiltrated stromal cells influence tumorigenesis
and the role played by TGF-β herein are currently topics of intense investigation.
In patients with breast cancer, loss of BMP-7 mRNA expression in primary tumor is
associated with the formation of bone metastasis [37]. In prostate cancer, the expression
of BMP-7 was shown to be down-regulated compared to normal prostate tissue [38].
Moreover, in a panel of cancer cell lines the expression of BMP-7 negatively correlated
with tumor cell aggressiveness [37, 38]. BMP-7 can counteract TGF-β signaling and
reverse TGF-β-induced EMT. This is mediated through re-expression of the key EMT
marker E-cadherin [39, 37, 40]. In MDA-MB-231 breast cancer cells, BMP-7 was shown
to counteract TGF-β at the transcriptional level and reverse the TGF-β-induced up-
regulation of vimentin [37]. When BMP-7 was ectopically expressed in MDA-BO2 cells
or human recombinant BMP-7 systemic administered to MDA-BO2 tumor-bearing mice
a significant inhibition in the number of osteolytic metastasis and progression of these
lesions was observed [37].
In chapter 5, we describe the identification of the functional BMP-7 receptor, ALK2,
in MDA-BO2 cells. Furthermore, we explore whether ectopic expression caALK2, a
genetically constitutively activated receptor, can mediate similar responses as over-
expression of BMP-7 ligand in vitro and in vivo. Ectopic expression of caALK2 resulted
in continuous activation of downstream BMP signaling, thus mimicking a state of contin-
uous BMP-7 signaling. When analyzing classical downstream target genes of BMPs, we
found sustained up-regulation of ID2, SMAD6, and SMAD7. Moreover, TGF-β signaling
was significantly abrogated at transcriptional level (see figure 6.1). Hence, these obser-
vations are directly in line with our findings in cells ectopically expressing the BMP-7
ligand [37].
Whether the inhibitory actions of BMP-7 on bone metastasis and intra-bone tumor
growth are caused by direct cell autonomous actions on the cancer cells or through
direct inhibitory signals on the tumor-associated stroma has remained elusive. With
over-expression of caALK2 we mimic a situation where BMP signaling is active only
in the tumor cells not in the entire microenvironment as is the case for BMP-7 over-
expressing cells (see figure 6.4). The metastatic behavior of BMP-7 versus caALK2
over-expressing cells was studied in intra-bone tumor growth and metastasis models.
In the intra-bone tumor growth model the effects of either caALK2 or BMP-7 over-
expression on tumor-induced bone remodeling was analyzed by quantifying changes in
bone mass and bone architecture by µ-CT. We found that the formation of overt oste-
olytic lesions was significantly inhibited in mice injected with either caALK2 of BMP-7
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Figure 6.4: Over-expression of BMP-7 or caALK2 inhibits osteolytic breast cancer metastasis.
A tumor cell-induced vicious cycle of osteolysis and tumor growth in the bone is dependent on active
TGF-β signaling. Tumor cells secrete pro-osteolytic factors which stimulate osteoclastogenesis and
osteoclastic activation hereby inducing bone resorption. Bone encapsulated growth factors such as
TGF-β is released into the microenvironment and these act back on the cancer cells to stimulate further
growth and osteolysis. We overexpressed BMP-7 (top insert) or caALK2 (lower insert) in osteotropic
breast cancer cells. BMP-7 secreted from MDA-BO2 cells over-expressing the ligand act both on the
tumor cells and cells in the bone microenvironment. Cells over-expressing caALK2 on the other hand
solely activate BMP-7 signaling in the tumor cells. Both cell lines displayed significantly reduced tumor-
induced osteolysis and metastatic progression. High up-regulation of Smad7, a well described inhibitor
of TGF-β and BMP signaling was also observed in these cell lines. We hypothesize that this induction
of Smad7 or alternatively ID proteins could play an important inhibitory role in breast cancer bone
metastasis and intra-bone tumor growth.
expressing breast cancer cells compared to control inoculated cells.
We further characterized the metastatic potential of caALK2 MDA-BO2 cells in
the bone metastasis model [41, 42]. Strikingly, ectopic expression of caALK2 inhibited
the number and progression of osteolytic metastasis compared to control MDA-BO2
inoculated animals. Similar observations were seen with MDA-BO2 cells over-expressing
BMP-7 [37]. Thus, progression and osteolytic bone destruction is largely dependent on
tumor cell autonomous signaling.
One of the mechanisms whereby BMP and TGF-β signaling confer dichotomous ac-
tions is, in part, through differential regulation of ID proteins [27]. Thus, caALK2
or BMP-7 may antagonize TGF-β signaling and hereby mediate inhibitory actions on
metastatic tumor growth through direct up-regulation of ID1 and ID2. Also, the nega-
tive regulator of TGF-β and BMP signaling, Smad7, was up-regulated in caALK2 and
BMP-7 over-expressing cells. Smad7 targets type I receptors and R-Smads for degra-
dation and inhibit complex formation with Smad4 [43, 44, 45, 46]. Ectopic expression
of Smad7 in NMuMG cells can block TGF-β-mediated EMT [26]. Also, over-expression
of Smad7 in melanoma cells significantly reduced in the progression of bone metasta-
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sis [47]. Furthermore, adenoviral administration of Smad7 to mice bearing jygMC(A)
murine mammary tumors or ectopic expression of Smad7 in these cells [48] significantly
inhibited metastasis and increased metastasis-free survival [48].
Thus, Smad7 plays a crucial role in metastatic progression of various cancers. Stable
overexpression of Smad7 inhibited the up-regulation of TGF-β-inducible genes such as
IL-11, CXCR4, PTHrP and Osteopontin in melanoma cells [47]. We analyzed the ex-
pression levels of IL-11, PTHrP and CTGF in cell over-expressing caALK2 or BMP-7
MDA-BO2 compared to control cells and found no changes in expression patterns. In
order to determine the contribution of either Smad7 or ID2 in our model it would be of
great interest to genetically deplete these proteins from caALK2 and BMP-7 cells and
analyze their changed metastatic behavior in vivo.
Continuous activation of ALK3, a receptor for BMP-2 and BMP-4 [49], was recently
shown to mediate invasion and metastasis of MDA-MB-231 breast cancer cells. This
pro-metastatic function of caALK3 could be blocked by over-expression of a dominant
negative ALK3 [50]. We show that in MDA-BO2 cells BMP-7 signals via ALK2 and over-
expression of continuous active ALK2 receptor gives rise to a less metastatic phenotype
in vivo. Thus, active BMP-7 signaling in tumor cells distinctively induce anti-metastatic
properties in these human breast cancer cells. Together, these observations highlight the
importance of discriminating between different BMPs when characterizing their func-
tions.
Taken together, these studies demonstrate that BMP-7 can block tumor progression
in bone via directly inhibiting tumor cell-induced osteolysis possibly by antagonizing
TGF-β signaling in the breast cancer cells (see figure 6.4). To determine the mechanism
in detail a more thorough gene analysis would have to be performed to analyze the
regulation of down-stream effectors in these cells.
6.2 Clinical applications and therapeutic opportuni-
ties
The dichotomous role of TGF-β in diseases represents a great therapeutic challenge.
Targeted strategies must be directed towards the pathogenic functions of the signaling
pathway and protect the normal homeostatic role of TGF-β such as its potent anti-
inflammatory actions and the anti-mitogenic effects of TGF-β on primary tumors (re-
viewed in [7, 51]). Moreover, to properly stratify patient subpopulations, which may
benefit from anti-TGF-β treatment regimens, new and robust diagnostic tools must be
developed [52].
Abrogating TGF-β signaling by means of synthetic inhibitors have been attempted
by several pharmaceutical companies and research groups, as introduced in chapter 1.
In chapter 5 we describe the characterization of a novel TGF-β receptor antagonist
GW788388 in epithelial cells of various origins [53, 54]. We show for the first time that
GW788388 targets the ATP binding domain of both the TGF-β type I and the type
II receptors. When analyzing downstream TGF-β signaling we found that GW788388
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efficiently blocked TGF-β-mediated EMT. Furthermore, the compound inhibited TGF-
β-induced growth arrest in NMuMG cells. Thus, down-steam mechanisms of TGF-β
signaling can efficiently be inhibited by low doses of GW788388 [53]. These findings are
summarized in figure 8 of chapter 5.
In a mouse model of diabetic nephropathy, the db/db model, we found that daily
administration of GW788388 (2 mg/kg/day for 5 consecutive weeks) significantly atten-
uated glomerulopathy in mouse kidneys [53]. This was correlated with reduced mRNA
expression of critical factors in ECM remodeling induced by TGF-β namely PAI-1, colla-
gen I, collagen III and Fibronectin in GW788388 treated animals versus controls. All to-
gether, these data provide a strong foundation for using TGF-β receptor kinase inhibitors
for treating advanced renal diseases. However, the use of such drugs for renoprotection
may require chronic treatment and the impact of blocking of TGF-β signaling in per-
spective of its immunosuppressive and tumor suppressor functions could have adverse
side effects [53, 55, 51].
In continuation of these studies, we initiated an curative drug administration regimen
in mice induced with metastatic breast cancer. GW788388 was given daily (at 3 and 15
mg/kg) mixed with powdered rodent chow. However, due to technical difficulties and
the publications of similar studies [18, 56, 57] during the course of these experiments this
project was discontinued and our attention was focused to other research areas. Other
groups elegantly showed that administration of small kinase inhibitors to ALK5 can
inhibit metastasis formation in mice both in a preventive setting [18] and with curative
treatment regimens [56, 57].
With genetic interference of the expression of downstream TGF-β signaling media-
tors, Smad2 or Smad3, we found that Smad2 can act as a negative regulator of breast
cancer metastasis. In contrast, downstream TGF-β signaling was dependent on Smad3,
which was shown to have a pro-metastatic function in metastatic breast cancer (chapter
2). Current therapeutic strategies aim at targeting TGF-β signaling through receptor
inactivation [51]. This leads to a complete halt of downstream Smad2 and Smad3 sig-
naling. Despite efficacious results using these approaches in animal models (reviewed
in [51]) our findings (chapter 2) together with those of others [10, 21] suggests that se-
lectively targeting Smad3 may lead to more effective anti-metastatic and anti-fibrotic
therapy [10].
HMGA2 was identified as a critical Smad-dependent TGF-β target gene which di-
rectly induce EMT and is crucial for TGF-β-mediated EMT [28]. Our preliminary find-
ings, in a breast cancer metastatic model, suggests that HMGA2 may be more important
in a primary tumor setting compared to the progression of metastasis at a secondary
site (unpublished observations). Thus, targeting HMGA2 in the primary tumor could
lead to preservation of the epithelial morphology and hereby inhibit the acquisition of
a migratory phenotype which facilitates metastatic progression. Since HMGA2 is lost
in normal cells and highly re-expressed in various cancerous tissues it presents as an
excellent target for anti-cancer therapy.
The let-7 family members of miRNAi’s are characterized as tumor suppressors and
clearly define an epithelial gene signature. Interestingly, the loss of miRNA let-7 and
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enhanced expression of HMGA2 were recently suggested as superior prognostic markers
with more clinical relevance than the classical markers E-Cadherin, vimentin and Snail1
in cancer [58].
We compared the intra-bone tumor growth of BMP-7 overexpressing breast cancer
cells with cells ectopically expressing a continuous active ALK2 receptor (chapter 4).
We found that BMP-7 can act as a negative regulator of TGF-β signaling likely by up-
regulating the expression of Smad7 and by reversing TGF-β-induced EMT [37]. Thus,
BMP-7 inhibits local tumor progression in the bone through tumor cell-autonomous
actions. These findings suggests, that systemic or local administration of BMP-7 could be
used to treat patients with breast or prostate cancer metastasis (reviewed in [37, 41, 59]).
Due to the pleiotropic nature of TGF-β the application of TGF-β receptor inhibitors
or drugs which target this signaling pathway present unique challenges that must be con-
sidered in drug development programmes. Targeted drug delivery using liposome-based
therapy can specifically deliver a drug to the site of interests. Systemic administration
Bisphosphonate-coupled liposome encapsulated ALK5 inhibitors, to patients with bone
metastasis, would allow specific delivery of biological relevant doses of compounds to sites
of extensive bone remodeling and hereby prevent systemic toxicity and severe immune
side-effects.
Also, novel studies examining combinatorial therapies targeting both HIF-1α and
TGF-β signaling are currently being explored [60]. Ectopic expression of DN-TβRII and
silenced expression of HIF-1α significantly enhanced survival of mice induced with cancer
metastasis. Thus, targeting both TGF-β and HIF-1α showed additive inhibitory effects
on tumor metastasis [60]. Whether combined therapy of human recombinant BMP-7 and
an ALK5 inhibitor synergistically could provide a more potent anti-metastatic therapy
would also be of great interest to examine in our osteotropic breast cancer models. In
addition, Dr. Theresa Guise and colleagues are further exploring whether Halofuginone
can block metastatic progression in mice models. This compound has been described
to interfere with TGF-β signaling through down-regulation of TβRII expression and
up-regulation of Smad7 [61]. In renal fibrosis, halofuginone was shown to prevent ECM
deposition in db/db mice by inhibiting TGF-β signaling [62]. Together, these examples
highlight the potential of targeting the TGF-β pathway in the treatment against cancer
and fibrosis.
6.3 Perspectives
By understanding the stochastic nature of the metastatic cascade and the molecular
mechanisms that facilitate metastasis we have begun to understand not only how metas-
tasis proceeds but also why they occur in the first place [63, 64]. Understanding the
role of the tumor-associated stroma and the cells herein on tumorigenesis is one field
which holds great promise for future research and novel therapeutic strategies [36]. The
pioneering work of Dr. Mina Bissell and many others have resulted in the design of
complex 3D multi-cellular models in vitro which allow simulation of in vivo settings.
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One model for tumorigenesis suggests that cancer develops through augmented cell-
autonomy and rare cellular variants survive a darwinian selection process for enhanced
metastatic abilities [65]. Another model proposes that metastatic traits are acquired
through exposure of epithelial cancer cells to paracrine signals received from mesenchy-
mal cell types in the tumor-associated stroma (reviewed in [66, 36, 67, 68, 69]). In
support of this theory, Karnoub et al. recently showed that MSCs dramatically promote
metastasis of breast cancer cells when these are co-injected orthotopically. When tu-
mor cells were isolated and re-injected without MSCs they no longer possessed enhanced
metastatic properties compared to controls [68]. Thus, supporting the hypothesis that
acquisition of an invasive metastatic morphology is reversible and maintenance of this
phenotype depends on continuous contact with stromal cells [68]. Furthermore, this
suggests that the metastatic characteristics are expressed transiently in a minority of
cells which respond to paracrine signals from the stromal compartment. Locating and
identifying these key genes which mediate invasiveness should therefore be done by pro-
cedures rather than bulk analysis of the primary tumor [68] and focus should be aimed
at analyzing the responsiveness of primary tumor cells to stromal signals and the effect
of the cancer cells on the tumor stroma and cells herein [36, 69].
The observations described in this thesis are based on the current models available
for studying metastatic bone disease [42, 41, 70]. Few human breast cancer cell lines give
rise to bone metastasis and most of our studies are based on an osteotropic subclone of
the MDA-MB-231 cell line. A cancer line originally isolated from a pleural effusion of
a breast cancer patient suffering from widespread metastasis many years after removal
of her primary tumors [65, 71]. That most research is based on this one model is a
drawback and it is therefore of high relevance to identify new in vivo models for breast
cancer bone metastasis. Furthermore, is it of great importance to correlate our finding
in mouse models with observations in human material to produce clinical relevant data.
The discovery of miRNAs and their potential tumor suppressor and tumor promoting
properties holds great promises for future drug design strategies [72] along with the use of
miRNAs as prognostic biomarkers [73]. Also, the emerging field of tumor-initiating can-
cer stem cells (CSCs) and the pathways that regulate self-renewal and survival of breast
CSCs may give rise to a promising novel cancer therapies. Moreover, the EMT pro-
gram was recently shown to support the differentiation of mammary epithelial cells with
self-renewal properties similar stem cell [74]. The impact of EMT on tumor-initiating
CSCs and on miRNAs and how these observations can be translated into therapy will
be interesting to follow in the near future.
On the prognostic side, the FDA recently approved an in vitro diagnostic test ”the
Mamma-print” which can predict the likelihood of distant metastatic recurrence in breast
cancer based on a 70 gene signature [75, 76]. The application of expression profiling
of primary human cancers is a promising approach to identify mechanisms responsible
for tumorigenesis. Well-defined EMT and tumor models can complement the human
cancer studies and the synergism between expression profiles could identify promising
key target genes and pathways involved in late-stage tumorigenesis. This would support
the identification of molecular markers and the development for anti-cancer therapies and
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eventually stratify patient group which could benefit from such treatment regimens.
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Transforming growth factor-β (TGF-β) is een gesecreteerd eiwit dat zeer veel verschil-
lende cellulaire functies kan reguleren. Genetische veranderingen en omgevingsfactoren
kunnen zowel in als tussen cellen ontsporingen van TGF-β signaaloverdracht veroorzaken,
welke in verband worden gebracht met een breed scala aan ziektes, waaronder kanker,
fibrotische ziektebeelden, auto-immuunziekten, spierziekten, botziekten en vaatziekten.
TGF-β maakt deel uit van een familie van 33 verschillende eiwit-liganden, waaronder eve-
neens de zogenaamde ”bone morphogenic proteins” (BMPs) en activinen. TGF-β fami-
lieleden signaleren via specifieke type I en type II serine/threonine kinase receptoren, die
gelegen zijn in de celmembraan. De type I receptoren worden ook wel activin-receptor-
like kinases (ALKs) genoemd. Na ligand-binding en onderlinge complexvorming geven
deze type I/type II receptorcomplexen op hun beurt, via fosforylering van specifieke tar-
gets, de door de liganden gëınitieerde signalen door aan meerdere intracellulaire second
messengers, waarvan de Smad-transcriptiefactoren de belangrijkste zijn. De TGF-β ei-
witten zelf activeren op deze manier Smad2 en Smad3, maar de BMP eiwitten activeren
juist Smad1, Smad5 en Smad8. Na deze activatie kunnen deze Smad eiwitten de celkern
binnendringen en daar specifieke, door TGF-β of BMP-reguleerbare genen activeren.
Deze door TGF-β of BMP gecontroleerde genen zijn ondermeer betrokken bij remming
van cel proliferatie, en bij celmigratie, celdifferentiatie en/of celdood.
De rol van TGF-β in kanker is complex. In de vroegste fasen van de tumor on-
twikkeling (tumorigenese) remt TGF-β meestal de proliferatie van kanker (en normale)
cellen en fungeert het dus als een tumorsuppressor. Maar in de latere fasen, wanneer de
tumorcellen door (verdere) DNA veranderingen ongevoelig geworden zijn voor groeirem-
ming door TGF-β en hoge hoeveelheden van TGF-β gaan maken, werkt TGF-β vaak
als een tumorpromoter. Het verhoogd aanwezige TGF-β stimuleert dan de migratie
en invasie van de tumorcellen, remt het immuun systeem en aktiveert de vorming van
bloedvaten in en rondom de tumor. In geval van fibrose, een overmatige toename in de
hoeveelheid bindweefsel die in veel verschillende organen kan plaatsvinden, is er ook een
correlatie met verhoogde TGF-β expressie. In dit geval stimuleert TGF-β de vorming
178 Miscellaneous
van extracellulaire matrixeiwitten en differentiatie van fibroblasten in myofibroblasten.
De in dit proefschrift beschreven studies hadden als doel de moleculaire mechanismen
te ontrafelen waarmee bepaalde leden van de TGF-β familie het gedrag van borstkanker-
cellen bëınvloeden. In het bijzonder is gekeken hoe TGF-β en BMP eiwitten in het
lichaam de kwaardaardige uitzaaiing van borstkankercellen naar bot kunnen reguleren.
Ten tweede zijn de effecten van een specifieke remmer van TGF-β receptoren op fibrose
in de nier bestudeerd. De belangrijkste resultaten die zijn verkregen, zijn hieronder
samengevat.
1. De Smad2 en Smad3 transcriptiefactoren blijken door verschillende typen TGF-β-
target genen te reguleren een tegengestelde rol te hebben bij TGF-β-gemedieerde
uitzaaiing van borstkanker cellen naar bot. Smad3 stimuleert hierdoor de bloed-
vatvorming rondom de uitzaaiingen, terwijl Smad2 dit juist remt (hoofdstuk 2).
2. Het eiwit HMGA2 is gëıdentificeerd als een Smad4-afhankelijk TGF-β-gereguleerd
gen in borstkankercellen, en blijkt noodzakelijk te zijn voor de door TGF-β gein-
duceerde epitheliale naar mesenchymale transitie (EMT). Verhoogde expressie van
HMGA2 veroorzaakt hierbij een verlaging van het epitheel-specifieke eiwit E-cadherine,
wat belangrijk is voor cel-cel interactie. De E-cadherine verlaging wordt gemedieerd
door de transcriptionele remmers Snail1, Slug en Twist (hoofdstuk 3).
3. De remmende werking van bepaalde BMP eiwitten op borstkankerprogressie is
nader bestudeerd met behulp van een genetisch geactiveerde BMP receptor. Over-
expressie van een actieve BMP type I receptor in de borstkankercellen bleek vol-
doende te zijn om zowel de uitzaaiing naar bot als ook de tumor-geassocieerde
osteolyse te remmen (hoofdstuk 4).
4. De rol van TGF-β in nierfibrose van diabetische muizen met vergevorderde ne-
fropathie is bestudeerd m.b.v. de TGF-β receptor kinase remmer GW788388.
Deze remmer bleek zowel fibrose als de expressie van belangrijke mediatoren van
fibrose in de nieren te remmen (hoofdstuk 5).
Deze resultaten laten zien dat het verloop van diverse ziekteprocessen in het lichaam
bëınvloed kan worden door specifiek ingrijpen in de signaaltransductie routes die gecon-
troleerd worden door leden van de TGF-β familie. Verder onderzoek naar (meer) spec-
ifieke inhibitoren van de diverse componenten van deze routes kan daardoor leiden tot
meer en betere therapeutische toepassingen.
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7.4 List of Abbreviations
Abbreviation Description
ActRII Activin type II receptor




BAMBI BMP and activin membrane-bound inhibitor
bHLH basic helix-loop-helix
BLI Bioluminescent imaging
BMP Bone morphogenetic protein
BMPRII BMP type II receptor
BRE BMP-responsive element
caALK Constitutively active ALK





CSCs Cancer stem cells
CTGF Connective tissue growth factor
CXCL CXC motif ligand
CXCR CXC motif receptor
DCIS Ductal carcinoma in situ
DN Dominant negative
ECM Extracellular matrix
EMT Epithelial mesenchymal transition
ER Estrogen receptor
ERK Extracellular signal-regulated kinase
FGFR Fibroblast growth factor receptor
FN Fibronectin
FOP Fibrodysplasia ossificans progressiva
GADD Growth arrest and DNA damage
GAPDH Glyceraldehyde-3’-phosphate dehydrogenase
GDF Growth/differentiation factor
GFP Green fluorescent protein
GSC Goosecoid
HMEC Human primary mammary epithelial cell
HIF Hypoxia inducible factor
HLH Helix-loop-helix
HMG High mobility group
HPC Hematopoietic progenitor cell
HSC Hematopoietic stem cell
hTERT Human telomerase reverse transcriptase
HTT Hemorrhagic telangiectasia
ID Inhibitor of differentiation/DNA binding
IDC Invasive ductal carcinoma
IL Interleukin
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Abbreviation Description
INK Inhibitor of CDK
JNK Jun N-terminal kinase
LAP Latency-associated peptide
LEF Lymphoid enhancer binding factor
LOX Loxyl oxidase
MAPK Mitogen activated protein kinase




miR RNAi miR RNA interference
MKK MAPK kinase kinase
MMP Matrix metalloproteinase
MSC Mesenchymal stem cell
MSI Microsatellite instability
MT-MMP Membrane-type MMP
NF-κB Nuclear Factor Kappa Beta
NMuMG Namru murine mammary gland
NSCLC Non-small cell lung cancer
N-T control Non-targeting control
OPG Osteoprotegerin
PAI-1 Plasminogen activator inhibitor-1
PAH Pulmonary arterial hypertension
PAS Periodic acid-shiff
PI3K Phosphatidylinositol 3-kinase
PlGF Placenta growth factor
PTHrP Parathyroid hormone related peptide
TAK TGF-β activated kinase
TIF Transcriptional intermediary factor
TIMP Tissue inhibitor of metalloproteinase-1
TGF-β Transforming growth factor-β
TβRII TGF-β type II receptor
TSG Twisted gastrulation
TSP Thrombospondin
RANK Receptor activator of nuclear factor-κB
RANKL Receptor activator of nuclear factor-κB ligand
RCC Renal cell carcinoma
SARA Smad anchor for receptor activation
S.D. Standard deviation
SDS-PAGE Sodium dodecyl sulphate-polyacrylaminde gel electrophoresis
S.E.M. Standard error of mean
Ski Sloan-Kettering virus
SHIP Src homologue SH2 domain containing 5’inositol phosphatase
shRNA Short hairpin RNA
SIP Smad-interacting protein
siRNA small interference RNA
α-SMA α-smooth muscle actin






Smurf Smad ubiquitin regulatory factor
SnoN Ski-related novel protein N
SNO Spindle-shaped N-cadherin+ CD45− osteoblast
SPARC Secreted protein acidic and rich in cysteine
TFF Trefoil protein
VCAM Vascular cell adhesion molecule
VEGF Vascular endothelial growth factor
VEGFR Vascular endothelial growth factor receptor
VHL von Hippel Lindau
Wnt Wingless int
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